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Congenital disorders are structural or functional anomalies that occur during intrauterine development 
and can be recognized at birth. Congenital structural disorders can be minor, for example, curvature of 
the 5th finger (clinodactyly) or dimples over the lower spine (sacral dimples). Major congenital structural 
anomalies can lead to significant medical problems for the patient and require specific surgical and 
multidisciplinary medical management. Major anomalies include craniofacial defects such as orofacial 
clefts (OFC), cardiac defects such as atrial septal defect or leaky heart valves, ectodermal defects such 
as sparse hair, nail dysplasia or skin erosions, and neural tube defects. When at least two congenital 
structural defects are caused by the same genetic variant and co-occur in the same individual, the 
disorder is considered to be a syndrome. There is a variety of syndromes in which patients have a 
combination of ectodermal defects and craniofacial malformations.
OFCs are congenital structural anomalies of the lip, the alveolus and/or the palate. OFCs affect around 
1 in 700 live births.1 Their prevalence varies widely across different ethnic backgrounds, geographic 
origin and socioeconomic status. Asian and Native American populations have the highest incidence 
rates, European-derived populations have intermediate rates, and African-derived populations have 
the lowest incidence rates.2 OFCs are characterized by incomplete formation and/or fusion of structures 
separating the oral and nasal cavities. The incomplete formation and/or fusion of these structures leads 
to an opening or cleft in the upper lip and/or the palate that may extend into the nose, thus obliterating 
the division between the nasal and the oral cavity. The cleft may be on one side or both the sides, 
unilateral or bilateral. Individuals may face problems with feeding, speaking, and hearing that can be 
corrected only to a certain extent by surgery and other treatments. OFC results in substantial lifelong 
morbidity to the affected individuals if left uncorrected and still may represent a psychological burden 
after surgical correction. OFC has a complex etiology with multiple genetic and environmental factors 
that can lead to the disruption of normal embryonic development of the lip and palate.
1.1 Normal development of the lip and palate structures
During early embryonic development in humans, neural crest cells (NCCs) migrate through the 
mesenchymal tissue into the developing craniofacial region. By the fourth week of development the 
NCCs take part in the emergence of the frontonasal prominence, the paired maxillary process, and the 
paired mandibular process. These structures enclose the primitive oral cavity (Figure 1.1a). By the fifth 
week, formation of nasal pits leads to the development of paired medial and lateral nasal processes 
(Figure 1.1b). By the end of the sixth week, the medial nasal processes merge with one another and 
with the maxillary processes, leading to the formation of upper lip and the primary palate. Meanwhile, 
the lateral nasal processes fuse to form the nasal alae, and the mandibular processes fuse to form the 
lower jaw (Figure 1.1c). 
During the sixth week, the development of secondary palate starts with the outgrowth from the 
maxillary processes of the paired palatal shelves which initially grow vertically down the sides of 
the tongue (Figure 1.1d). During the seventh week of development, the palatal shelves elevate to a 
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horizontal position above the tongue, contact one another and commence fusion (Figure 1.1e). The 
palatal shelves finally fuse in the midline with the primary palate and nasal septum, giving rise to 
separate oral and nasal cavities (Figure 1.1f ). 
Figure 1.1 Development of the lip and the palate. Schematic diagrams of the development of the lip and 
palate in humans. [Adapted from Nature Reviews Genetics volume 12, pages 167–178 (2011)]
1.2 Cellular processes and molecular mechanisms underlying lip and 
 palate development
The development of the lip and the palate requires a cooperation of a complex series of processes 
such as cell migration, growth, apoptosis and differentiation. All these diverse cellular events are tightly 
orchestrated by various signaling pathways, such as bone morphogenetic proteins (BMP) signaling, 
WNT/β-catenin signaling, Fibroblast growth factors (FGFs) and their receptors, and Sonic Hedgehog 
(SHH) signaling.
Analyses of mouse models have aided the identification of signaling molecules and their downstream 
targets involved in the development of the lip and the palate. The formation of upper lip and facial 
morphogenesis relies on mesenchymal proliferation, promotion of epithelial cell proliferation, and 
apoptosis of regions of epithelia that fuse as a whole. BMP signaling is necessary for the proliferation 
of the facial mesenchyme to direct outgrowth of the facial processes during the lip development. 
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Subsequently, it is also involved in apoptosis of facial epithelia and facilitates fusion. Deficiency of 
Bmp4, encoding a member of the BMP family of proteins, results in cleft lip in mice.3 Msx1 and Trp63 are 
downstream targets of BMP signaling. 
Both Msx1 and Trp63 null mice show craniofacial defects, including cleft palate. Msx1 is known to 
regulate the growth of the palatal shelves. WNT/ β-catenin signaling acts upstream to BMP signaling in 
the development of lip. It is necessary for the fusion of facial epithelia with the underlying mesenchyme. 
Mutations in Wnt9b, a member of WNT family, is known to cause cleft lip and palate.3 
FGFs and FGF Receptors (FGFRs) play a predominant role in facial development. Many FGFRs are 
expressed throughout the facial and nasal regions during the development. Fgf8 is required for the 
epithelial cell survival and mesenchymal signaling. Conditional mutant mice with Fgf8 inactivated 
from E10.5 to birth in olfactory epithelium that lines nasal cavity, develop small and flattened medial 
and lateral nasal processes during the lip development, as a result of increased cell death.4 FGFs and 
transforming growth factors (TGFs) are also involved in the growth of palatal shelves. Fgf10, together 
with Irf6 and Pax9, is important for elevation of palatal shelves.5 Adequate elevation of shelves to a 
horizontal position above the tongue is crucial for subsequent adhering. The elevated palatal shelves 
must adhere and fuse giving rise to separate oral and nasal cavities. When palatal shelves come into 
contact, the midline epithelial seam is formed. For the fusion of shelves and the mesenchymal continuity 
across the palate, this epithelial seam must degenerate. The seam degenerates by a combination of 
three processes: apoptosis of the epithelial cells, migration of the medial edge epithelial cells (periderm) 
to the oral or nasal surface of the palatal shelves, and the epithelial to mesenchymal transformation. 
Tgfβ3 is expressed in the medial edge epithelia of the palatal shelves and is important for adhesion and 
fusion of palatal shelves.
SHH signaling plays a role in cell survival during early stages and proliferation at later stages of 
development. Conditional ablation of Smoothened from NCCs, a receptor essential for the activation of 
Shh targets results in increased apoptosis up to E10.5 followed by decreased levels of proliferation from 
E11.5, which translates into severely truncated facial processes.6  
Perturbations in any of these signaling pathways during the development can result in orofacial 
abnormalities.
1.3 Genetics of orofacial clefting
The genetic component to orofacial clefting has been recognized since long after observing an 
increased frequency of OFC in relatives of a patient with a cleft (Fogh-Andersen, 1942).7 Approximately, 
30% of the OFC patients have additional phenotypic manifestations, such as ectodermal dysplasia, 
limb malformations, dental anomalies, ankyloglossia, and are considered to be part of one of the 
400 OFC syndromes. These syndromic forms of OFC result from single gene mutations or chromosomal 
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abnormalities that are inherited in a Mendelian fashion. Some of the well-studied syndromic forms 
of OFC result from mutations in TP63 and in IRF6. Mutations in TP63 can cause five distinct human 
developmental disorders that are characterized by various combinations of ectodermal dysplasia, 
orofacial clefts, and limb abnormalities. These disorders include ectrodactyly-ectodermal dysplasia-
clefting (EEC3; MIM: 604292) syndrome and ankyloblepharon-ectodermal dysplasia-clefting (AEC 
[MIM: 106260) syndrome. Mutations in the gene encoding the transcription factor interferon regulatory 
factor 6 (IRF6) have been demonstrated to underlie Van der Woude syndrome (VWS; MIM: 119300) and 
popliteal pterygium syndrome (PPS; MIM: 119500). VWS is an autosomal dominant form of orofacial 
clefting where the affected individuals present with pits in the lower lip and dental anomalies, whereas 
PPS has a similar orofacial phenotype together with skin and genital anomalies. Besides TP63 and IRF6, 
mutations in many other genes regulating the development of lip and palate are known. Examples of 
such genes are, WNT3 causing tetra-amelia syndrome (TETAMS; MIM: 273395) with OFC, FGFR1 causing 
Kallmann syndrome (KAL2; MIM: 147950), FGFR2 causing Crouzon syndrome (MIM: 123500) and Apert 
syndrome (MIM: 101200), SHH causing holoprosencephaly, and TGFBR1 and TGFBR2 causing Loeys-Dietz 
syndrome (LDS2; MIM: 610168).1 Nonsyndromic forms of OFC (nsOFC) account for 70% of the total OFC 
cases. In these cases, affected individuals exhibit no additional clinical features. There is compelling 
evidence for the involvement of genetic variants with high effect size to the occurrence of nsOFC based 
on familial clustering of affected individuals8 and an higher concordance rate in monozygotic twins 
(25–40%) compared to their dizygotic counterparts (3–6%).9,10 There are different genetic models for 
nsOFC. First model is close to the Mendelian inheritance model, where very rare variants with high 
penetrance and very strong effect size are considered causative. But more prevailing model for nsOFC 
discards Mendelian inheritance patterns and considers the combined action of multiple genetic and 
environmental risk factors. Among the genetic factors are the rare variants with high effect size and 
common variants with low effect size. This genetic heterogeneity and complex etiology makes the 
identification of specific genetic mutations that cause nsOFC difficult. Candidate gene and genome-
wide association studies (GWAS) have identified various “risk factors” associated with OFC. These “risk 
factors” are single nucleotide polymorphisms (SNPs) which have a significantly higher frequency in 
patients compared to controls. Seven risk factors have been identified so far by four GWAS. These risk 
factors are said to impart risk towards the disease, however mere presence of a single risk factor may 
not cause the phenotype. Recently, a genome-wide meta-analysis of nonsyndromic cleft lip with or 
without cleft palate supported association with all previously risk factors and identified six additional 
risk factors. Predictably, the GWAS for nsOFC have identified risk variants in both TP63, IRF6, and in 
many other genes well-known for various forms of syndromic OFC. Extrapolations from syndromic 
studies have identified the role of various genes in nsOFC, such as PVRL1 and IRF6.11 
Interestingly, the GWAS performed for nonsyndromic OFC so far have identified genetic risk factors 
both in coding and even more so in non-coding regulatory regions of the genome.12–14 Variations in 
non-coding regulatory elements may cause the regulation of the otherwise normal OFC gene. This has 
indeed been supported by a study which identified a VWS family where the affected individuals do not 
contain any pathogenic mutation in the IRF6 itself, but in the upstream enhancer element, MCS9.7.15 
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Recently, a duplication in this upstream element was identified as the etiologic mutation in the affected 
individuals of the family.16
For the identification of mutations underlying syndromic and nsOFC, previous positional cloning and 
candidate gene approaches have given way to genome-wide approaches, like exome sequencing, 
whole genome sequencing, genome-wide association studies (GWAS), and molecular inversion probes 
(MIPs) sequencing. 
1.4 Aim of the thesis
OFCs are one of the most common congenital birth defect in humans and cause a considerable 
psychological, financial, and societal burden. To date, many different genetic factors have been 
associated with OFC, however, for a significant proportion of cases the genetic defects are still elusive. 
The understanding of genetic basis of orofacial clefting is crucial for diagnosis, treatment, and assessing 
recurrence risk in families. The aim of this thesis is to expand the current knowledge on the genetic 
mechanisms underlying OFC.
The thesis aims to use novel genomic approaches to decipher the genetics of OFC. This was 
accomplished by:
 • candidate gene approach for identifying mutations in genes previously implicated in OFC,
 • explorative approach of exome sequencing when known gene associated with the disease has 
been ruled out, and 
 • identifying mutations in non-coding regulatory elements
1.5 Outline of the thesis
Chapter 2 reviews the candidate gene and genomic approaches employed in understanding of causes 
of syndromic and nonsyndromic OFC, and discusses the applications, advantages, and challenges of 
various approaches.
Candidate gene approach for identifying mutations in genes previously implicated in OFC: 
Chapter 3 reports on the identification of novel loss-of-function deletions and mutations in TP63 in 
OFC patients. The data describes three OFC families and the large OFC case and control cohorts where 
molecular inversion probes (MIPs) sequencing was used for sequencing TP63. This is the first study 
supporting the haplosufficiency model for p63 phenotypes. 
Chapter 4 describes the novel IRF6 mutations identified with MIPs in nonsyndromic OFC cases. 
Explorative approach of exome sequencing:
Chapter 5 reports on identification of novel LRP6 mutations in patients with OFC and tooth agenesis 
(TA), by combining whole-exome sequencing (WES) and MIPs in a large cohort of OFC and TA patients. 
This is the first report on LRP6 mutations in TA-OFC and TA-only phenotypes.
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Chapter 6 describes a case study of a patient with an EEC/AEC syndrome-like phenotype together with 
orofacial clefting and hypogammaglobulinemia. The study reports on the identification of a de novo 
variant in CHUK through exome sequencing. 
Mutations in non-coding regulatory elements:
Chapter 7 presents the method for identifying functional variants in p63-bound non-coding regulatory 
elements involved in orofacial clefting.
Chapter 8 discusses the findings reported in this thesis in the scheme of things.
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Abstract
Fast developing technologies in genomics have driven genetic studies of human diseases from classical 
candidate approaches toward hypothesis-free and genome-wide screening methods. Compared to 
the low-resolution cytogenetic techniques that were the only available methods to visualize genomic 
changes at the chromosomal level until some 15 years ago, genome-wide studies including analyses of 
copy number variation (CNV), genome-wide association and linkage studies, and exome sequencing 
(ES) provide more accurate information for unraveling the genetic causes of diseases. Moreover, 
genome sequencing (GS) which interrogates the genome of a single individual at the nucleotide 
resolution has also been applied in genetic studies. Here we review genomic approaches in craniofacial 
disorders, with the emphasis on orofacial clefts, and discuss the applications, advantages, limitations, 
challenges, and future perspectives.
2.1 Introduction
Craniofacial developmental disorders are congenital structural defects of the face and/or cranium, 
owing to disruptions in various developmental processes. Orofacial clefts (OFCs) are among the most 
common craniofacial birth defects and they may present in isolated form or as part of a syndrome 
[Jugessur andMurray, 2005; Hennekam et al., 2010]. OFCs are characterized by incomplete formation or 
fusion of structures separating the nasal and oro-pharyngeal cavities and can affect the upper lip, the 
hard and/or soft palate, as well as other parts of the face. OFCs encompass a broad clinical spectrum 
and may be uni- or bilateral with complete or incomplete clefts of either lip or/and (hard or soft) palate. 
Previous genetic and embryologic studies suggest that cleft lip with or without cleft palate (CL/P) and 
cleft palate only (CPO) result from distinct etiological mechanisms [Fraser, 1955; Sivertsen et al., 2008; 
Rahimov et al., 2012]. Recent studies also suggest that cleft lip only (CLO) may have a separate etiology 
than cleft lip with cleft palate (CLP) [Harville et al., 2005; Jugessur et al., 2011; Rahimov et al., 2012].
Complex inheritance patterns are associated with OFC-related disorders. While a variety of syndromic 
as well as non-syndromic (NS) familial forms of OFCs with presumed Mendelian inheritance have 
been described, the majority of isolated NS OFCs are considered to represent complex multi-factorial 
diseases, with implication of gene-gene interactions, gene-environmental interactions, environmental, 
and mechanical factors [Wyszynski et al., 1997]. Collectively, NSOFCs affect approximately 1/700 live 
births worldwide [Dixon et al., 2011]. Evidence for a genetic role in the complex etiology of the NSOFCs 
has come from the observation that the risk of CL/P and CPO is respectively 32- and 56-fold higher 
in siblings than in the normal population [Sivertsen et al., 2008]. In addition, the concordance rate in 
monozygotic twins is approximately 25–45% as compared to 3–6% for dizygotic twins [Mitchell and 
Risch, 1992].
The presence of both Mendelian and complex forms of OFCs in humans requires tailored analysis 
approaches to identify specific etiologies. Given that OFCs are among the most common craniofacial 
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disorders [Hennekam et al., 2010], we focus on them in this review. Cytogenetic studies were among the 
first approaches to study the whole genome. Such studies have identified a broad range of structural 
and numerical chromosome aberrations involving a large number of genes which cause multiple 
congenital malformations including OFCs. With the recent availability of novel genomic approaches 
such as exome and genome sequencing (GS), it is now possible to identify single-gene disruptions 
in individuals with OFCs. In this review, we aim to discuss genome-wide approaches used in genetic 
studies of OFC including copy number variations (CNVs), genome-wide linkage studies, genome-wide 
association studies (GWAS), exome sequencing (ES), and the identification of genetic variants in non-
coding regulatory elements. The applicability of these approaches and future perspectives of genomic 
studies in OFCs including GS are also discussed.
2.2 Detection of chromosomal aberrations
Many deletions, insertions, inversions, and translocations associated with syndromic CL/P have been 
identified by traditional cytogenetic techniques such as G-Banding and fluorescent in situ hybridization 
(FISH) and by comparative genomic hybridization (CGH), array comparative genomic hybridization 
(aCGH), and single nucleotide polymorphism (SNP) arrays. Although there is a clear progression of 
the technology, these techniques are currently often used in combination to provide confirmative 
information. In this review, we summarize key findings in OFC-related chromosomal aberrations 
(Table 2.1) and discuss the advantages and limitations of each technique. G-banding of metaphase 
chromosomes has been used for more than 50 years and has detected a large number of translocations 
and other structural chromosomal anomalies associated with isolated and familial forms of CL/P 
[Lindsten et al., 1965; Walzer et al., 1966]. However, the resolution of G-banding chromosome analysis is 
low and re-arrangements of genomic segments smaller than 5–10Mb are usually not detected [Bejjani 
and Shaffer, 2008; Ledbetter, 2008; Takenouchi et al., 2012]. FISH uses fluorescent probes that can bind 
to specific regions of the chromosome by sequence complementarity and has better resolution than 
G-banding chromosome analysis. It can detect genomic re-arrangements as small as 35 kb [Bejjani and 
Shaffer, 2008]. The utility of these techniques was demonstrated by the identification of SATB2 as a cleft 
palate gene on 2q32–q33 by high-resolution FISH mapping of a translocation breakpoint [FitzPatrick et 
al., 2003]. The limitation of FISH is that it can only target pre-selected small regions of interest. 
In CGH, differentially labeled test (affected individual) and reference (normal individual) genomic DNAs 
are co-hybridized to normal metaphase chromosomes and fluorescence ratios along the length of 
chromosomes provide a cytogenetic representation of the relative DNA copy-number variation. This 
technique visualizes chromosomal abnormalities with a resolution of 5–10Mb. A method that combines 
the strength of genome-wide analysis of CGH with the high resolution offered by FISH is aCGH. In the 
early versions of aCGH, genomic fragments such as yeast or bacterial artificial chromosomes (YACs 
and BACs, respectively), P1 phagemids, cosmids, or cDNA clones were used for hybridization instead 
of metaphase chromosomes in conventional CGH technique. An early aCGH study was performed 
on syndromic and NS CL/P cases [Osoegawa et al., 2008]. Out of 63 syndromic cases, a deletion of 
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2.7Mb at chromosome 22q11.21 was identified in one patient. In 104 NS cases, two deletions, a 3.2Mb 
deletion at chromosome 6q25.1–q25.2 in one patient and a 2.2Mb deletion at 10q26.11–q26.13 in 
another patient, were identified. These deleted genomic regions included eleven and nine genes, 
respectively. Further prioritization of the genes in these regions was based on the hypothesis that the 
novel candidate genes play a similar role or share biological processes with the genes known to be 
associated with CL/P. Estrogen receptor 1 (ESR1) and fibroblast growth factor receptor 2 (FGFR2) were 
ranked as most likely causative genes at 6q25.1–q25.2 and 10q26.11–26.13 loci, respectively.
Table 2.1 Studies of chromosomal aberrations in OFCs
Locus Chromosomal 
aberration
Condition CNV 
length
Techniques Number 
of genes
Predicted 
causative 
genes
Reference
2q32–q33 Translocation CPO – FISH – SATB2 [FitzPatrick  
et al., 2003]
6q25.1–q25.2 Deletion CL/P 3.2 Mb aCGH 11 ESR1 [Osoegawa  
et al., 2008]
10q26.11–q26.13 Deletion CL/P 2.2 Mb aCGH 9 FGFR2 [Osoegawa  
et al., 2008]
5p15.33 Duplication syndromic 
CLP
300kb aCGH 5 CLPTM1L [Izzo et al.,  
2013]
1p32.2– p32.3 Deletion syndromic 
CLP
5.4 Mb aCGH 55 LRP8, DAB1 [Mulatinho  
et al., 2008]
8p23.1 Duplication 8p23.1 
duplication 
syndrome
3.68 Mb aCGH 26 – [Barber  
et al., 2013]
3q29 Deletion syndromic 
CLP
1.5 Mbp Human SNP 
Array
22 – [Petrin  
et al., 2011]
The clone-based aCGH has been further refined by oligonucleotide microarrays. A SNP array is a type 
of DNA microarray which is used for linkage and association studies as well as for the detection of 
CNVs. These arrays offer a good genome-wide coverage with millions of SNPs and CNV probes. 
With these arrays, microdeletions and microduplications of a length as small as a few hundred base 
pairs have been detected in studies of syndromic forms of CL/P [Mulatinho et al., 2008; Petrin et al., 
2011; Barber et al., 2013; Izzo et al., 2013]. One example of using oligoarrays is shown by Izzo et al. 
[2013]. In this study, a patient with syndromic CLP and developmental delay was initially analyzed 
with G-banding chromosome analysis and was shown to have normal karyotype. With oligoarray 
analysis, an approximately 300 kb microduplication was identified at 5p15.33 encompassing only five 
protein-coding genes, with CLPTM1L hypothesized to be the best candidate gene based on previous 
cytogenetic and linkage studies [Wyszynski et al., 1996; Yoshiura et al., 1998]. 
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With the advances of these array methods, previously unidentifiable mutations can now be identified 
as causes for many congenital anomalies. CNVs of the size of a few kb or even a single exon may be 
detected and therefore these microarray analyses are currently used as the first investigation step 
in many laboratories [Miller et al., 2010]. The identified CNVs can further be examined by searching 
CNV databases such as Database of Genomic Variants [Iafrate et al., 2004] to exclude common CNVs 
and to identify rare ones. However, there are limitations to these methods. Balanced chromosomal 
rearrangements such as translocations and inversions cannot be identified using aCGH or SNP arrays, as 
these methods only detect gains and losses of chromosomal material. Recently, CNV studies using Next 
Generation DNA Sequencing (NGS) approaches (CNV-seq) have been reported [Xie and Tammi, 2009]. 
Although the CNV-seq method needs further validation, balanced and unbalanced rearrangements 
may be detected by NGS genomic sequencing methods, which may provide new possibilities for 
developing diagnostic tools.
2.3 Genome-wide linkage studies
Genome-wide linkage analysis has been used for more than 20 years in classical genetic studies. The 
aim of linkage studies is to map a disease locus to a specific genomic region by identifying genetic 
markers that co-segregate with the disorder in a family. It is a parametric method and only useful for 
disorders that are hypothesized to be Mendelian traits. Large families with multiple affected individuals 
are most suitable for linkage studies. Highly polymorphic DNA markers are ideally used in genome-
wide linkage studies as it maximizes the ability to detect recombination events. Such analyses enable 
narrowing down of regions carrying co-segregating variants and thus ultimately aiding the gene or 
gene variant to be identified by Sanger sequencing. Such positional cloning approaches have been 
used successfully to identify CL/P genes, such as IRF6, PVRL1/nectin-1, MSX1, TBX22, and TP63, for 
syndromic forms of CL/P [Dixon et al., 2011] (Table 2.2). 
Table 2.2 Identification of OFC genes by linkage and sequencing
Gene Syndrome Reference
MSX1 tooth agenesis and various combinations of CPO and CLP [van den Boogaard et al., 2000]
PVRL1 CL/P-ectodermal dysplasia (ED) syndrome (CLPED1) [Suzuki et al., 2000]
TBX22 X-linked cleft palate and ankyloglossia [Braybrook et al., 2001]
IRF6 Van der Woude and Popliteal Pterygium Syndromes [Kondo et al., 2002]
TP63 LMS/EEC Syndrome [Celli et al., 1999]
In many of these studies, large families with clinically recognizable syndromes involving OFC phenotype 
were used. For example, the identification of mutations in IRF6 as being responsible for the CL/P 
disorders of Van der Woude syndrome (VWS) and popliteal pterygium syndrome (PPS) was assisted by 
a linkage analysis in large families [Lees et al., 1999] followed by sequencing of the IRF6 gene [Kondo 
et al., 2002]. PVRL1/nectin-1 was identified as the causative gene for a specific form of CL/P-associated 
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with ectodermal dysplasia that is indigenous in the population of Margarita Island by homozygosity 
mapping followed by sequencing [Suzuki et al., 2000]. Another example is the identification of 
mutations in the TP63 gene that encodes a transcription factor for Ectrodactyly-Ectodermal Dysplasia-
Cleft syndrome (EEC) and related disorders [Celli et al., 1999; Van Bokhoven et al., 2001; Rinne et al., 
2007]. EEC syndrome is an autosomal dominant disorder, characterized by ectrodactyly, ectodermal 
dysplasia, and OFC. Genome-wide linkage analysis was initially carried out in a large family with a 
syndrome resembling EEC, limb-mammary syndrome (LMS), and later followed by locus-specific 
linkage analysis in five small families with EEC syndrome [Van Bokhoven et al., 1999]. Sequencing of 
genes in the identified 3q27 locus showed that mutations causing EEC syndromes are localized in the 
region of the TP63 gene encoding the DNA binding domain and therefore these mutations may disrupt 
p63 DNA binding and transactivation of p63 target genes (Figure 2.1A, B). In addition to EEC and LMS, 
two other syndromes exhibiting CL/P as a feature are associated with mutations in the TP63 gene, 
Hay–Wells syndrome and Rapp-Hodgkin syndrome [McGrath et al., 2001; Rinne et al., 2007]. Later TP63 
mutations were also reported for NSCL/P [Leoyklang et al., 2006].
2.4 Candidate gene and genome-wide association studies
Association studies have been extensively applied to non-Mendelian forms of OFCs. Association studies 
compare the frequency of single-locus alleles, genotypes of a particular variant or haplotypes between 
subjects and healthy controls. In these studies, genes that are predicted to be involved with the disease 
on the basis of biological hypotheses are selected. For example, common IRF6 variants at the IRF6 gene 
that is known to be involved in VWS [Zucchero et al., 2004] and PPS [Kondo et al., 2002] have also been 
associated with isolated CL/P in several studies [Jugessur et al., 2008; Birnbaum et al., 2009a].
Association studies using the candidate gene approach have confirmed a number of genes such as 
MSX1 and the family of TGF genes in NSCL/P [Dixon et al., 2011]. As opposed to the candidate-gene 
approach, GWAS investigate association of variants distributed across the entire genome with disease 
phenotypes. This is commonly done using SNP microarrays. The haplotypes which are found more 
frequently in patients than in controls are considered to be “associated” with the disease. Such loci 
are called “risk loci” and they influence the risk of disease. By calculating which variants co-occur with 
the disease symptoms, a statistical estimate for increased risk associated with each SNP is made. So 
far, GWAS have identified many genomic regions significantly associated with NSCL/P in different 
populations (Table 2.3).
The first GWAS for NSCL/P involved 224 CL/P affected individuals and 383 controls of Central European 
origin and identified loci on 8q24.21 and 1q32.2 with strong evidence of association [Birnbaum et al., 
2009b]. These findings were confirmed in larger patient–control sample groups in the same study. 
As the 1q32.2 locus contains the IRF6 gene, these GWAS supported the notion that IRF6 variants 
contribute to multifactorial NSCL/P as well as to Mendelian forms of OFCs. In contrast, the locus on 
8q24.21 is a gene desert, and therefore the causative element within this region is still to be identified. 
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An extension of this study with increased sample size and added replication populations (401 affected 
individuals and 1,323 controls) confirmed both the associated regions [Mangold et al., 2010]. This study 
also identified two additional loci on 17q22 near NOG and 10q25.3 near VAX1. Another group also 
found strong evidence for involvement of the 8q24 locus with 111 NSCL/P patients and 5,951 controls 
of European descent [Grant et al., 2009]. However, this study lacked a replication sample. In addition, 
another confirmation of 8q24 region was provided by a nuclear-trio-based GWAS of Europeans and 
Asians [Beaty et al., 2010] which included 1,908 case-parent trios of various ancestries with 825 trios of 
European ancestry and 1,038 of Asian ancestry. In the replication sample, 8,115 individuals from 1,965 
families from different populations were included. Two new susceptibility loci, 1p22 and 20q12, were 
identified with genome-wide significance, and their signals were found to be stronger in Asians than 
in Europeans. This study was replicated with an independent sample of trios and all previous loci were 
confirmed [Beaty et al., 2013].
Recently, the first genome-wide meta-analysis study of NSCL/P was published. It included 666 European 
trios (including European Americans) and 795 Asian trios from Beaty et al. [2010] and 399 patients 
and 1,318 controls of Europeans origin from Mangold et al. [2010]. This combined sample represented 
approximately 95% of all previously reported individuals with NSCL/P [Ludwig et al., 2012]. As a result, 
this meta-analysis supported association with all previously identified loci (8q24.21, 1q32.2, 17q22, 
10q25.3, 1p22, and 20q12) and identified six additional susceptibility regions (1p36, 2p21, 3p11.1, 
8q21.3, 13q31.1, and 15q22). A further study has also recently confirmed previously identified loci on 
chromosome 1p36 and 10q25.3 [Butali et al., 2013]. Therefore, meta-analysis in GWAS may boost the 
power to detect more associations by providing bigger patient and control groups, and enables an 
examination of the consistency or heterogeneity of previously identified associations across diverse 
datasets and study populations [Zeggini and Ioannidis, 2009]. However, in order to identify the true 
causal variants, extensive fine-mapping, targeted re-sequencing, and finally functional analyses are 
required [McCarthy et al., 2008].
Compared to candidate-gene association studies which usually involve a few hundred SNPs at most and 
rely on assumption of the genomic location or the identity of the potential causal variants, the GWAS 
approach is genome-wide and hypothesis-free. However, many issues related to the GWAS approach 
still need to be addressed. GWAS rely on the “common disease, common variant” hypothesis [Reich 
and Lander, 2001]. SNPs used in GWAS are often common SNPs, and therefore they might not have a 
major effect on the phenotype. Larger sample sizes are crucial in order to detect those risk variants that 
have smaller odds ratio and lower allele frequencies. However, large sample sizes may include mixtures 
of ethnic groups and phenotypes. As different ethnic subgroups may differ in disease prevalence, a 
mixture of the ethnic groups may lead to detection of a false-positive association related to ethnicity 
rather than phenotype. In addition, most studies have combined both non-syndromic cleft lip (NSCL) 
and NSCL/P patients as one group, although these two conditions may have different etiological 
mechanisms [Marazita, 2012; Rahimov et al., 2012]. Therefore, the collection of large consistently and 
accurately phenotyped cohorts is the main challenge in GWAS. Another important issue with GWAS is 
to understand the disease mechanism underlying statistically significant GWAS variants. For example, 
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the SNP rs987525 in 8q24 locus has been found to be significantly associated with NSCL/P in various 
studies, but until now it is not understood how exactly this SNP, or other variants co-segregating with 
it, contributes to higher susceptibility to CL/P. As mentioned above, the SNP rs987525 lies within the 
640-kb locus of association on 8q24.21 which is a gene desert. No cis- or trans-regulatory effects have 
been identified for rs987525 or for other SNPs in the same haplotype block. Thus, functional studies 
are necessary to determine the role of the identified SNP in the biological mechanisms and pathways 
of the disease.
Table 2.3 Genome-wide association studies in NSCL/P
Initial sample Replication sample Platform used Region Strongest  
SNP-risk allele
Reference
224 cases,  
383 controls 
(CEU)
462 cases,  
954 controls
(CEU)
Illumina 
HumanHap550V3 
BeadChip
8q24.21 rs987525
[Birnbaum  
et al., 2009b]1q32.2 rs642961
111 cases, 5951 
controls 
(CEU)
NR
Illumina Infinium 
II HumanHap550 
BeadChip
8q24 rs987525
[Grant  
et al., 2009]
401 cases, 1323 
controls 
(CEU)
793 trios 
(CEU)
Illumina Human610-
Quad and 
HumanHap 550k 
BeadChips
8q24 rs987525
[Mangold  
et al., 2010]
10q25 rs7078160
17q22 rs227731
1,908 case-
parent trios  
(825 CEU,  
1038 Asian)
8115 individuals  
(1965 families) 
(CEU, Asian,  
South Asian, South/
Central America)
Illumina  
Human610-Quad  
v.1_B BeadChip
8q24.21 rs987525
[Beaty  
et al., 2010]
1q32.2 rs10863790
20q12 rs13041247
1p22 rs560426
1461 trios  
(Beaty et al., 
2010) and 399 
cases,  
1,318 controls 
(Mangold  
et al., 2010)
Meta-analysis of 
Beaty  
et al., 2010  
and  
Mangold  
et al., 2010.
1p22 rs560426
[Ludwig  
et al., 2012]
1q32.2 rs861020
8q24 rs987525
10q25 rs7078160
17q22 rs227731
20q12 rs13041247
1p36 rs742071
2p21 rs7590268
3p11.1 rs7632427
8q21.3 rs12543318
13q31.1 rs8001641
15q22.2 rs1873147
aNR, not recorded.
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2.5 Exome sequencing
Since 2005 when the first NGS platform was released [Margulies et al., 2005], many NGS platforms 
have become available and applied more and more commonly as gene discovery strategies [Bamshad 
et al., 2011; Veltman and Brunner, 2012]. NGS reduces the cost of DNA sequencing by four orders of 
magnitude relative to Sanger sequencing [Metzker, 2010]. Although the protein-coding regions cover 
less than 2% of the genome, they are estimated to contain the majority of the disease-causing mutations 
in Mendelian disorders. Almost 85% of mutations have been found in coding regions at Mendelian 
loci [Cooper et al., 1995], although this may be somewhat biased as only positive results are typically 
reported. Exome Sequencing (ES) is an efficient NGS method to selectively sequence the coding regions 
(exons) of the genome. Therefore, ES is a powerful and cost-effective tool for understanding the genetic 
basis of diseases that are proven to be difficult to resolve by using traditional gene-discovery methods, 
especially those for which the genetic basis is not evident from the phenotype [Choi et al., 2009]. ES is 
also sufficiently robust to allow the detection of variants in diseases that have variable clinical features 
(phenotypic heterogeneity) or disorders with causal variants in different genes (genetic heterogeneity) 
[Ku et al., 2011]. 
The successful examples include many non- Mendelian diseases such as cancers [Gartner et al., 2013; 
Makishima et al., 2013; Sato et al., 2013; Stephens et al., 2013] and neurodevelopmental diseases 
including autism and intellectual disability [Veltman and Brunner, 2012]. ES analysis sometimes 
starts with Sanger sequencing to pre-screen predicted candidate genes based on the phenotype. If 
mutations are not identified in candidate genes, ES is performed usually in two or more individuals 
depending on the pedigree or patient cohort. Many filters and prioritization criteria can be applied 
to ES data to enrich for causal variants. Filtering and prioritization of variants include the sequencing 
quality (the number of independent reads and read depth), the inheritance model (percentage variant 
reads), whether the variants are localized in the coding regions and whether they are synonymous, 
known or common SNPs, etc. [Gilissen et al., 2011]. These filtering and prioritization steps can also be 
combined with mapping data from SNP arrays or linkage studies. The presence of candidate variants 
and their appropriate segregation is confirmed by Sanger sequencing. Further evidence of causality 
can be obtained by identifying mutations in the same gene in other unrelated but similarly affected 
patients and with the addition of functional analysis. So far, no genes have been identified by ES for 
NSOFCs, whereas a number of genes, including many for syndromes with OFC, have been identified by 
ES [De Ligt et al., 2012; Koolen et al., 2012; O’Roak et al., 2012; Rauch et al., 2012; Roscioli et al., 2012]. We 
have summarized some of these studies where syndromic OFC patients were included in the studies 
(Table 2.4) and discuss one example where CL/P is one of the main features of the condition.
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Table 2.4  ES studies of syndromes where CL/P or CPO* is one of the features in some patients
Disease/Trait Inheritability OFC Enrichment Sequencing Genes Reference
Bartsocas-Papas 
Syndrome
Autosomal 
recessive
CL/P
Agilent SureSelect 
Human All Exon 50 MB 
Kit
SOLiD 4 
sequencer 
(Life 
Technologies)
RIPK4
[Mitchell  
et al., 2012]
Say-Barber-
Biesecker-Young-
Simpson syndrome 
(SBBYSS or Ohdo 
syndrome)
Autosomal 
dominant
CPO
Agilent SureSelect 
Human All Exon 50 MB 
Kit
SOLiD 4 
sequencer 
(Life 
Technologies)
KAT6B
[Clayton-Smith 
et al., 2011]
Nager Syndrome
Autosomal 
dominant/ 
recessive
CPO
CPO
Agilent SureSelect 
Human All Exon 50 MB 
Kit
Illumina 
HiSeq2000 
sequencer
SF3B4
[Bernier  
et al., 2012]
Roche NimbleGen 
Human SeqCap EZ v2.0 
Kit
Illumina 
HiSeq2000 
sequencer
SF3B4
[Czeschik  
et al., 2013]
Kabuki syndrome
Autosomal 
dominant
CPO
Custom array (Agilent) 
covering 31,922,798 
bases
Illumina 
Genome 
Analyzer II 
(GAII)
MLL2
[Ng  
et al., 2010]
Auriculocondylar 
syndrome (ACS)
Autosomal 
dominant
CPO
Roche NimbleGen 
SeqCap EZ v1.0 Kit
Illumina 
GAIIx and 
HiSeq 2000 
sequencer
PLCB4 and 
GNAI3
[Rieder  
et al., 2012]
Mandibulofacial 
dysostosis with 
microcephaly 
(MFDM)
Autosomal 
dominant
CPO
Agilent SureSelect 
Human All Exon  
50 MB Kit
Illumina Hiseq EFTUD2
[Lines  
et al., 2012]
Oto-facial 
syndrome
Autosomal 
recessive
CPO
Roche NimbleGen 
Human SeqCap EZ v3.0 
Kit
Illumina 
HiSeq2000 
sequencer
EFTUD2
[Voigt  
et al., 2013]
Orofaciodigital 
syndromes (OFD 
IV, Mohr-Majewski 
syndrome)
Autosomal 
recessive
CPO
A 5.3 Mb customized 
Agilent SureSelect  
Target Enrichment  
library
SOLiD 4 
sequencer 
(Life 
Technologies)
TCTN3
[Thomas  
et al., 2012]
Sensenbrenner 
Syndrome
Autosomal 
recessive
CPO
Roche NimbleGen 
SeqCap EZ Human 
Exome Library v2.0
Illumina HiSeq WDR35
[Bacino  
et al., 2012]
Hartsfield 
syndrome
Autosomal 
dominant/ 
recessive
CLP
TruSeq Capture kit 
(Illumina)
Illumina 
HiSeq2000 
sequencer
FGFR1
[Simonis  
et al., 2013]
*As CPO is often one of the features in many syndromes, this list of mainly CPO syndromes might not be complete.
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Bartsocas-Papas syndrome is an autosomal recessive disorder characterized by popliteal pterygia, 
ankyloblepharon, filiform bands between the mandible and maxilla, cleft lip and palate, and syndactyly 
[Veenstra-Knol et al., 2003]. ES was performed in a consanguineous family where one of the children 
displayed the features of Bartsocas-Papas syndrome [Mitchell et al., 2012]. An analysis was performed 
using an autosomal recessive disease model and a homozygous nonsense mutation was identified 
in RIPK4, a gene that encodes an ankyrin repeat-containing kinase which is essential for keratinocyte 
differentiation. Subsequently, additional mutated alleles were identified in RIPK4 in an unrelated 
affected individual. Functional analyses demonstrated that RIPK4 is a direct transcriptional target of 
the transcription factor p63 which is also involved in syndromic OFCs [Celli et al., 1999; Van Bokhoven 
et al., 2001; Rinne et al., 2007]. A limited number of ES studies for a condition which includes CL/P have 
been reported to date. There are however many successful examples of ES studies in patients with 
syndromes which include a variable CPO phenotype (Table 2.4). The inheritance of these syndromes can 
be autosomal dominant (e.g., Auriculocondylar syndrome, Kabuki syndrome) or autosomal recessive 
(e.g., Miller syndrome). It is important to note that the identified variants in some of the syndromes 
such as Auriculocondylar syndrome could exhibit incomplete penetrance.
As the costs for ES rapidly decrease, and data analysis strategies improve, ES is becoming the methodology 
of choice in many research and diagnostics laboratories to identify the genetic basis for Mendelian 
disorders. However, many challenges remain for the ES approach. Not all genes can be sequenced due 
to technical issues such as the applied exome enrichment methods, repetitive sequences and GC-rich 
regions [Ku et al., 2012]. Not all conditions can easily be resolved by ES. The success of ES analysis 
methods is also dependent on the inheritance model, the pedigree or patient cohorts, the accuracy 
and reliability of the phenotypic data and the availability of additional information such as mapping or 
linkage analyses. Published ES data confirm that it is a successful approach in families with autosomal 
recessive disorders, whereas for dominant disorders, more affected individuals and even other mapping 
information seem to be necessary [Gilissen et al., 2011]. Furthermore, lack of penetrance is an additional 
factor that may complicate the analysis of families with autosomal dominant OFCs [Dixon et al., 2011]. 
This may raise an intriguing question of the applicability of ES trio studies in orofacial disorders. ES of 
parent–child trios have been demonstrated as a powerful approach to identify de novo mutations in 
various diseases, which may be causative in a dominant model of inheritance [Bamshad et al., 2011; Xu 
et al., 2012; Chesi et al., 2013; Zaidi et al., 2013]. However, to our knowledge, this approach has not yet 
been applied to selected cohorts of OFC patients, possibly due to the often incomplete penetrance and 
heterogeneity in presentation of OFCs [Dixon et al., 2011]. As the genetic basis of isolated OFC is more 
complex and may be significantly influenced by non-genetic/environmental factors, ES is currently not 
applied to large numbers of isolated OFC patients as GWAS may be the most appropriate methodology 
to identify causative variants. However, ES might be a powerful approach in selected OFC families with 
multiple affected individuals in a Mendelian inheritance pattern to identify novel causative genes.
520163-L-bw-Khandelwal
Processed on: 6-6-2018 PDF page: 33
33Genomic approaches for studying craniofacial disorders  | 
2
2.6 Genetic variants in the non-coding genome
Genetic studies of human diseases have so far been mainly focused on protein-coding genes that 
represent 2% of the human genome. The functional relevance of the non-coding genome has not been 
explored in detail in most diseases. However, non-coding regions in the genome clearly play important 
roles in human diseases. For example, Pierre Robin sequence which manifests with a U-shaped cleft 
palate and mandibular micrognathia, has been reported to be secondary to disruption of non-coding 
regulatory elements for SOX9 in some cases [Benko et al., 2009]. In GWAS, the vast majority of the disease- 
or trait-associated SNPs are found outside protein-coding regions (>80%) [Manolio et al., 2009]. It has 
become clear that disturbance of gene regulation during development of the embryo can give rise to 
developmental disorders such as OFC. Orchestrated control of gene expression is often regulated by 
elements in the non-coding regions of the genome, the arrangement of the chromosomes and nuclear 
domains. These aspects have recently been characterized by the large scale (epi-) genomics projects 
such as ENCODE [Dunham et al., 2012] and NIH Roadmap Epigenomics [Bernstein et al., 2010]. 
One of the functional non-coding elements is non-coding RNAs (ncRNA). Different types of ncRNAs, 
including long non-coding RNAs (lncRNA) and microRNAs (miRNA) have been shown to regulate gene 
expression and potentially linked to human diseases [Calin et al., 2005; Hirota et al., 2008; Sahoo et 
al., 2008; Mencia et al., 2009; Batista and Chang, 2013]. Relevant to OFC, most miRNA studies have 
been performed in model systems showing that several miRNAs play a role in palatogenesis and gene 
regulation in orofacial tissues [Eberhart et al., 2008; Mukhopadhyay et al., 2010; Sheehy et al., 2010; Nie 
et al., 2011]. In one study of NSCPO in the Chinese population, a SNP in the precursor of miRNA-140 that 
is involved in dispersion and migration of neural crest cells during palatogenesis was shown to lead to 
increased risk for NS cleft palate in the Chinese population [Li et al., 2010]. Genomic studies in OFCs 
should therefore also include the analysis of miRNAs.
In addition to ncRNAs, non-coding regulatory elements, sometimes acting over long distances, have 
been also associated with developmental diseases including orofacial abnormalities [Benko et al., 2009; 
Anderson et al., 2012; Spielmann et al., 2012]. For many years, the identification of these non-coding 
functional elements was mainly based on the evolutionary (ultra-) conservation of these sequences, 
with one excellent example in OFC research. In a study by Rahimov and colleagues, the protein-
coding and splice-site regions of IRF6 were sequenced in 160 individuals with NSCL/P, and no obvious 
causative variants were detected [Rahimov et al., 2008]. Therefore, the authors searched for possible 
regulatory elements within an approximately 140 kb linkage disequilibrium (LD) block around IRF6 
where an NSCL/P-associated SNP rs2235371 lies [Birnbaum et al., 2009b]. In this genomic region, they 
identified 41 multispecies conserved sequences (MCSs). A SNP rs642961 identified in one of the MCSs 
(MCS9.7) showed significant differences in allelic frequencies and genotypic distribution between 
patients with CLO and controls and was in strong LD with the SNP rs2235371. To understand the 
underlying mechanism of MCS-9.7 and the SNP, transcription factor binding analyses such as Chromatin 
Immunoprecipitation (ChIP) were performed and data showed that this risk allele alters DNA binding of 
AP-2α, a transcription factor involved in craniofacial development. In a mouse transgenic experiment, 
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gene expression controlled by the MCS-9.7 region was consistent with the expression pattern of the 
endogenous Irf6, which suggested that the MCS-9.7 region functions as an enhancer element for IRF6 
expression. This study thus showed proof-of-principle that a non-coding regulatory element could play 
a role in pathogenesis of OFCs.
Figure 2.1 Model of disease mechanism of CL/P associated with TP63 mutations and p63-dependent 
regulatory elements. A: Proper regulation of CL/P genes through binding of p63 near CL/P genes. B: Disruption 
of p63 binding near CL/P genes due to mutations in p63 leading to CL/P, for example, in EEC syndrome. C: 
A p63 binding site upstream to IRF6 functions as a regulatory element for IRF6 expression. A variant in this 
region gives rise to increased risk of CLO. D: In loci associated to CL/P identified by GWAS, SNPs identified with 
the highest risk might not be functionally relevant to CL/P. Instead, SNPs in some p63 binding sites in these 
loci which are in LD with the highest risk alleles could be the true etiological variants. BS, binding site; MCS, 
multispecies conserved site.
Although evolutionary conservation has been successful in some examples for the identification of 
causative variants in non-coding genomic regions, it is evident that non-coding regulatory elements 
are not always conserved [Blow et al., 2010; Schmidt et al., 2010], and that factors controlling regulatory 
elements may not easily be deduced from genomic sequences. The fast-developing genomic 
technology has provided opportunities to study gene regulation with an unprecedented speed. For 
example, in a ChIP-seq study to map the genome-wide p63 DNA binding profile, a p63 binding site 
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was found to co-localize with the regulatory region MCS9.7 that functions as an enhancer element of 
IRF6 [Thomason et al., 2010], suggesting that p63 and AP-2α co-regulate IRF6 expression. Disturbance 
of the fine-tuned expression of IRF6 and other OFC genes by sequence variants in regulatory elements 
could lead to OFCs (Figure 2.1C). Therefore, a systematic study of non-coding regulatory elements such 
as p63 and AP-2α binding sites and regulated gene expression of OFC genes will be of great interest for 
understanding orofacial development and related pathogenesis. Such studies will assist in resolving 
OFCs with currently unknown genetic bases, and provide mechanistic insights for genomic loci that 
show statistically significant association in CL/P GWAS (Figure 2.1D).
2.7 Genome sequencing and future perspectives
Genome Sequencing (GS) has been used in several studies to identify genes for human diseases 
[Morin et al., 2013; Shi et al., 2013; Zhang et al., 2013]. Studies also showed that GS data can be used 
for CNV analyses [Xie and Tammi, 2009] and for studying the combined effect of common and rare 
variants in association studies [Aschard et al., 2011]. Up until now, most GS studies have focused on 
the coding regions, mainly due to the difficulties in the interpretation of the non-coding genomic 
regions. As the 1000 Genome Project proceeds, common and rare genetic variants in individuals from 
different populations are being identified by GS and ES and have become accessible to the public 
[Abecasis et al., 2012]. However, the acquisition of sequences alone is not sufficient for understanding 
the etiology of developmental diseases, especially for diseases with heterogeneous phenotypes that 
are caused by multiple genetic and environmental factors such as OFCs. The addition of multilayered 
information is required. At the individual and population levels, more patients with different ethnic 
backgrounds and with more detailed phenotyping are important. At the molecular and cellular levels, 
-omics studies including genomics, epigenomics, transcriptomics, and proteomics in various cells 
and tissues will assist in elucidating the underlying mechanisms of these diseases. In this respect, the 
international consortiums ENCODE and Roadmap Epigenomics projects have provided global maps 
of regions of transcription, functional cis-regulatory DNA elements, chromatin structure and genomic 
organization in a large number of cell lines and tissues [Bernstein et al., 2010; Dunham et al., 2012]. 
Epigenomic profiling of enhancer-associated chromatin features such as occupancy of co-activator 
(e.g., p300) binding, DNaseI hypersensitivity sites and enrichment of certain histone marks allows 
the genome-wide identification of cell-type specific enhancers [Maurano et al., 2012; Thurman et al., 
2012]. Gene transcription is also regulated in a higher order of chromatin structure within domains, and 
chromosomal interaction assays such as 4C [Splinter et al., 2012; Van de Werken et al., 2012], 5C [Sanyal 
et al., 2012], Hi-C [Dixon et al., 2012; Dekker et al., 2013], and ChIA-PET [Fullwood et al., 2009; Handoko 
et al., 2011; Li et al., 2012] have shown that enhancers can regulate gene expression from a distance. 
The data provided by these consortia enable interpretation of functionality of the non-coding genome 
and of rare variants in the non-coding regions generated by GS in studies of Mendelian disorders. 
Furthermore, ENCODE data have shown that functional SNPs localized in regulatory elements can be 
associated with phenotypes either through direct implication from GWAS or indirectly through linkage 
disequilibrium with a GWAS association [Schaub et al., 2012]. Therefore, multi-layered epigenomic 
520163-L-bw-Khandelwal
Processed on: 6-6-2018 PDF page: 36
36 | Chapter 2
profiling data obtained in relevant cell types can also be used to dissect the disease mechanisms 
underlying GWAS signals detected in complex diseases such as OFC.
2.8 Conclusions
In the past 20 years, genetic studies of human diseases have evolved from low-resolution cytogenetic 
techniques (G-banding, FISH, and CGH) and candidate gene-based molecular analyses to the state-
of-the-art genome-wide arrays (CNV and GWAS) and NGS (ES and GS) at single nucleotide resolution. 
These techniques have been developed and used to examine genetic variants at different levels in 
various disease models including syndromic and NSOFCs. Although the classical genetic tools are still 
utilized and informative, the fast-developing sequencing technology has made ES feasible, and soon 
GS is also likely to become routine in many research labs and diagnostic settings. Large international 
collaborations and consortia with combination of different expertise have been set up to obtain 
sequences at the base pair level in healthy and diseased individuals from different populations and 
to understand the functional relevance of detected variants. These efforts need to be continued and 
expanded. The establishment of a disease encyclopedia is the prerequisite for prediction, prevention 
and treatment of diseases and for the realization of personalized medicine.
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Abstract
Purpose: We aimed to identify novel deletions and variants of TP63 associated with orofacial clefting 
(OFC).
Methods: Copy-number variants were assessed in three OFC families using microarray analysis. 
Subsequently, we analyzed TP63 in a cohort of 1072 individuals affected with OFC and 706 population-
based controls using Molecular Inversion Probes (MIPs).
Results: We identified partial deletions of TP63 in individuals from three families affected with OFC. 
In the OFC cohort, we identified several TP63 variants predicting to cause loss-of-function alleles, 
including a frameshift variant (p.Ser189Serfs*6) and a nonsense variant (p.Gln333*) that introduces a 
premature stop codon in the DNA-binding domain. In addition, we identified the first missense variants 
in the oligomerization domain (p.Val405Met), which occurred in individuals with OFC. This variant was 
shown to abrogate oligomerization of mutant p63 protein into oligomeric complexes, and therefore 
likely represents a loss-of-function allele rather than a dominant-negative. All of these variants were 
inherited from an unaffected parent, suggesting reduced penetrance of such loss-of-function alleles.
Conclusion: Our data indicates that loss-of-function alleles in TP63 can also give rise to OFC as the 
main phenotype. We have uncovered the dosage-dependent functions of p63 which were previously 
rejected.
3.1 Introduction
Transcription factor p63 encoded by TP63 is a key regulator in epithelial commitment and development.1,2  
TP63 encodes a large number of p63 isoforms. The two different transcription start sites give rise to 
transactivation (TA) isoforms, which contain a TA domain and to ΔN isoforms which lack the canonical 
TA domain, but contain an N-terminal transactivation-competent domain, called TAΔN. Alternative 
splicing at the 3’ end of the gene adds to the complex variety of p63 isoforms by generating at least 
five different C-terminal ends (α, β, γ, δ, and ε).3–5 All isoforms contain a DNA-binding domain (DBD) and 
an oligomerization domain (OD), but differ in the TA domain, sterile-alpha-motif domain (SAM), auto-
regulatory transactivation inhibiting domain (TI domain), and a second TA domain, TA2 (Figure 3.1).3,4,6 
p63 is engaged in dimeric and tetrameric complexes regulating a network of genes important for 
development of ectodermal structures. Mutations in TP63 lead to three major phenotypes: ectodermal 
dysplasia, orofacial clefting (OFC) and split-hand/split-foot malformations (SHFM).7 Heterozygous TP63 
mutations have been associated with five different syndromes with overlapping phenotypic features. 
These syndromes are: Ectrodactyly, Ectodermal dysplasia, and Cleft lip/palate syndrome 3 (EEC3 [MIM: 
604292]8), Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC [MIM: 106260]), Rapp-
Hodgkin syndrome (RHS; MIM: 129400), Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT [MIM: 
520163-L-bw-Khandelwal
Processed on: 6-6-2018 PDF page: 50
50 | Chapter 3
103285]), and Limb mammary syndrome (LMS [MIM: 603543]). Rare TP63 mutations are causative for 
nonsyndromic orofacial clefting (OFC8 [MIM: 129400])9, and for nonsyndromic SHFM4 (MIM: 605289)10.
So far, a broad spectrum of different heterozygous mutations has been reported in TP63, leading to 
the developmental disorders stated above. The vast majority of mutations give rise to amino acid 
substitutions. A striking genotype-phenotype correlation for TP63 missense mutations is apparent 
in EEC and AEC syndromes.10–12 Mutations causing EEC syndrome are almost exclusively found in 
the DBD, whereas the mutations causing AEC syndrome are either found in the SAM and TI domains 
or in the TAΔN domain of the ΔN isoforms. This distinctive pattern of mutations highlights specific 
pathogenic mechanisms for each syndrome. The EEC mutations which are heterozygous and found 
in DBD abolish the DNA binding fully or partially in all p63 isoforms, and affect the transactivation 
capacity of the protein in a dominant-negative fashion.7 This is in agreement with the fact that p63 
acts as a transcriptional regulator in homomeric complexes. The AEC mutations in the SAM domain 
also affect the transactivation activity in a dominant-negative way.11 The ADULT syndrome mutations 
uniquely affect amino acid Arginine 337 (298 according to former nomenclature). Arginine 337 also 
maps to the DBD like in EEC syndrome mutations, but exerts gain-of-function effects by conferring 
novel transactivation properties to the ΔNp63γ isoform.13
Rare mutations have been reported that lead to truncations at the C-terminal end of the α isoform12 
and at the N-terminal end of the TA isoform in individuals affected with AEC14. All of these mutations 
are shown or predicted to give rise to mutant proteins carrying N-terminal or C-terminal truncations 
but fully maintain their DNA-binding and oligomerization domains. Thus, these mutations do not lead 
to haploinsufficient alleles. Few individuals with a constitutive terminal deletion of the long arm of 
chromosome 3 encompassing TP63 along with other genes have been reported, who did not have the 
typical p63-related phenotype.15 Also, mice carrying heterozygous deletion of Trp63 present no p63-
related phenotype, whereas homozygous Trp63 knockout mice present features similar to EEC, AEC and 
LMS syndrome.1,3 Taken together, the spectrum of mutations affecting TP63 has led to the rejection of a 
haploinsufficiency model7, and supported the notion that TP63 mutations exhibit dominant-negative 
and gain-of-function effects.7,9-12
In the current study, we identified deletions of TP63 in individuals from three families affected with 
OFC and/or hypodontia and occasional other ectodermal features. We also identified two mutations 
that are predicted to lead to a premature stop codon in individuals affected with nsOFC. Finally, we 
identified the first missense mutations in the OD, one of which was shown to abrogate oligomerization 
of mutant p63 protein into oligomeric complexes. Together, our data provide evidence for loss-of-
function variants in TP63, giving rise to a phenotype dominated by orofacial clefting.
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3.2 Materials and methods
3.2.1 Subjects
Probands from three families were referred to a Clinical Genetics Center because of the presence of 
cleft lip palate. Standard diagnostic testing was offered, including microarray-based CNV analysis. A 
CNV affecting TP63 was identified in three families.
In family W11-4934, a 53-year-old male (II4) and his 55-year-olds brother (II3), third and fourth child 
from Dutch non-consanguineous parents, were born with a cleft lip and cleft palate (CLP), and 
showed hypodontia and nail hypoplasia (Figure 3.2, Table 3.1). Their parents are of Caucasian origin. 
Interestingly, seven family members (I1, II2, II5, III1, III2, III4, III5) demonstrated a variety of clinical 
features that might be related to the mutant TP63 phenotypic spectrum, ranging from prominent to 
very subtle ectodermal symptoms. Most striking were the hypodontia and tooth anomalies in most 
affected family members and the choanal atresia in a daughter of the eldest male with CLP (III2), and 
in one affected sister (II5) and her offspring (III4, III5). Both children (III4, III5) had coarse fair hair. The 
mildest features in affected family members (I1, II2) were hypoplastic nails and dry skin. To the best of 
our knowledge, Nabothian cysts, epithelial inclusion cysts of the cervix, were not previously reported 
as p63-related features. No congenital limb anomalies, lacrimal duct abnormalities, ankyloblepharon 
nor intellectual disability were present in affected members. 
In family W12-0831, a 37-year-old male (IV3), the only child of non-consanguineous Dutch parents with 
a Caucasian origin, was born with a unilateral cleft lip and cleft palate and showed a mild hypodontia, 
with agenesis of three teeth (Figure 3.2, Table 3.1). The mother (III4) was born with a cleft palate. Family 
history revealed two additional family members (III3, V5) with a cleft lip and cleft palate. In addition, two 
family members (II2, IV1) were born with a duplicated thumb. In one family member (II4), a duplication 
of the thumb was suspected. SHFM or other limb anomalies were not reported. There was no history 
of ankyloblepharon, lacrimal duct anomalies, or ectodermal involvement in affected family members, 
except for dry skin in the mother (III4). No intellectual disability was present.
Finally, in family W16-065 the affected individual is a now 33-year-old woman, born as the second of 
four children of non-consanguineous Danish parents. She was born with a unilateral cleft lip and cleft 
palate. She had several teeth extracted and had mandibular surgery for correction of asymmetry and 
overbite. She was also diagnosed with lichen sclerosus.
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Table 3.1 Summary of phenotypic features of the three families with deletions of TP63
Family 
number
Individual 
ID
Orofacial  
clefting
Dental  
phenotype
Additional features
W11-4934
I1 – unknown
Hypoplastic nails, Plantar Hyperkeratosis,  
coarse hair, Skin cancer
II2 – Hypodontia Hypoplastic nails, Psoriasis
II3 CLP (bilateral) Hypodontia Hypoplastic nails, Plantar Hyperkeratosis
II4 CLP (unilateral) Hypodontia
Hypoplastic nails, 
Plantar Hyperkeratosis Pyloric stenosis
II5 – –
Choanal atresia (unilateral), psoriasis,  
Plantar Hyperkeratosis, Coarse hair,  
Nabothian cervix cysts SADNI
III1 – Hypodontia Unknown
III2 – Hypodontia Choanal atresia (unilateral)
III4 –
Taurodontism upper 
molars
Choanal atresia (unilateral), psoriasis,  
fair coarse hair
III5 –
Duplicated upper 
incisor, broad dental 
pulp incisor
Choanal atresia (unilateral), fair coarse hair, 
mandibular hypoplasia, low IgA
W12-0831
II2 – – Duplicated thumb
II4 – – Duplicated thumb
III3 CLP – –
III4 CPO – –
IV1 female – – Dry skin, duplicated thumb
IV3 CLP (unilateral) Hypodontia –
V1 CLP – –
W16-065 II1 CLP (unilateral)
Several teeth extracted 
and had mandibular 
surgery for correction of 
asymmetry and overbite
Lichen sclerosus
CLP: Cleft Lip with or without cleft palate; CPO: Cleft Palate only; SADNI: Selective Antibody Deficiency with Normal 
Immuneglobulins.
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Figure 3.1 Schematic representation of the deletions and point variants in TP63 identified in affected 
individuals and controls. The upper part of the figure depicts the complete deletions and the genes covered 
by deletions in the three families, W11-4934, W12-0831, and W16-065 respectively. The middle part of the 
figure presents a zoom-in image of the TP63 gene depicting the deletions in the families at the exon level and 
the splicing routes for various isoforms. The lower part of the figure shows the protein structure highlighting 
the various domains between different isoforms, with the variants in affected individuals and controls 
indicated.
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Figure 3.2 Pedigree structure of the three OFC 
families carrying a deletion affecting the TP63 
gene. Black symbols indicate those individuals who 
are clinically affected with OFC and/or other features 
of ectodermal dysplasia. A complete overview of 
clinical features for each individual is provided 
in Table 3.1. Individuals used for SNP microarray 
analysis are indicated by the arrow. Individuals with 
underlined identifiers were tested by qPCR (Table 
S3.2) for the presence of the deletion, which was 
confirmed in all cases.
A cohort of 1072 individuals affected with OFC and 706 population-based controls was analyzed for 
variants in TP63 using Molecular Inversion Probes (MIPs) sequencing. All of these individuals were of 
European ancestry. The OFC cohort included 647 Cleft Lip and cleft Palate (CLP), 194 Cleft Palate only 
(CPO), 127 Cleft Lip Alveolus (CLA), and 104 Cleft Lip only (CLO) affected individuals. The MIPs analysis 
involved subjects from Bonn, Leuven, and Nijmegen as part of a larger project in which other genes 
were also analyzed.16 Approval was obtained from the Institutional Review Boards of the respective 
University Hospitals. Informed consent was obtained from all individuals who participated in the study.
3.2.2 CNV microarray analysis
We assessed copy-number variations in the three families by genome-wide high resolution cytogenetic 
array analysis (CytoScan HD, Affymetrix, Santa Clara, CA, USA). Data analysis was performed with the 
Chromosome Analysis Suite software (ChAS, Affymetrix; V3.0.0.42) using default settings (Table S3.1).
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Confirmation of the identified deletions and their segregation within families was carried out by 
quantitative PCR (qPCR). SYBR green-based genomic real-time qPCR analysis was performed on a 7500 
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) by using Power SYBR Green PCR Master 
Mix (Applied Biosystems) according to the manufacturer’s instructions. Primers were developed by the 
Primer3 program (Table S3.2) and validated as previously described.17
3.2.3 MIPs sequencing
All seventeen coding exons of TP63 were sequenced using a total of 40 molecular inversion probes 
(MIPs; Supplemental spreadsheet), which represented a subset of MIPs that were part of a previously 
performed experiment.18 The final pooled MIPs libraries were run on a NextSeq500 sequencer (Illumina, 
San Diego, CA, USA) using 2x79bp reads. Data was analyzed with an in-house analysis pipeline.16 The 
identified variants from affected individuals and control cohorts were filtered for quality-by-depth 
higher than 500, rare (dbSNP freq ≤ 0.1 and <5 samples in MIPs screen), non-synonymous variants with 
CADD PHRED-like score >15 (Table 3.2, Figure 3.1).19 Alamut® Visual was used to evaluate the effect 
of the variants using genetic and genomic information from different sources (phyloP, Grantham, 
SIFT) as described. The variants in affected individuals were validated using Sanger sequencing and 
segregation analysis was performed in all available family members.
3.2.4 Analysis of functional effects of missense mutations in the oligomerization 
 domain
The thermal shift assay was performed using an iCycler IQ Real Time PCR Detection System (Bio-Rad, 
Hercules, California, USA). Highly concentrated protein samples were diluted at least 100-fold into the 
measurement buffer (10 mM Na-Phosphate, 140 mM NaCl, pH 4.5) to a final concentration of 20 µM. 
36 µl of protein solution was combined with 4 µl of a 1:200 dilution of SYPRO Orange (ThermoFisher, 
Waltham, Massachusetts, USA). Samples were measured in MicroAmp Optical 96-well plates 
(ThermoFisher, Waltham, Massachusetts, USA). Temperature was increased a rate of 1°C/min while 
fluorescence measurements were taken at 0.2°C increments. The resulting data was smoothed by a 
rolling average over 5 data-points. The first derivative of the result was plotted to obtain the melting 
point. The experiment was performed in duplicates. Analytical SEC of Rabbit Reticulocyte Lysate 
expressed ΔNp63α variants was done as described previously.20
3.2.5 Constructs and site directed mutagenesis
Modified pcDNA3 vectors, containing various forms of human and mouse TP63 were used to create the 
mutations identified by MIPs analysis (Table 3.2). Mutations were created through polymerase chain 
reaction, using Phusion® High-Fidelity DNA Polymerase (New England Biolabs, Thermo Scientific) and 
PAGE purified primers containing the mutations. The PCR program consisted of an initial denaturation 
at 95°C for five minutes followed by 18 cycles of 30 seconds denaturation at 95°C, one minute annealing 
at 55°C and 7 minutes extension at 68°C. This was followed by final extension at 68°C for 5 minutes.
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3.2.6 Cell culture and transfection
The Saos-2 cell line, which lacks endogenous p63, was maintained in Gibco™ Dulbecco’s modified Eagle’s 
medium (DMEM) (Thermo Fisher Scientific, Waltham, Massachusetts, USA) with 10% fetal bovine serum, 
1% sodium pyruvate at 37°C, 5% CO2. For transfection, approximately 2*10
5 cells were seeded into one 
well of a 6-well tissue culture plate. Cells were transfected with the pcDNA, a mammalian expression 
vector containing mutant TP63, Renilla pRL-SV40 reporter vector and modified pGL3 enhancer vector 
(Promega, Fitchburg, Wisconsin, United States) containing a TP63 binding site that has been shown 
before to work as an enhancer.21 Effectene™ Transfection Reagent (Qiagen, The Netherlands) was used 
as per the protocol described previously.14 pcDNA vector containing wild type inserts of TP63 isoforms 
were used as negative control and pcDNA vector with mutated TP63 containing p.Arg343Trp was used 
as positive control.14
3.2.7 Transactivation assays
Twenty-four hours after the transfection, subconfluent cells were collected for luciferase (transactivation) 
assay. Cells were lysed and the luciferase assay was performed using the Dual Luciferase assay system 
(Promega, Fitchburg, Wisconsin, United States) according to the manufacturer’s instructions. For the 
measurements a Lumat LB 9507 (Berthold Technologies, Germany) was used. The level of activation 
was calculated in comparison with transfection with an empty pcDNA3 vector. Data were normalized 
to the Renilla reporter signal.14
3.3 Results
Using CNV microarray analysis at our diagnostics services, deletions encompassing parts of the TP63 
gene were identified in three families (Figure 3.1, Table S3.1, Figure S3.1A). Family W11-4934 contained 
a deletion of ~528kbp at 3q28, affecting TP63, CLDN1 and CLDN16. The proximal endpoint of the 
deletion in TP63 was identified between exon 13 and 14 using qPCR (Figure S3.1B). The segregation 
of the deletion was confirmed in other affected individuals in the family. Family W12-0831 contained a 
deletion of ~810kbp at 3q28, affecting TP63, CLDN1, CLDN16 and TMEM207. The deletion was confirmed 
to segregate in another affected member of the family. Family W16-065 contained a deletion of 
~880kbp at 3q28, affecting TP63, and TPRG1. This deletion was confirmed to be de novo. 
3.3.1 TP63 variants identified in individuals affected with OFC 
All of the samples (1072 OFC, and 706 population-matched controls) had an average coverage >1000-
fold over all TP63 targeting MIPs. The average coverage for the samples from affected individuals (1010-
fold) and controls (1023-fold) was comparable. In total seven variants were identified in the individuals 
affected with OFC and four in the controls. All of the latter variants were missense substitutions, of 
which three were present in the DBD and one in the TA domain. Each of the seven variants identified 
in OFC individuals were present in a single person and were not found in controls (Table 3.2). These 
variants were located in different domains of p63, i.e. the DBD, OD, and TA2 domains. Among these 
variants we found several variants which represent loss-of-function alleles, including frameshift and 
stop variants in DBD and missense variants in OD.
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3.3.2 The frameshift and stop variants in DBD
Amongst the confirmed TP63 variants are two mutations that predict the generation of premature stop 
codons. Variant c.567_574del (p.Ser189Serfs*6) was identified in an individual with a unilateral cleft 
lip and alveolus on the left, and in his/her unaffected parents. This deletion was paternally inherited 
and creates a frameshift starting at codon Ser189 and a new reading frame that ends in a stop codon 
six positions downstream. Different from previously reported premature stop mutations, the mutant 
transcript is likely to be targeted for nonsense mediated decay (NMD) (Table 3.2). The other premature 
stop variant is a c.997C>T nonsense variant predicting a premature stop codon p.Gln333* in the DBD. 
This variant was identified in an individual with bilateral CLP. Due to unavailability of parental DNA, it 
could not be confirmed whether the variant was inherited or occurred de novo. This premature stop 
codon is also predicted to lead to NMD (Table 3.2).
3.3.3 Missense variants in the oligomerization domain of p63
The two variants identified in the oligomerization domain of the p63 protein are c.1213G>A 
(p.Val405Met) and c.1223G>A (p.Arg408His). The variant p.Val405Met was identified in an individual 
with a cleft lip and alveolus on the left side. The variant inherited from an unaffected parent occurs at 
a moderately conserved nucleotide (phyloP: 3.76) and affects an amino acid conserved up to frog. A 
small physicochemical difference exists between the reference amino acid valine and the variant amino 
acid methionine (Table 3.2). The other variant in the OD, p.Arg408His, was identified in an individual 
with a cleft lip and alveolus (left), and a split velum and uvula (hard palate intact), with unaffected 
parents. This known rare variant, rs751698974 (MAF=0.000008; ExAC database), was inherited from an 
unaffected parent. It occurs at a highly conserved nucleotide (phyloP: 4.40) and affects an amino acid 
conserved up to zebrafish. The physicochemical difference between the reference amino acid arginine 
and the variant amino acid histidine is small (Table 3.2). 
3.3.4 Other missense variants in affected individuals 
Besides the above-mentioned variants, three other missense variants were identified in affected 
individuals. The c.670G>A (p.Val224Ile) in DBD was identified in an individual with bilateral CLP with 
unaffected parents. This is a known rare variant, rs757669482 (MAF=0.000008; ExAC database). This 
paternally inherited variant occurs at a highly conserved nucleotide (phyloP: 4.32) and affects an amino 
acid conserved up to zebrafish. The physicochemical difference between the reference amino acid 
valine and the variant amino acid isoleucine is small (Table 3.2). The variant c.1459C>T (p.Arg487Cys) 
in the TA2 domain of p63 was identified in a CLP individual with unaffected parents. This is a known 
rare variant, rs777306829 (MAF=0.0001; ExAC database). This maternally inherited variant occurs at a 
moderately conserved nucleotide (phyloP: 2.87) and affects an amino acid conserved up to zebrafish. 
The physicochemical difference between the reference amino acid arginine and the variant amino acid 
cysteine is large (Table 3.2). Finally, one γ form specific variant, c.1390C>T (p.Arg464Trp), was identified 
in an individual with cleft lip and alveolus of the left side, with unaffected parents. The variant was 
maternally inherited and present in exon 10’. This is a known rare variant, rs369826042 (MAF=0.0001), 
with ExAC frequency 0.00004. It occurs at a weakly conserved nucleotide (phyloP: 1.66) and affects a 
weakly conserved amino acid. There is a moderate physicochemical difference between the reference 
amino acid arginine and the variant amino acid tryptophan (Table 3.2).
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3.3.5 Isomerization domain variant p.Val405Met affects p63 oligomerization 
A thermal shift assay (TSA) was performed to determine whether the stability of the mutant 
tetramerization domains was affected compared to the wild type protein (Figure 3.3). The p.Val405Met 
variant indeed leads to a significant reduction of the unfolding equilibrium temperature by ~24°C, 
while the p.Arg408His variant causes only a slight reduction in melting temperature. Investigation 
of the oligomeric state of the mutant domains by size exclusion chromatography revealed that the 
p.Val405Met variant tetramerization domain is less stable than the wild type domain showing a 
significant dimer population. In contrast, no reduction in the population of the tetrameric state could 
be detected for the p.Arg408His variant. 
Figure 3.3 Melting points of different tetramerization domain mutants and wild type. The melting point 
of the wild type p63 tetramerization domain (blue line) as well as the p.Val405Met (orange line) and the 
p.Arg408His (grey line) variants was determined by a thermal shift assay. Due to the extraordinary stability of 
the tetramerization domains the pH had to be shifted to 4.5 to ensure melting in a temperature range which is 
accessible to this assay. Under these conditions the measured melting temperatures were 85.6±0.1°C for the 
wild type tetramerization domain, 51.6±2.5°C for the p.Val405Met variant and 82.1±0.1°C for the p.Arg407His 
variant. The reduction in stability of the p.Val405Met variant is also reflected in a shift of ΔNp63α from a clear 
tetramer in wildtype protein towards a dimer-tetramer mix in the p.Val405Met variant on analytical SEC.
520163-L-bw-Khandelwal
Processed on: 6-6-2018 PDF page: 60
60 | Chapter 3
3.3.6 Isomerization domain variant p.Val405Met decreases the transactivation 
 capacity of p63
A transactivation assay was performed to analyze the effects of the variants identified in this study. The 
fold induction of a luciferase reporter gene under control of a minimal promoter and p63 binding site 
was compared between the empty pcDNA vector and the p63WT vector.21 One of the identified variants, 
p.Arg464Trp, was specific to p63γ isoforms. In this case, the variant was created in the ΔNp63γ isoform, 
which contains a smaller but transactivation-competent domain, called TAΔN. The measurements of 
all constructs was normalized to the respective p63WT construct. A clear luciferase induction was 
measured for all p63WT constructs compared to the empty pcDNA vector (Figure 3.4). This means that 
the WT p63 protein binds to the TP63 enhancer element and induces the expression of downstream 
luciferase. For the positive control, a mutation p.Arg343Trp in p63 known to cause EEC syndrome was 
used, which has been previously shown to reduce transactivation activity in a dominant-negative 
pattern (Figure 3.4).7 
The EEC-associated mutation p.Arg343Trp reduced the induction of the luciferase reporter by 
82% (P-value=0.011) (Figure 3.4). The previously published variant p.Arg352Gly identified in an 
individual affected with nsOFC was also tested.9 This variant, which resides in the DBD, reduced 
transactivation activity by 63% (P-value=0.025) (Figure 3.4). The two variants in OD, p.Val405Met and 
p.Arg408His reduced the activation of luciferase reporter, but only by 32% (P-value=0.048) and 10% 
(P-value= 0.094), respectively (Figure3. 4). These data are consistent with our results from structural 
studies of these variants/functional characterization (Figure 3.3). The remaining variants identified in 
affected individuals were also tested and were found not to affect the activation drastically (Figure 
S3.2). 
Figure 3.4 Transient transfection assay 
(luciferase induction) for the OD variants. 
The fold inductions for the different mutant 
constructs are calculated relative to the 
WT isoform. p.Arg343Trp, an EEC causing 
mutant was used as control. p.Val405Met 
and p.Arg408His are the two OD variants 
tested. p.Arg352Gly, the only variant 
previously found responsible for nsOFC was 
also tested. The data are represented as the 
mean ± SEM.
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3.4 Discussion
So far, the mutations identified in TP63 which lead to various developmental disorders were found 
to have dominant-negative or gain-of-function effects only. Also, individuals identified earlier with 
deletions including TP63 did not present the typical features seen for TP63 mutations.11,13 In this study, 
we report three families with deletions encompassing part of the TP63 with affected individuals 
presenting OFC, hypodontia, nail abnormalities, and other phenotypic features (Figure 3.2, Table 3.1). 
This is inconsistent with the earlier notion that TP63 does not function in a dosage dependent manner. 
We also report seven variants in individuals affected with nsOFC identified using MIPs analysis. These 
seven variants identified in the affected individuals were not seen in the control cohort. These variants 
include two variants (p.Ser189Serfs*6 and p.Gln333*) in the DBD predicting a premature stop which 
can lead to complete loss-of-function by NMD or otherwise the ablation of most of the critical p63 
protein domains, including DBD, OD, SAM and TI domains. Two variants that were identified in the 
OD (p.Val405Met and p.Arg408His) were shown to cause partial loss-of-function in the transactivation 
assay (Figures 3.3, 3.4).
The mutations identified so far in the individuals affected with p63 syndromes lie outside the OD. 
Interestingly, the two OD variants reported in this study were identified in individuals affected 
with nsOFC who presented no additional TP63-related phenotype. This difference in distribution of 
variants between nsOFC and p63 syndromes revealed different pathogenic mechanisms in syndromic 
versus nonsyndromic conditions. The two variants in OD, p.Val405Met and p.Arg408His, reduced the 
activation of luciferase reporter by 32% and 10% respectively, whereas the other variants identified in 
the study lead to no or only a slight increase compared to the respective wild-type isoforms (Figure 
3.4). We propose a model to explain the functional effects of different kinds of mutations in p63. The 
normal tetrameric complex with all wildtype p63 molecules leads to a normal level of transactivation. 
A heterozygous dominant-negative mutation in TP63, as seen in individuals affected with p63 
syndromes, produces only half the total wildtype copies of p63 molecules.22 The remaining half are 
mutant copies which retain the ability to oligomerize. Theoretically, 6.25% of the total tetrameric 
complexes will be formed by all wildtype monomers, which will have normal transactivation activity. 
The rest of the complexes will have one or more mutant monomers, which will affect transactivation. 
The loss-of-function mutations, which can be deletions or nonsense variants as reported in this study, 
also produce only half the total wildtype copies of p63 molecules. With only half the protein molecules, 
complexes formed will be normal but 50% less abundant. The heterozygous OD variants, as reported 
in this study, will produce only half the normal copy of the protein, leaving the other half with an 
impaired ability to oligomerize. As a result, there will be normal protein complexes but they will be 
almost half in number. These OD variants will therefore lead to partial loss-of-function (Figure 3.5). This 
model is also supported by analysis of the biophysical properties of the respective mutant proteins, 
which showed reduced thermo-stability in p.Val405Met mutant proteins compared to wildtype. Where 
the normal protein denatures at 85.6±0.1°C, the p.Val405Met mutant unfolds at 51.6±2.5°C (Figure 3.3). 
In contrast to the p.Val405Met mutant, no obvious explanation based on the biophysical properties of 
the p.Arg408His is possible. Nevertheless, our data suggest that dominant-negative or gain-of-function 
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variants in TP63 cause developmental disorders including more than one phenotype, while the loss-of-
function variants lead to nsOFC. 
Figure 3.5 Model explaining the functional 
effects of different kind of mutations in p63 on 
the transactivation activity. The normal complex 
with all wildtype p63 molecules leads to regular 
level of transactivation. A heterozygous dominant-
negative mutation in TP63 will lead to half mutant 
copies of p63 molecules. Theoretically, 6.25% of 
the total tetrameric complexes will be formed by 
all wildtype monomer, which will have normal 
transactivation activity. The rest of the complexes 
will have at least one (or more) mutant monomer 
which will block transactivation. The loss-of-
function mutations will lead to production of only 
half the total wildtype copies of p63 molecules. 
With only half the protein molecules, complexes 
formed will be normal but 50% less abundant. The 
heterozygous OD variants will produce only half 
normal copy of the protein, leaving the other half 
incapable to oligomerize. As a result, there will be 
normal protein complexes but they will be almost 
half in number. These OD variants will therefore 
lead to partial loss-of-function.
All seven variants in affected individuals except for p.Gln333* were inherited from an unaffected 
parent. Due to unavailability of parental DNA, we could not confirm whether the p.Gln333* variant was 
de novo or inherited. This suggests that the variants are not always completely penetrant. Incomplete 
penetrance has also been observed for other TP63 mutations, including common mutations such as 
those affecting arginine 319 (280 according to former nomenclature). Arg319 is considered a hotspot 
for EEC syndrome mutations,10,23 but there are also reports on families in which Arg319Cys is inherited 
as isolated SHFM. These families have cases of non-penetrance as well.24 Thus, clinical variability and 
reduced penetrance is typical for TP63 mutations. The penetrance of the loss-of-function alleles 
reported here seems to be even more reduced as compared to dominant-negative mutations. 
Recent genome-wide association studies (GWAS) have identified intronic variants in TP63 which impart 
the risk of nsOFC.25 The other variants (p.Val224Ile, p.Arg464Trp, and p.Arg487Cys) identified in our 
study are located in various domains of p63 and did not show any dramatic decreases in transactivation 
activity in our assay. These variants could represent risk factors which would cause only nsOFC in 
conjunction with other genetic and/or environmental factors with strong effect sizes. Importantly, 
all seven TP63 variants identified were present in individuals affected with CL/P (n=878) and none 
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in individuals with CPO (n=194). This has also been seen previously in a genome-wide meta-analysis 
which identified a statistically significant association between TP63 and CL/P but not CPO.25
In conclusion, we identified three deletions and seven probably disease-causing variants in TP63 which 
uncover a dosage dependent function of p63 and a loss-of-function mechanism behind nsOFC. Our 
findings also change the previous assumption that loss-of-function alleles in TP63 do not give rise to 
any clinical phenotype.
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Supplementary data
Table S3.1 Summary of CNV analysis data
Family Endpoints Size (kb) Marker count Median Log2 Ratio Genes in deletion
W11-4934
3:189,611,193-
190,139,080
528 576 -0.563 TP63, P3H2, CLDN1, CLDN16
W12-0831
3:189,372,066-
190,181,598
810 1,256 -0.509 TP63, P3H2, CLDN1, CLDN16
W16-065
3:188,700,996-
189,580,682
880 1,148 -0.506 TPRG1, TP63
Table S3.2 Primer sequences
Detailed information about the smMIPS primers can be found in the Supplemental spreadsheet: MIPs_TP63.
xlsx at https://www.nature.com/gim/.
Oligonucleotide primers for qPCR 
Primer Sequence
A_QPCR_TPRG1_F attttctcctttccacacagC
A_QPCR_TPRG1_R AAGCCTTGAATGGTCTCTCC
A_QPCR_TP63_F TTTCGTAGAAACCCCAGCTC
A_QPCR_TP63_R ATGCTGGAAAACCTCTGGAC
B_QPCR_TP63_ex12_F TGGAGACATGAATGGACTCAG
B_QPCR_TP63_ex12_R TGACAATGCTGCAATCTGTG
C_QPCR_TP63_ex11_F AACGCCCTCACTCCTACAAC
C_QPCR_TP63_ex11_R ctagcctgttcatccttcagc
C-QPCR_TP63_ex13_F GTTGGGCTGTTCATCATGTC
C-QPCR_TP63_ex13_R CCATGGAGTAATGCTCAATCTG
C_QPCR_TP63_ex14_F TCTCCTCCCCTTCTCATCTC
C_QPCR_TP63_ex14_R GCATCAATAACACGCTCACC
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Figure S3.1 CNV-microarray analysis
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Figure S3.2 Transient transfection assay (luciferase induction) for the variants other than OD variants. The 
fold inductions for the different mutant constructs are calculated relative to the WT isoform. p.Arg343Trp, an 
EEC causing mutant was used as control. The variants tested are p.Val224Ile, p.Arg487Cys and p.Arg464Trp. 
The data are represented as the mean ± SEM.
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Abstract
Common variants in IRF6 have been associated with nonsyndromic cleft lip with or without cleft palate 
(NSCL/P) as well as with tooth agenesis (TA). These variants contribute a small risk towards the two 
congenital conditions and explain only a small percentage of heritability. On the other hand, many 
IRF6 mutations are known as a monogenic cause of disease for syndromic orofacial clefting (OFC). We 
hypothesize that IRF6 mutations in some rare instances could also cause nonsyndromic OFC. In order 
to find novel rare variants in IRF6 responsible for nonsyndromic OFC and TA, we performed targeted 
multiplex sequencing using molecular inversion probes (MIPs) in 1072 OFC patients, 67 TA patients, 
and 706 controls. We identified three potentially pathogenic de novo mutations in OFC patients. In 
addition, three rare missense variants were identified, for which pathogenicity could not unequivocally 
be shown, as all variants were either inherited from an unaffected parent or the parental DNA was not 
available. Retrospective investigation of the patients with these variants revealed the presence of lip 
pits in one of the patients with a de novo mutation suggesting a Van der Woude syndrome phenotype, 
while in other patients no lip pits were identified.
4.1 Introduction
Interferon regulatory factor 6 (IRF6) belongs to a family of transcription factors that share a highly 
conserved N-terminal DNA-binding domain (DBD) and a less conserved C-terminal protein-binding 
SMIR/IAD (Smad-interferon regulatory factor binding domain) domain (Figure 4.1). The DBD of IRF6 
facilitates it to bind to DNA and function as a transcription factor. The SMIR/IAD mediates the formation 
of homo- or heterodimers of IRF6. IRF6 variants are known to cause syndromic orofacial clefting 
(OFC) and to contribute towards risk of isolated or nonsyndromic cleft lip with or without cleft palate 
(NSCL/P) and tooth agenesis (TA). Mutations in IRF6 have been described as a cause of Van der Woude 
syndrome (VWS; MIM #119300). VWS is an autosomal dominant form of OFC associated with lip pits 
and hypodontia, and is the most common (1/35,000 live births) syndromic form of CL/P (Burdick 1986; 
Dixon et al. 2011. Around 70% of the causal VWS mutations occur in IRF6 (Kondo et al. 2002; de Lima 
et al. 2009). Another syndromic form of CL/P caused by IRF6 mutations, popliteal pterygium syndrome 
(PPS; MIM #119500) additionally presents with skin and genital anomalies (Gorlin et al. 1968). PPS 
is estimated to affect 1 in 300,000 live births (Kousa and Schutte 2016). The majority of mutations 
leading to VWS and PPS affect the DBD or the SMIR/IAD domain of IRF6 (de Lima et al. 2009). Besides 
the syndromic clefting (Kondo et al. 2002), IRF6 also contributes to NSCL/P which is one of the most 
common congenital disorders (1/700 live births) (Dixon et al. 2011) and to TA. TA, which is congenital 
absence of permanent teeth in the absence of any other malformation, is prevalent in 3 to 11% of the 
European and Asian population respectively (Polder et al. 2004; Vieira et al. 2007). Both NSCL/P and TA 
are complex disorders (Lidral and Murray 2004; Dixon et al. 2011), that are likely to be associated with 
multiple genetic loci in combination with environmental factors.
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Common variants in IRF6 locus have been associated with NSCL/P (Rahimov et al. 2008) and TA 
(Vieira et al. 2007). These variants confer a small risk towards the disorder and are not sufficient by 
themselves to give rise to facial clefts and TA. Mutations in Irf6 hampers the development of tooth in 
mice by causing evagination of incisor epithelium (Blackburn et al. 2012). A recent study supports the 
role of Irf6 in a spectrum of dental phenotypes (Chu et al. 2016). The reported Irf6 knock out mouse 
model displays variable hypodontia, occasional supernumerary, as well as crown and root patterning 
anomalies. A previous study on IRF6 concluded that rare coding IRF6 mutations may not have a major 
role in nonsyndromic OFC, because of the misdiagnosed VWS families considered as nonsyndromic 
initially (Leslie et al. 2015). Here, we hypothesize that IRF6, a gene in which mutations are causative for 
syndromic OFC, and common variants confer risk towards NSCL/P and TA, could in some rare instances 
also cause nonsyndromic OFC and TA. 
We sequenced all exons of the IRF6 gene in 1072 OFC and 67 TA patients, as well as in 706 controls 
using molecular inversion probes (MIPs) (O’Roak et al. 2012) to identify novel rare variants causal for 
nonsyndromic OFC and TA.
4.2 Subjects and methods
4.2.1 Patients and controls
A total of 1139 patients, 1072 with OFC and 67 with TA (Dreesen et al. 2014), and 706 population 
matched controls, all of European ancestry, were included in this study. The 1072 OFC patients included 
194 Cleft Palate Only (CPO), 127 Cleft Lip Alveolus (CLA), 104 Cleft Lip Only (CLO) and 647 Cleft Lip and 
Palate (CLP) patients. This study was part of a larger sequencing project involving subjects from Bonn, 
Leuven, and Nijmegen (Ockeloen et al. 2016). Nineteen of the 1139 patients were already screened for 
IRF6 variants in a previous study(Birnbaum et al. 2008). Approval from the Institutional review boards of 
the respective university hospitals and informed consent from all individuals was obtained. 
4.2.2 Sequencing and in silico analysis
All nine exons of IRF6 were sequenced using a total of 20 molecular inversion probes (MIPs) (Table 
S4.1) at conditions described previously (O’Roak et al. 2012). MIPs sequencing of IRF6 was performed as 
part of a larger study comprising 431 probes (Ockeloen et al. 2016). The final pooled MIP libraries, each 
consisting of 384 samples, were sequenced using 2x79bp reads on a NextSeq500 sequencer (Illumina, 
San Diego, CA, USA). All samples with an average coverage over all IRF6 targeting MIPs <100-fold were 
excluded. MIP data was analyzed with an in-house analysis pipeline (Ockeloen et al. 2016). Briefly, reads 
were aligned by Burrows-Wheeler Aligner (BWA) to the reference genome (GRCh37/hg19). Subsequently 
MIP extension and ligation arms were removed from all the alignment files and reads were trimmed 
to remove overlap between the paired-ends. The alignment was split by barcode identifier resulting 
in a single BAM files per sample after which small variants were called by the Genome Analysis ToolKit 
(GATK) (McKenna et al. 2010), multiple sample calling using the Unified Genotyper resulting in a single 
Variant Call Format (VCF) file. A custom annotation pipeline was used to annotate the variants (for 
instance, effect on protein and variant frequency in populations).
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Table 4.1  Filter criteria and the numbers of IRF6 variants in OFC and TA patients versus controls at every 
 filter
In patients 
(OFC+TA)
OFC TA In controls
Rare variants (dbSNP freq ≤ 0.1 and  
<5 samples in MIPs screen)
22 19 3 9
Splice site or coding variants 17 15 2 7
Non-synonymous variants 13 13 0 7
Deleterious variants 
(CADD PHRED-like score>20)
6 6 0 1
De novo 3 3 0 NA
The above filtering steps were applied in successive order and were preceded by a step where reads were filtered by depth 
greater than 500. OFC: Orofacial clefting; TA: Tooth agenesis; NA: Not applicable
From the identified variants, only those with a quality-by-depth higher than 500 were considered. 
These variants were further filtered based on the criteria mentioned in Table 4.1. The variants obtained 
were selected for possible deletions, possible frameshifts, splice sites variants, known HGMD (Stenson 
et al. 2003) variants (Table S4.2; Figure 4.1) and high CADD Phred Score (>20; (Kircher et al. 2014)
conservation) (Table 4.2). The effect of the variants was also assessed by Alamut® Visual, that integrates 
genetic and genomic information from different sources (phyloP, Grantham, SIFT). Those variants 
passing all filtering steps were validated using Sanger sequencing and segregation analysis was 
performed in all available family members.
Figure 4.1 The structure of the IRF6 gene. Boxes with numbers 1 to 9 represent the nine exons of IRF6. Exons 
1 and 2 are not translated. The predicted IRF6 protein has a helix-turn-helix DNA-binding domain (blue) and a 
SMIR/IAD protein-binding domain (green). The arrowheads represent the relative positions of the variants in 
the controls (above exons) and the patients (below exons).
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4.2.3 Molecular modeling
In order to obtain more insight in the effects of the mutations on the molecular structure of IRF6 we 
created a homology model. We used the YASARA (Krieger et al. 2002) & WHAT IF (Vriend 1990) twinset 
homology modeling script with standard parameters. The program created two models representing 
the two different domains of the protein. PDB file 3DSH was used to create a model for residues 202-
455 (identity 62%) which make up the SMIR/IAD domain, and PDB file 2IRF was used to create a model 
for residues 1–123 (identity 43%), which make up the DNA-binding domain. 
4.3 Results
After excluding samples with an average coverage <100-fold (Table S4.3), the average coverage over 
all IRF6 targeting MIPs was 665-fold for all (1045 OFC and 67 TA) patients and 674-fold for all controls 
(n=706). A total, 19 out of 1045 OFC patients (1.81%) and 8 out of 706 controls (1.13 %) were found to 
have at least one rare, non-synonymous coding or splice site variant (Table S4.2). Six variants in OFC 
patients compare to one in controls had CADD PHRED-like scores >20 (Table 4.2). These variants were 
validated by Sanger sequencing and segregation analysis was also performed in the parents and the 
other available family members of the probands. 
Table 4.2 De novo and inherited IRF6 variants validated in patients
Variant 
cDNA
Amino acid 
change
Inheritance Protein 
domain
SIFT (Class; 
score)
PhyloP Grantham 
score
CADD 
PHRED-
like score
Pheno-
type (s)
c.1139C>A Pro380Gln De novo SMIR/IAD
Deleterious; 
0.0
4.16 76 24.5 CPO
c.673G>C Asp225His De novo –
Deleterious; 
0.0
5.77 81 27.8 CLA, VWS
c.25C>T Arg9Trpa De novo –
Deleterious; 
0.0
6.02 101 32 CPO
c.1124T>C Phe375Sera NA SMIR/IAD
Deleterious; 
0.0
3.35 155 24.8 CLP
c.385_398del Thr129Leufs*3
Paternally 
inherited
– – – – 22.1 CPO
c.103C>T Arg35Cys
Maternally 
inherited
DBD
Deleterious; 
0.0
3.19 180 21.4 CLA
a These variants have been previously identified. SMIR/IAD: Smad-interferon regulatory factor binding domain; DBD: DNA-
binding domain CPO: Cleft palate only; CLA: Cleft lip alveolus; VWS: Van der Woude syndrome; CLP: Cleft lip and palate; NA: 
Not applicable
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In OFC patients, three de novo IRF6 variants were identified (Table 4.2). Based on the gene specific 
mutation rate (Samocha et al. 2014), the identification of three de novo mutations in a cohort of 1112 
patients is highly unlikely a chance finding (p=7.79x10-5), after multiple testing correction for testing 
13 genes in the entire MIP pool). Each of these three variants, c.1139C>A (p.Pro380Gln), c.673G>C 
(p.Asp225His) and c.25C>T (p.Arg9Trp) were present only in single patients and were not found in 
controls, neither in the present study nor in ExAC or GoNL. 
The variant p.Pro380Gln was present in a patient who was diagnosed with nonsyndromic CPO and 
no lip pits (Figure 4.2a), and the father and mother were not reported to have any facial clefting. The 
variant occurs at a highly conserved nucleotide (g.209963052G>T, phyloP: 4.16), and affects a highly 
conserved amino acid, up to Tetraodon, of SMIR/IAD domain of the IRF6 protein. There is a significant 
physicochemical difference between the reference amino acid proline and the variant amino acid 
glutamine. The second variant, p.Asp225His, was identified in a patient initially diagnosed with CLA 
but after in-depth phenotyping subsequent to identification of this variant found to have lip pits in 
the lower lip, which is suggestive of VWS (Figure 4.2b). The father and the mother had no OFC. This 
variant occurs at a highly conserved nucleotide (phyloP: 5.77) and affects a highly conserved amino 
acid up to Tetraodon. The third variant, Arg9Trp, was found in a patient with CPO and no lip pits (picture 
not available). This variant also occurs at a highly conserved nucleotide (phlyoP: 6.02) and affects a 
highly conserved amino acid, up to Tetraodon and has been previously identified in two VWS patients 
(Matsuzawa et al. 2004) and in a CL/P patient with atypical lower lip pits (Jehee et al. 2009).
Figure 4.2 Clinical photographs (A-C) 
and orthopantomogram (OPT) (D) of 
patients. A: Frontal oral photograph of the 
patient carrying the p.Pro380Gln de novo 
variant, showing Cleft Palate Only (CPO). 
The patient also exhibits submucous cleft 
of the hard palate. B: Patient carrying the 
p.Asp225His de novo variant, showing 
unilateral cleft lip and cleft alveolus (CLA), 
and with a lip pit (VWS). C: Patient carrying 
p.Thr129Leufs*3 variant, showing a cleft 
of the soft palate and uvula. D: OPT of the 
patient carrying p.Thr129Leufs*3 variant 
showing tooth agenesis of 15, 25, 35 and 
45.
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Figure 4.3 Homology model for the (A) DNA binding domain (DBD) and (B) SMIR/IAD domain. Dark grey 
colored molecules are interacting A: DNA molecule and B: protein monomer respectively. Mutated bases are 
depicted in red. The p.Arg9Trp variant changes a positively charged amino acid to a very big neutral amino 
acid. Attractions with negative phosphates will be lost. In the inset the wildtype residue sidechain is indicated 
in green, the mutant sidechain is shown in red. The large sidechain of tryptophan was being seen to interfere 
with the DNA molecule. The p.Arg35Cys variant will reduce the overall stability of the protein due to loss of 
interactions with a close by aspartate residue. The p.Asp225His variant will cause loss of some interactions 
because a negatively charged amino acid is changed to a neutral amino acid. The variant p.Phe375Ser is 
highly deleterious. This will leave a big empty space and change the core of the protein. In the inset the 
surrounding hydrophobic sidechain are shown to indicate the interactions made by this Phenylalanine 
residue. The p.Pro390Gln variant will cause loss of hydrophobic interactions and this might have an effect on 
the backbone.
Besides the three de novo variants, three other variants with CADD PHRED-like score >20 and strong 
functional prediction were identified in patients, two of which were inherited from one of the 
unaffected parents (Table 4.2). One of the inherited variants is p.Thr129Leufs*3, caused by a deletion of 
14 nucleotides in exon 5. This variant was identified in a CPO patient. The posteriori review of collected 
phenotypic data revealed no lip pits (Figure 4.2c, d). This deletion creates a frame shift starting at codon 
Thr129. The premature stop leads to the loss of SMIR/IAD domain in the protein. The mRNA produced 
might be targeted for nonsense mediated RNA decay (NMD). The other inherited variant p.Arg35Cys 
was also found in a nonsyndromic CLA patient, with no lip pits. This variant is a known polymorphism, 
rs771539601, with ExAC allele frequency 0.00003 in the European (Non-Finnish) population. It affects 
a highly conserved amino acid in the DBD of the IRF6 protein, and the physicochemical difference 
between the reference and the variant amino acid is large. A variant at the same position, Arg35Pro, 
was previously identified in a VWS pedigree (de Lima et al. 2009). The third variant, p.Phe375Ser, was 
identified in a CLP patient. The posteriori review of collected phenotypic data revealed no lip pits. 
This variant has been reported previously in three VWS families (Leslie et al. 2013). It affects a highly 
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conserved amino acid in the SMIR/IAD domain. The variant was not present in the mother’s DNA, 
however, due to unavailability of the father’s DNA, it could not be confirmed whether the variant is 
inherited or occurs de novo in the patient.
An experimentally derived protein structure for IRF6 is not yet known. We were able to build separate 
homology models for the DBD and the SMIR/IAD domain (Figure 4.3). A detailed analysis of these 
models revealed that none of the mutations occurred on the dimerization surface of the SMIR/IAD 
domain. Only one mutation, p.Phe375Ser, is positioned in the core of the domain and will severely affect 
the folding and function of the domain. The change from a larger hydrophilic residue into a smaller 
hydrophilic one will abolish many stabilizing hydrophobic interactions made by the Phenylalanine 
sidechain. Also, mutant p.Arg9Trp is located in the DBD and necessary for electrostatic interactions 
with the DNA phosphate backbone. This mutation is predicted to affect DNA binding because the 
ionic interaction between the negatively charged DNA backbone and the positively charged Arginine 
sidechain will be lost. Tryptophan has an even larger sidechain, and, more importantly, does not carry 
a charge which does not allow it to make the same interactions with the DNA backbone. All other 
mutations occur on the surface of the protein where they may change the local structure and thereby 
affect interactions with other proteins in the biological complex. 
4.5 Discussion
Both NSCL/P and TA are genetically complex birth defects. The phenotype can result from multiple 
genetic, environmental and lifestyle factors. Several common genetic risk factors have been discovered 
by Genome Wide Association Studies (GWAS), but these genetic factors represent only part of 
the  risk  associated with NSCL/P (Khandelwal et al. 2013). While dominant mutations in GRHL3 are 
known to cause VWS (Peyrard-Janvid et al. 2014), a recent study showed that 1.7% of the cases with 
nonsyndromic CPO actually have rare truncating mutations in GRHL3 (Mangold et al. 2016). We aimed 
at identifying rare monogenic variants responsible for nonsyndromic OFC and/or TA.
We employed MIPs for targeted re-sequencing of IRF6 in 1072 OFC and 67 TA patients and 706 controls. 
This massively multiplex targeted sequencing resulted in rapid and cost-effective screening of multiple 
genes in large cohorts, as shown in the initial reports (O’Roak et al. 2012) and numerous subsequent 
applications (Hildebrand et al. 2016; Schueler et al. 2016). We identified six variants that are likely to be 
deleterious variants in OFC patients, out of which three were confirmed to be de novo. The identification 
of three de novo mutations in a cohort of 1112 cases is highly unlikely a chance finding (p=7.79x10-5). 
These six variants were not present in controls in the MIPs assay. In one of the OFC patients with cleft of 
soft palate and uvula containing the IRF6 variant p.Thr129Leufs*3, TA of 4 premolars (15, 25, 35 and 45) 
was present (Figure 4.2d). Hence we show that from the wide spectrum of dental phenotypes recently 
found in a novel Irf6 knockout mouse model (Chu et al. 2016), TA of 4 premolars is also present in 
a patient with orofacial clefting carrying a rare IRF6 variant. We however did not identify any major 
contribution of rare IRF6 variants in patients with solitary TA. A larger solitary TA cohort could probably 
indicate the role of rare of IRF6 variants. 
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In a previous study, 1521 nonsyndromic OFC families were screened for IRF6 mutations (Leslie et al. 
2015). The authors identified three de novo and four inherited variants. In all three families with de novo 
variants, lip pits were not explicitly reported, but they were not checked for other signs of VWS. One 
of the three de novo variants were also previously reported in VWS families. The four inherited variants 
were present in index patients and a parent where either the index patient or a parent had VWS, or 
where the carrier parent was not inspected for lip pits at all. In the present study, we also identified 
three deleterious de novo variants in our OFC cohort. Out of the three de novo variants, Pro380Gln, 
Asp225His and Arg9Trp, the variant Asp225His was present in a CLA patient, in whom lip pits were 
also observed, thus fulfilling the diagnostic criteria of VWS. This emphasizes the need of careful and 
accurate phenotyping. The other patients with other de novo or inherited variants were not reported 
to have any lip pits. A posteriori review of the collected phenotypic data did not reveal any lip pits. 
Approximately 15% of VWS patients only present OFC as the phenotype, thus making it difficult to 
distinguish from nonsyndromic OFC. In such patients, phenotype data of the family can be useful to 
establish the syndromic nature of the disease (Leslie et al. 2015). In large patient cohorts however, 
“genotype first” approach as presented here, could be used as this allows a post-test check or an a 
posteriori refinement of the clinical diagnosis (Stessman et al. 2014). 
We also identified two predicted deleterious variants, which were inherited from one of the unaffected 
parents. Besides, some variants which were present in both patients and controls were also found. 
These variants might have low penetrance and lead to the corresponding phenotype only in the 
presence of genetic modifiers, which would account for the unaffected parent and controls. Besides the 
coding variants in IRF6, a variant 9.7 kb upstream of IRF6 in a highly conserved non-coding regulatory 
element, rs642961, has been also associated with NSCL/P (Rahimov et al. 2008). It was shown that this 
variant (rs642961) disrupts one of the four binding sites for AP-2α, which is in the same developmental 
pathway as IRF6. Perhaps the genetic modifiers needed for the inherited variants or the variants found 
in both, patients and controls, to be causative, are present in this regulatory element. Overall, we see 
that in affected patients for whom we validated the IRF6 variants, one was found to have VWS and the 
rest, either nonsyndromic CLP, nonsyndromic CLA or nonsyndromic CPO. 
In conclusion, our data further add to the increasing evidence that rare IRF6 variants play a role in the 
etiology of nonsyndromic OFCs. Moreover, our study highlights the need for deep clinical phenotyping 
and medical history of families that present at genetic counseling and the advantage of a “genotype 
first” approach when studying large patient cohorts.
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Abstract
Purpose: We aimed to identify a novel genetic cause of tooth agenesis (TA) and/or orofacial clefting 
(OFC) by combining whole-exome sequencing (WES) and targeted resequencing in a large cohort of 
TA and OFC patients.
Methods: WES was performed in two unrelated patients: one with severe TA and OFC and another with 
severe TA only. After deleterious mutations were identified in a gene encoding low-density lipoprotein 
receptor-related protein 6 (LRP6), all its exons were resequenced with molecular inversion probes in 67 
patients with TA, 1,072 patients with OFC, and 706 controls.
Results: We identified a frameshift (c.4594delG, p.Cys1532fs) and a canonical splice-site mutation 
(c.3398-2A>C, p.?) in LRP6, respectively, in the patient with TA and OFC and in the patient with severe 
TA only. The targeted resequencing showed significant enrichment of unique LRP6 variants in TA 
patients but not in nonsyndromic OFC patients. Of the five variants in patients with TA, two affected 
the canonical splice site and three were missense variants; all variants segregated with the dominant 
phenotype, and in one case the missense mutation occurred de novo.
Conclusion: Mutations in LRP6 cause TA in humans. 
5.1 Introduction
Tooth agenesis (TA) and orofacial clefting (OFC) are distressing to families. Both are common 
congenital disorders and can occur as isolated entities or accompanied by other symptoms or as part 
of a syndrome.1,2 As an isolated condition, TA in the severe form involves six or more teeth failing to 
develop (oligodontia) and has a prevalence of 0.1–0.5% in populations worldwide; the frequency of 
the mild form of TA, which involves one to five teeth missing (hypodontia), is 3–20% of the population.2
For isolated nonsyndromic OFC, a worldwide prevalence of 0.1–0.2% has been reported.1 Although 
genetic heterogeneity is present for selective tooth agenesis (STHAG), including causal mutations in 
MSX1 (STHAG1; MIM 106600),3 PAX9 (STHAG3; MIM 604625), WNT10A (STHAG4; MIM 150400), or EDA 
(STHAGX1; MIM 313500), mutations of WNT10A, ligand of the Frizzled (FZD) coreceptor in the canonical 
WNT/β-catenin signaling pathway, are most frequently associated with isolated TA.4 Of all genes in 
which mutations causing STHAG have been identified, only MSX1 has the annotation “with or without 
orofacial cleft,” which refers to the rare combination of TA and different types of OFC in the affected 
members in two families identified to date.5,6
Mutations in other genes, e.g., IRF6 (MIM 607199) and TP63 (MIM 603273), have also been shown to 
cause combined TA-OFC, in syndromic as well as nonsyndromic phenotypes.7
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Although individuals with OFC present with higher frequencies of dental anomalies, including TA in their 
maxillary primary and permanent dentitions, than controls, it has been suggested that the combined 
TA-OFC phenotype is only rarely due to genetic factors; rather, it is due to acquired disturbances of the 
physical environment surrounding the developing dentition. Only some families carry rare mutations in 
specific genes that influence both tooth development and palatogenesis, suggesting rare monogenic 
conditions in such cases.8
Here, we report the discovery of truncating mutations in LRP6 (MIM *603507) by whole-exome 
sequencing in a case with TA-OFC and a case with TA only, and we hypothesize that LRP6 mutations 
can cause TA, OFC, or combined TA-OFC. Through targeted resequencing, we identified five additional 
patients with TA harboring LRP6 mutations. To support our hypothesis, we analyzed the expression of 
Lrp6 in frontal sections of developing mouse heads at embryonic day 13 and embryonic day 15 (E13 
and E15) using immunohistochemistry. Because mutations in TP63 have been shown to underlie the 
combined TA-OFC phenotype, we investigated whether Trp63 and Lrp6 function in the same molecular 
pathway.
5.2 Materials and methods
5.2.1 Patient phenotype description
The first index patient was a boy born with a bilateral cleft lip, a left-sided cleft of the alveolus, and a 
complete cleft of the hard and soft palate. He had agenesis of 4 deciduous and 17 permanent teeth. 
Additional features were growth retardation, hypermetropia, and a small median alveolar cleft in the 
mandible (Figure 5.1a–h). His mother also had severe TA, but not OFC, as did the maternal grandmother 
and her brother. The second index patient had agenesis of two deciduous and nine permanent teeth 
(Figure 5.1i–q). Other dental features included impaction of tooth 24 and conical teeth 13 and 23. He 
has clinodactyly of the fifth fingers and hypermobile joints. We obtained written consent from patients 
and their parents to publish their photographs (Figure 5.1). For the full phenotype description and 
medical family history of both index patients, we refer to Supplementary Materials and Methods online.
5.2.2 Whole-exome sequencing
Two protocols for whole-exome sequencing and subsequent data analysis were used for the two index 
patients. The first one was performed through the Baylor-Hopkins Center for Mendelian Genomics using 
the methods previously reported;9 the second was performed in a clinical setting at the Department 
of Human Genetics of the Radboud University Medical Center, similar to previous reports.10 To identify 
additional patients with LRP6 variants, 29 in-house diagnostic exomes sequenced in patients with 
a range of craniofacial disorders were queried for rare (<1% in dbSNP141), nonsynonymous, and 
canonical splice-site variants in LRP6.
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5.2.3 Immunohistochemistry for Lrp6 in mouse heads
To check the expression of Lrp6 in developing teeth and palates of mice, we generated paraffin sections 
of E13 and E15 mouse embryo heads and stained them with antihuman LRP6 polyclonal antibody (cat. 
number orb18907, Progen, Sanbio, The Netherlands) counterstained with hematoxylin.
5.2.4 Regulation of Lrp6 by Trp63
We checked for Trp63 binding sites in Lrp6 using chromatin immunoprecipitation quantitative PCR 
analysis. To generate additional evidence for regulation of Lrp6 by Trp63, the expression of Lrp6 in facial 
processes of Trp63-/- embryos was compared with that of their wild-type littermates. The breeding 
of the genetically modified mice was performed after ethical review and in accordance with the UK 
Animals (Scientific Procedures) Act of 1986.
5.2.5 Resequencing with molecular inversion probes
Table 5.1 Overview of LRP6 variants identified with MIP screen in OFC and TA patients vs. controls
Total cases with 
variant (n=1139)
TA cases with 
variant (n=67)
OFC cases with 
variant (n=1072)
Controls with 
variant (n=706)
Rare (<0.1%) coding & SS$ variants 30 8 22 16
Of which synonymous 3 1 2 3
Of which non-synonymous 27 7a 20b 13a, b
Unique/private variants 13 5 8 5
  Of which synonymous 1 0 1 2
Of which non-synonymous 12 5c 7d 3c, d
Of which CADD PHRED >20 7 4e 3f 1e, f
All variants were coding or canonical splice site variants with a population frequency of <0.1% (based on dbSNP142 and 
an in-house database with >5,000 samples), ≤3 samples in this study with the same variant and a ‘GATK quality by depth’ 
of >1,000, the latter was based on previous MIP data and extensive validations by Sanger sequencing showing low false 
positive rates and high sensitivity. Minimal average coverage over all MIPs of included samples was 100-fold. Most unique 
and rare non-synonymous variants reported here in cases have been validated by Sanger sequencing.
$Splice site canonical dinucleotide; CADD PHRED-like score is based on31.
a,b 7 rare, non-synonymous variants in LRP6 in 67 cases with OD were highly significant when compared to the variant load 
in 706 controls (Fisher’s exact test after Bonferroni correction P=0.0056022); while 20 rare, non-synonymous variants in LRP6 
in 1072 cases with OFC does not show significance when compared to the variant load in 706 controls.
c,d 5 unique, non-synonymous variants in LRP6 in 67 cases with OD were highly significant when compared to 3 such variants 
in 706 controls (Fisher’s exact test after Bonferroni correction P=0.0012354); while 7 unique, non-synonymous variants in 
LRP6 in 1072 cases with OFC does not show significance when compared to the variant load in 706 controls.
e,f 4 unique, predicted damaging variants in LRP6 in 67 cases with OD were highly significant when compared to 1 such 
variant in 706 controls (Fisher’s exact test after Bonferroni correction P=0.001515); while 7 unique, non-synonymous 
variants in LRP6 in 1073 cases with OFC does not show significance when compared to the variant load in 706 controls.
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To genetically test our hypothesis regarding the contribution of rare LRP6 coding variants to the 
etiology of TA and common OFC, we aimed to resequence all exons of LRP6 in a large patient cohort 
and in controls. Molecular inversion probes were used to resequence LRP6 in 67 patients with TA,11 
1,073 patients with OFC, and 706 controls (CO). The cases and controls were identified as part of the 
sample-collection efforts from Bonn (OFC, CO), Nijmegen (OFC), and Leuven (OFC, TA) (Table S5.1). 
Approval from the institutional review boards involving human subjects and the ethical committees of 
the respective university hospitals was obtained, as was written informed consent from all individuals.
A total of 69 molecular inversion probes were designed for the coding exons of LRP6 and used for 
targeted enrichment as previously described,6 with minor modifications. All coding exons of LRP6 were 
covered, on average, 1,045±480-fold (average ± SD) per sample. This was comparable for cases (1,040-
fold) and controls (1,051-fold) (Supplementary Materials and Methods online). The identified variants 
were filtered using the same filter steps for cases and controls (Table 5.1).
5.3 Results
5.3.1 Exome sequencing of index patients 1 and 2
After filtering for rare coding variants found with whole-exome sequencing (Table S5.2), we identified 
a deleterious frameshift (c.4594delG, p.Cys1532fs) and a canonical splice-site mutation (c.3398-2A>C, 
p.?) in LRP6 in index patient 1 with severe TA and OFC and in the unrelated index patient 2 with severe 
TA only, respectively. The frameshift mutation was predicted to cause a premature stop 15 codons 
downstream. Because this mutation is located in the last exon of LRP6 (Figure S5.1), the mRNA is 
predicted to escape nonsense-mediated decay, resulting in a truncated protein missing all terminal 
phosphorylation domains (PPPSP) and thereby disrupting further downstream WNT signaling. LRP6 
mutants lacking two of the five PPPSP motifs are mostly inactive.12
The canonical splice-site mutation, located at a highly conserved canonical splice acceptor of intron 
15, is predicted to severely disrupt splicing (Table S5.2 and Figure S5.1). Based on their location, 
conservation, protein function, and segregation, these LRP6 mutations were considered causal for the 
two patients’ TA phenotypes.
5.3.2 Immunohistochemistry for Lrp6 in mouse heads
Immunohistochemistry staining of Lrp6 on sections of the embryonic mouse heads (Figure S5.2a, 
b) showed that Lrp6 is expressed in areas of bone formation at E13 (Figure S5.2a) but more clearly 
expressed and including palatal bone at E15 (Figure S5.2b). Interestingly, Lrp6 is expressed in the tooth 
follicle, especially in the inner enamel epithelium (Figure S5.2b), suggesting a role for Lrp6 in early tooth 
development.
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5.3.3 Regulation of Lrp6 by Trp63
The presence of a functional Trp63 binding site in intron 7 of Lrp6 was identified using chromatin 
immunoprecipitation quantitative PCR analysis (Figure S5.2c). Although Lrp6 expression is down/
regulated in the facial processes of Trp63-/- embryos compared with their wild-type littermates, this 
reduction was not significant (Figure S5.2d, e). Furthermore, Lrp6 displayed reduced expression within 
the mesenchyme of E11.5 medial nasal processes between Trp63+/+ and Trp63-/- embryos (data not 
shown), but this effect was subtle.
5.3.4 Resequencing with molecular inversion probes
Significant enrichment of rare variants was found only in cases with TA, as compared with controls 
(7/67 vs. 13/706; Fisher’s exact test after Bonferroni correction P=0.0056022 (Table 5.1)), with a similar 
significant enrichment found when considering unique variants (5/67 vs. 3/706; P=0.0012354) or 
predicted damaging variants (CADD PHRED-like score >20) (4/67 vs. 1/706; P=0.001515). There was 
no difference between cases and controls for rare or unique synonymous variants. There was no 
statistically significant enrichment for unique LRP6 variants in OFC cases compared with controls.
All unique variants in TA cases were validated by Sanger sequencing, and segregation analysis showed 
segregation in all families (Figure S5.3a–e); hence all five variants were considered likely pathogenic 
(Table S5.3a). These contained two canonical splice-site variants as well as three missense variants. 
Of note, the sporadic case, TA2, showed de novo mutation. Based on the gene-specific mutation rates 
of Samocha et al.,13 the chance of identifying a de novo missense mutation in LRP6 in 67 TA cases is 
extremely low (P=0.006076 exact Poisson test). The ultimate proof of pathogenicity of the presented 
missense variants will require additional functional evidence.
Careful inspection of all medical records of the seven described cases harboring unique LRP6 mutations 
(Figure S5.4 and Table S5.3b) revealed additional dental anomalies, including tooth ankylosis (n=2), 
abnormal tooth shape (n=2), enamel defects (n=1), and other symptoms, such as clinodactyly (n=3). 
Furthermore, growth hormone supplementation therapy had been considered for four of these seven 
patients. Severe TA was also present in a patient carrying a rare LRP6 variant (Figures S5.3f and S5.4j, k). 
This suggests that several of the rare variants may still be involved in the phenotype.
5.2 Discussion
We report that loss of function of LRP6 causes TA. LRP6 is a transmembrane cell surface protein that 
is a member of the low-density lipoprotein receptor gene family. LRP6 acts as a coreceptor for WNT 
together with Frizzled (FZD), transmitting signals in the canonical WNT/β-catenin-TCF signaling 
cascade, which is well known for its role in differentiation, proliferation, and migration processes 
during dental and orofacial development. Two genes of this pathway have already been implicated in 
human TA. Mutations in AXIN2 (MIM 608615) were associated with TA–colorectal cancer predisposition, 
and mutations in WNT10A can cause either isolated4 or syndromic TA (WNT10A; MIM 606268). Lrp6 
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has been described as positively regulating WNT/β-catenin signaling by Wnt receptor internalization 
(GO:0038013) in LRP6 signalosomes.14
Our findings regarding TA further expand the spectrum of LRP6 phenotypes. Although loss- or gain-
of-function mutations in LRP6 and in another closely resembling Wnt coreceptor, LRP5, had already 
placed the Wnt pathway central in bone biology, Wnt has emerged as an important regulator of skeletal 
modeling and remodeling.15 LRP6 is also key to parathyroid hormone (PTH) signaling, which regulates 
osteoblast activity; PTH binds to its receptor PTH1R and thereby induces the PTH-PTH1R-LRP6 protein 
complex, leading to increased bone formation in rats.16 Because LRP6 mutations may disrupt this 
PTH-PTH1R-LRP6 interaction, effects on growth could result. This could explain why growth hormone 
supplementation therapy was being considered for four of our seven patients with unique LRP6 
mutations. Other human diseases related to LRP6 variants include atherosclerosis,17 osteoporosis,15 
and metabolic syndrome.18 Recently, rare LRP6 mutations were reported in spina bifida.19
Although genetic inactivation of Lrp6 was also reported to lead to cleft lip with cleft palate in a mouse 
model,20 our genetic data do not support a role for LRP6 mutations in nonsyndromic OFC in humans. 
Moreover, our functional data fail to show significant regulation of Lrp6 by Trp63. Because we only 
found evidence for molecular underpinning of TA by LRP6 mutations, it remains unsolved whether the 
LRP6 mutation in our index patient with combined TA-OFC also contributed to the OFC development 
in this patient.
Based on our results, an estimate can be made regarding the frequency of LRP6 mutations in the normal 
population because frequencies of TA in general populations are known. In our cohort, 3 of 706 control 
individuals (0.4%) were carriers of unique LRP6 variants. Although this frequency matches population 
frequencies for severe TA ranging between 0.1 and 0.5%, it remains unclear whether those variants are 
pathogenic. We hypothesize that LRP6 is a major cause of severe TA but not a cause of common TA (3 
to 20% in populations worldwide). 
In conclusion, we show that LRP6 mutations cause severe TA with or without other dental anomalies 
such as ankylosis, enamel defects, and tooth-shape anomalies. However, our genetic data do not 
provide evidence that rare monogenic LRP6 mutations underlie nonsyndromic orofacial clefts.
Note: during the preparation of this article, the following paper was published: MP Massink et al., Loss-
of-function mutations in the WNT coreceptor LRP6 cause autosomal-dominant oligodontia, Am J Hum 
Genet; 2015;97:621–626. This study provides additional independent evidence for the causative role of 
LRP6 mutations in TA.
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Supplementary data
Full clinical history and phenotype description of index cases 1 and 2
Index patient 1
The pregnancy was uncomplicated except for a vaginal bleeding at 13 weeks. Mother smoked cigarettes 
during the pregnancy. The individual was born at 36 weeks gestation with a birth weight of 2260 g and 
had a bilateral cleft lip with a left-sided cleft alveolus, and a cleft palate, anteriorly and posteriorly. He 
had agenesis of 4 deciduous teeth (#52, #62, #72 and #82) and of 17 permanent teeth (#12, #13, #14, 
#15, #22, #23, #24, #25, #31, #32, #33, #34, #35, #41, #42, #44, #45) moreover tooth #36 was extracted. 
As a child he had recurrent infections. At the age of 9 years and 2 months he was seen by a clinical 
geneticist because of the combination of cleft lip and palate and growth retardation. His length at that 
time was 121 cm (<-2.5 SD), high weight was 22.2 kg (+1 SD) and his head circumference was 52 cm 
(0 SD). He had a proportionate short stature. His hairs and nails grew normally and his skin showed 
no abnormalities. Sequence analysis and multiplex ligation-dependent probe amplification (MLPA) 
of SHOX showed no abnormalities. MLPA analysis for subtelomeric deletions or duplications showed 
no abnormalities. Because of the combined OD-OFC phenotype single gene tests were performed to 
exclude mutations in MSX1, IRF6 and TP63. At the age of 14 years and 3 months he was reviewed in the 
clinic. At that time, he experienced a growth spurt and his length was 159 cm (-1.2 SD). He followed 
special education because of psychiatric problems (depression). His IQ was tested and was normal. 
He had hypermetropia of +8 D and +10 D. He showed broad proximal interphalangeal joints of the 
hands. He has mild facial dysmorphic features, namely a broad nasal bone, base and tip, and a dip in 
the chin. He has a small median alveolar cleft in the mandible. His mother has oligodontia and has 
somewhat thin scalp hair. She has no cleft lip, alveolus or cleft palate and she shows no other orofacial 
abnormalities. Her length is 155 cm (-2.5 SD) and her head circumference is 53 cm (-1.3 SD). 
The maternal grandmother also suffers from oligodontia, but shows no other orofacial abnormalities 
on examination by an orthodontic specialist. 
Index patient 2
The pregnancy was unremarkable and this boy was born at term with a birth weight of 4110 g, a birth 
length of 54 cm and a skull circumference of 34 cm. He had a normal motor and speech development, 
he started walking at the age of 1 year. He did have problems with fine motor skills and riding a 
bicycle, for which he received physiotherapy. He has hypermobility of joints, but no skin abnormalities. 
There probably was agenesis of 2 teeth in his deciduous dentition (#52 and #62) and of 9 teeth in his 
permanent dentition (#17, #15, #14, #12, #22, #25, #27, #35, and #45), thus presenting with oligodontia 
(OD). He has clinodactyly of the fifth fingers and has hypermobile joints. He also has one ectopic tooth in 
the upper right retromolar area and an impacted tooth #24. His hair and nails grow normally. Sweating 
is normal. He has problems with social interaction. He has dyslexia and received speech therapy 
because he had a mild delay in his speech development. He goes to a regular school. His brothers had 
a delayed eruption of the permanent teeth. There are no other family members with oligodontia. He 
was seen by a clinical geneticist at age 9 and physical examination showed a length of 135 cm (-0.5 D), 
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weight 26.7 kg (-0.8 SD) and skull circumference 52.2 cm (-1.4 SD). He shows mild dysmorphic features: 
protruding, posteriorly rotated ears with a thin helix, small earlobes, a long superior crus antihelix, 
and a full nasal tip with narrow nasal ridge. He has fair hair. He has a mild scoliosis and clinodactyly of 
the 5th fingers. The Beighton hypermobility score was 6/9. Previus genetic tests included a SNP array 
performed using an Affymetrix 250K SNP array platform (Affymetrix, Santa Clara, CA, USA) prior to WES, 
as well as sequence analysis of EDA, EDAR, EDARRAD, PAX9, WNT10A and MSX1 was normal.
Description of control cohort
The controls from Bonn were retrieved from a population-based sample recruited among voluntary 
blood donors, in cooperation with the Institute of Experimental Hematology and Transfusion Medicine, 
University of Bonn. Only controls of Central European descent were included. All controls were OFC 
negative, but their dental status was not available. The latter was also the case for many OFC cases, 
depending on the age at inclusion. Ethical approval of the regional Committee on Research involving 
Human Subjects, the Ethical Committees of the respective University Hospitals was obtained as well as 
written informed consent from all individuals.
MIP screen methodology
A total of 69 MIPs were designed for the coding exons of LRP6 and used for targeted enrichment as 
described by O’Roak et al. (Science 2012). This target enrichment was performed as part of a larger 
study, in total comprising 431 MIP probes. The final pooled MIP libraries each consisted of 384 samples 
and was sequenced on a high output run, using 2x79bp reads on a NextSeq500 sequencer (Illumina, 
San Diego, CA, USA). All samples with an average coverage <100-fold were excluded. The 69 MIPs 
targeting LRP6 were covered on average 1045±480-fold (average ± standard deviation) per sample and 
was comparable for cases (1,040-fold) and controls (1,051-fold). 
MIPs were analyzed using a custom analysis pipeline. Briefly, reads were first trimmed to remove overlap 
between the paired-ends and subsequently aligned by BWA to the hg19 genome. Aligned reads were 
then split by barcode identifier into single bam files per case. At the same time MIP extension and 
ligation arms were removed from the alignment files. Substitutions, insertions and deletions were 
then called by GATK multiple sample calling using the Unified Genotyper resulting in a single vcf file. 
A custom annotation pipeline was used to annotate variants with information such as the effect on 
protein and variant frequency in populations (Exome Aggregation Consortium (ExAC), Cambridge, MA: 
http://exac.broadinstitute.org [July 2015]). 
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Figure S5.1 LRP6 protein with the locations of the identified mutations. The LRP6 gene is located on 
chromosome 12 and the LRP6 protein with its different domains. All unique variants identified in OFC 
(purple) and OD (green) patients as well as controls from this study. Mutations indicated with an asterisk 
represent truncating or canonical splice site events, mutations indicated with a circle represent missense 
changes (Modified from Cnossen et al., Proc Natl Acad Sci U S A. 2014). 
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Figure S5.2 Lrp6 protein staining embryonic mouse head, identification of a p63 binding site within 
intron 7 of Lrp6 and the LRP6 protein with the locations of the identified mutations. (A-B) Lrp6 protein 
expression in mouse embryo heads at E13 A: and E15 B). Lrp6 is expressed in osteoid tissue of calvaria, maxilla 
an mandible (arrows A,B). High expression of Lrp6 protein is revealed in the molar follicles at E13 but the 
signal is more specific in the inner enamel epithelium of the developing molars at E15. Paraffin sections of 
the embryo heads were treated with anti-Human LRP6 polyclonal antibody (cat. nr.orb18907,Progen, Sanbio, 
the Netherlands) and counterstained with Hematoxylin. The shown sections photographed with a Zeiss 
microscope (Carl Zeiss Microimaging GmbH, Jena, Germany). C: The position of the p63 binding site within 
intron 7 of Lrp6 coincides with highly conserved regions of the genome that are DNaseI hypersensitive. D: 
ChIP-qPCR analysis using the p63 antibody H129 in facial processes dissected from E11.5 mice performed 
using previously described methods (Thomason et al. J. Clin. Invest. 2010) confirms specific binding of p63 to 
the binding site (T-test, P<0.01) but not to the negative control myoglobin exon 2 (Myo). A putative binding 
site proximal to Wnt7b failed to display positive enrichment (T-test, P=0.43), while the positive control Pvrl1 
(Nectin) was enriched (T-test, P<0.01). For the ChIP-qPCR analysis outbred CD1 mice were used. E: qPCR 
analysis of facial processes dissected from E11.5 Trp63-/- mice (Thomason et al. J. Clin. Invest. 2010) indicates 
that Lrp6 transcript levels were reduced compared to their wild-type littermates; however, the difference 
was not significant. Data represent mean ± SEM (standard error of the mean). The Trp63 mutant mice are 
on a BALB/c background with the controls being their wild-type counterparts and therefore on the same 
background. 
Figure S5.3 Pedigrees of the 5 TA cases with unique LRP6 variants and the segregation in their respective 
families (A-E) and 1 TA case with a rare LRP6 variant (F).
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Figure S5.4 Orthopantomograms (OPTs) of the 5 TA cases with unique LRP6 variants and their respective 
family members (A-I); and 1 TA case and his affected father with a rare LRP6 variant (J,K). The following 
OPTs are shown and their respective STHAG status: A: TA2, 7 STHAG; B: TA3-M, SR STHAG, SR extr.; C: TA3-F, SR 
extr.; D: TA3, 10 STHAG; E: TA3-S, 2 STHAG; F: TA4-M, 1 STHAG; G: TA4, 13 STHAG; H: TA5-M, SR STHAG, SR extr.; 
I: TA5, 6 STHAG; J: TA6-F, 13 STHAG; K:TA6, 17 STHAG. Abbreviations: TA patient with Tooth Agenesis; STHAG 
selective tooth agenesis; M mother; F father; S sibling; SR self-reported; extr: extractions.
Supplementary Tables
Table S5.1 Overview of phenotypes in cohorts used in re-sequencing through MIPs
Cases Controls
OFC
TA
CPO
CL/P
CLA CLO CLP
Nijmegen 77 40 50 121
Leuven 23 5 11 32 67
Bonn 94 82 43 494 706
Total 1072 67 706
OFC: Orofacial Clefting; CPO: Cleft Lip Only; CL/P: Cleft Lip with or without Cleft Palate; TA:Tooth Agenesis; CLA: Cleft Lip and 
Cleft Alveolus; CLO: Cleft Lip Only; CLP: Cleft Lip and Palate
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Table S5.3B Detailed phenotypes of OD cases and family members
Samples Phenotypes (OFC-
OD,OD,OFC)
TA phenotypes affected 
relatives
Additional features
Case 1
OFC (BCLAP) 
TA of 4 DT: #52, #62, #72; #82 
and 
17 PT: #12, #13, #14, #15, #22, 
#23, #24, #25, #31,
#32, #33, #34, #35, #41, #42, 
#44, #45; 1 extr: #36
Mother: TA of 12 PT: 
#12, #14, #15, #22, #24, #25, 
#31, #32, #34, #35, #41, #42, 
#44, #45 
Grandmother: SR TA
Proband: inclined #43; very small 
prolabium at birth; GHT is considered;  
bad vision
Mother is short; smoking during 
pregnancy
Case 2
TA of 2DT:#52, #62 and
9 PT:#17, #15, #14, #12, #22, 
#25, #27, #35, #45
/
Proband: malpositions of #17, #32, 
impaction of #24; conic shape of #13 and 
#23; mild dysmorphic ears, clinodactyly
TA1
TA of 9 PT: #12, #13, #15, #22, 
#23, #24, #25, #35, #45
NA
11 months growth retardation at  
12yrs of age 
GHT considered
TA2
TA of 7 PT: 
#12, #13, #22, #23, #34, #42, 
#44
Both parents: SR many extr. NA
TA3
TA of 10 PT: 
#12, #14, #15, #17, #22, #25, 
#26, #34, #35, #45
Mother: SR TA and extr.; 
Sister: TA of 2 PT (#12, #22)
Proband: clinodactyly; 
GHT considered
TA4
TA of 13 PT: #15, #14, #13, #12, 
#22, #23, #24, #25, #35, #34, 
#43, #44, #45
Mother: TA of 1 PT (#45, 
common STHAG)
Proband: ankylosis of many deciduous 
teeth; long thin condyles, clinodactyly, 
GHT considered
TA5
TA of 6 PT: 
#12, #22, #27, #37, #35, #45
Mother: SR TA and many extr; 
Grandmother: SR DT present 
at old age
Proband: ankylosis of second deciduous 
molars, thin enamel layer on all teeth, 
enamel defects 
Mother: long thin condyles
NA, not available; SR, self reported; extr., tooth extractions; STHAG, selective tooth agenesis; PT, permanent teeth; DT; 
deciduous teeth; GHT, growth hormone treatment
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CHAPTER 6
Identification of a de novo variant 
in CHUK in a patient with an EEC/
AEC syndrome-like phenotype and 
hypogammaglobulinemia
Khandelwal KD, Ockeloen CW, Venselaar H, Boulanger C, Brichard B, 
Sokal E, Pfundt R, Rinne T, van Beusekom E, Bloemen M, Vriend G, Revencu N, 
Carels CEL, van Bokhoven H, Zhou H.
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Abstract
The cardinal features of Ectrodactyly, Ectodermal dysplasia, Cleft lip/palate (EEC) and Ankyloblepharon-
Ectodermal defects-Cleft lip/palate (AEC) syndromes are ectodermal dysplasia, orofacial clefting, 
and limb anomalies. EEC and AEC are caused by heterozygous mutations in the transcription 
factor p63 encoded by TP63. Here, we report a patient with an EEC/AEC syndrome-like phenotype, 
including ankyloblepharon, ectodermal dysplasia, cleft palate, ectrodactyly, syndactyly, additional 
hypogammaglobulinemia, and growth delay. Neither pathogenic mutations in TP63 nor CNVs at 
the TP63 locus were identified. Exome sequencing revealed de novo heterozygous variants in CHUK, 
PTGER4, and IFIT2. While the variant in PTGER4 might contribute to the immunodeficiency and growth 
delay, the variant in CHUK appeared to be most relevant for the EEC/AEC-like phenotype. CHUK is a 
direct target gene of p63 and encodes a component of the IKK complex that plays a key role in NF-κB 
pathway activation. The identified CHUK variant (g.101980394T>C; c.425A>G; p.His142Arg) is located 
in the kinase domain which is responsible for the phosphorylation activity of the protein. The variant 
may affect CHUK function and thus contribute to the disease phenotype in three ways: 1) the variant 
exhibits a dominant negative effect and results in an inactive IKK complex that affects the canonical 
NF-κB pathway; 2) it affects the feedback loop of the canonical and non-canonical NF-κB pathways that 
are CHUK kinase activity-dependent; 3) it disrupts NF-κB independent epidermal development that 
is often p63-dependent. Therefore, we propose that the heterozygous CHUK variant is highly likely to 
be causative to the EEC/AEC-like and additional hypogammaglobulinemia phenotypes in the patient 
presented here.
6.1 Introduction
Ectrodactyly-ectodermal dysplasia-cleft lip/palate (EEC) syndrome (OMIM 604292) is a rare genetic 
ectodermal dysplasia (ED) syndrome. Patients with EEC syndrome present with variable features 
of ectrodactyly, defects in skin, hair, and nails, and orofacial clefts (OFC). A related ED syndrome, 
Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome (OMIM 106260), is characterized 
by ankyloblepharon (fusion of the eyelids), severe malformations of ectoderm-derived tissues, such as 
skin, hair, nails, sweat glands, orofacial clefts, and limb anomalies [Rinne et al., 2007; Sutton et al., 2009]. 
The clinical findings of EEC and AEC can overlap. For instance, ankyloblepharon, which is pathognomonic 
for AEC syndrome has been reported in some patients who were classified as EEC syndrome [Berdón-
Zapata et al., 2004]. In contrast to EEC syndrome, severe limb malformations such as ectrodactyly were 
not considered to be typical for the AEC syndrome phenotype. However, syndactyly and hammertoe 
deformities appeared to be surprisingly common (17/18 cases) in a cohort of AEC patients, suggesting 
that mild limb anomalies are a significant factor in AEC syndrome [Sutton et al., 2009]. Hearing loss 
which has been reported in more than 90% of the AEC patients [Cole et al., 2009] rarely occurs in EEC 
patients also [Rinne et al., 2006]. ED symptoms such as skin erosions, sparse hair, and nail dysplasia 
are more severe in AEC than in EEC. Many AEC and EEC patients do not present with any OFC features. 
Patients with overlapping features of both EEC and AEC have been described [Rinne et al., 2006]. 
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For instance, Celik and colleagues (2011) reported a neonate with diffuse skin erosions, which are 
suggestive of AEC, while no ankyloblepharon or orofacial clefts, but with ectrodactyly and polydactyly, 
which are severe limb abnormalities and suggestive of EEC [Celik et al., 2011]. Clinical heterogeneity is 
typical for both syndromes [Rinne et al., 2006]. 
Mutations in the transcription factor p63 encoded by TP63 are the underlying cause in the majority of 
diagnosed EEC and AEC syndrome cases. The p63 protein is important for the normal development 
of ectoderm-derived tissues. It plays an essential role in the development of the epidermis, the limbs, 
urinary system and orofacial structures. TP63 is located on chromosome 3q28 [Yang et al., 1998; Celli 
et al., 1999] and encodes several p63 isoforms resulting from the use of two different promoters (TA 
and ΔN) and due to extensive alternative splicing routes. All the isoforms contain a DNA-binding 
domain (DBD) and an Oligomerization domain (OD), but they differ in their transactivation domain, 
the C-terminal sterile alpha-motif (SAM) and auto-regulating transactivation inhibiting domain (TID). 
Striking genotype-phenotype correlations have been observed for TP63 mutations in EEC and AEC 
syndromes. EEC syndrome mutations are located in the DBD of p63, which disrupts the p63 binding to 
DNA and hence affect transactivation [Celli et al., 1999]; while mutations leading to AEC are mainly seen 
in the SAM and TID domain as well as in the N-terminus that is unique for ΔN-isoforms of p63 [McGrath 
et al., 2001; Rinne et al., 2008].
Phenotypically related disorders are often caused by functionally related genes [Oti et al., 2008]. TP63 
and its target genes constitute a gene network governing ectodermal development. Mutations in 
these p63 target genes and regulatory elements are known to give rise to various conditions that have 
overlapping features with the p63 associated syndromes. For example, IRF6 is a direct transcriptional 
target of p63 [Thomason et al., 2010]. Mutations in IRF6 are known to cause Van der Woude syndrome 
(VWS, OMIM #119300) and Popliteal Pterygium Syndrome (PPS, OMIM #119500), which often present 
with cleft lip and/or cleft palate (CL/P) [Kondo et al., 2002]. Similarly, mutations and genomic alterations 
of DLX5/6 genes that are controlled by p63 lead to split hand/foot malformations [Kouwenhoven et al., 
2010b; Shamseldin et al., 2012; Velinov et al., 2012; Gurrieri and Everman, 2013].
The patient reported in the present study exhibited an EEC/AEC syndrome-like phenotype with 
additional hypogammaglobulinemia and growth delay, which are not typically included in p63 mutant 
phenotypes. Using trio exome sequencing, we identified three de novo variants, affecting CHUK, 
PTGER4, and IFIT2. As CHUK is known to be regulated by p63 [Candi et al., 2006] and plays a role in 
epithelial development [Hu et al., 2001; Sil et al., 2004], we propose that the de novo mutation in CHUK 
is responsible for the ectodermal phenotype in this patient.
520163-L-bw-Khandelwal
Processed on: 6-6-2018 PDF page: 111
111A de novo variant in CHUK in a patient with an EEC/AEC syndrome-like phenotype andhypogammaglobulinemia  | 
6
6.2 Clinical report
The patient, a 10-year-old girl, is the third child of healthy, non-consanguineous parents of Caucasian 
origin. The family history is unremarkable. The parents had no features of ED or hypogammaglobulinemia. 
At conception, the mother was 33 years old and the father 36 years old. During pregnancy, hypoplastic 
thumbs with reduced mobility and 3–5 syndactyly in feet with the absence of the second rays were 
observed. The child was born at 38.5 weeks. The growth parameters at birth were: weight 3305 g, 
length 49 cm, and OFC 33.5 cm. The clinical examination revealed sparse hair, absent eyebrows and 
eyelashes, ankyloblepharon, buccal synechia, posterior cleft palate, retrognathia and hypoplastic 
external genitalia. The limb anomalies seen prenatally were confirmed, and the nails were dysplastic. 
The X-rays showed complex hand and foot anomalies (Figure 6.1). The phenotype suggested EEC/AEC 
syndrome. The evolution of the child was marked by severe gastro-oesophageal reflux with swallowing 
problems, growth retardation and frequent upper and lower respiratory tract infections. She was tube 
fed from birth until four months of age when a gastrostomy was required. At the age of five months, 
gammaglobulin deficiency and increased AST, ALT, and γ-GT were observed. The work-up showed 
normal cellular immunity and normal phagocytosis and discrete inflammation on hepatic biopsy. Since 
then, she has been under intravenous immunoglobulin therapy every three weeks and ursodeoxycholic 
acid. She developed bronchiectasis in the lower and middle right lobes and atelectasis of the left lower 
lobe. At the age of seven years, coeliac disease was diagnosed. At the age of ten years, her height was 
118.8 cm (-3.5 SD) and the weight 20.5 kg (-3SD). The deciduous teeth were conical and fragile. The 
panoramic radiograph showed agenesis of many permanent teeth.
Figure 6.1 Clinical photographs of the index patient. a-b: the patient at birth – sparse hair and absent 
eyebrows; c-d: the patient at 9 years of age – sparse hair, eyelashes and eyebrows hypoplastic alae nasi, 
thin vermillion border; e-j: hypoplastic thumbs and first metacarpals; i-l: four metatarsal bones with large 
proximal extremity of the 4th ray on the left side and fusion between the 4th and the 5th rays on the right side; 
bilateral toes syndactyly of three rays with dysmorphic phalanges. 
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6.3 Methods
The coding region of the TP63 gene and the intron-exon boundaries were sequenced, and no 
pathogenic mutation was detected. Molecular karyotyping was performed using 250K NspI Affymetrix 
SNP-array according to the manufacturer´s instructions. No genomic rearrangement was observed.
6.3.1 Exome Sequencing
Exome sequencing analysis was performed in a trio approach (patient and both parents), essentially 
as described before [Neveling et al., 2013]. Exome capture was performed with the Agilent SureSelect 
Human All Exon v4 enrichment kit (Agilent Technologies). Whole-exome sequencing was performed 
on the Illumina HiSeq platform (BGI, Copenhagen, Denmark). Data were analyzed with BWA (read 
alignment) [Li and Durbin, 2009] and GATK (variant calling) [McKenna et al., 2010] software packages. 
Variants were annotated using an in-house developed pipeline. Prioritization of variants was done 
by an in-house designed ‘variant interface’ and manual curation. Potentially causative variants were 
confirmed by Sanger sequencing.
6.3.2 Sanger sequencing
All 21 exons of CHUK were amplified in eleven additional patients with features reminiscent of EEC 
(Ectrodactyly Ectodermal Dysplasia Cleft Lip/Palate) and AEC without mutations in TP63. Specific 
primers were designed through Primer3 [Untergasser et al., 2012] and sequences are shown in Table 
S6.1. The PCR products were purified to remove excess primers and dNTPs using two hydrolytic 
enzymes, Exonuclease I (Exo I) and Thermosensitive Alkaline Phosphatase (FastAP) and sequenced.
6.3.3 Molecular Structural Modeling
The molecular effects of the IFIT2 mutation were studied using the experimentally solved protein 
structure (PDB file 4G1T) [Yang et al., 2012]. For both CHUK and PTGER4, no known protein structure 
is available and therefore a homology model was created to study the CHUK mutation. The modeling 
script with standard parameters in the YASARA [Krieger et al., 2002] & WHAT IF Twinset [Vriend, 1990]
was used to create this model based on PDB-file 4KIK [Liu et al., 2013]. This template PDB-file contains 
the structure of human IKKβ, which has 56% sequence identity with CHUK over 593 residues (Figure 
6.2). No modeling template for PTGER4 could be found. The mutation in this protein was analyzed 
using standard amino acid properties and knowledge obtained from the Uniprot database [UniProt 
Consortium, 2015] (entry: P35408). 
6.4 Results
Given the EEC/AEC syndrome-like phenotype observed in this patient, we hypothesized that the p63 
pathway is likely involved in the pathogenesis. Therefore, we first sequenced TP63 in the index patient, 
but no pathogenic mutation was detected. A genome-wide copy number analysis did not reveal any 
pathogenic CNVs. Subsequently, exome sequencing was performed in the index patient and the 
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unaffected parents. Three heterozygous de novo variants were identified after the filtering steps as 
mentioned in Methods. These variants were present in PTGER4 (g.40691969C>T; p.Ser319Phe), IFIT2 
genes (g.91066224A>G; p.Asn171Asp) and CHUK (g.101980394T>C; c.425A>G; p.His142Arg) (Table 6.1). 
Table 6.1 Three de novo variants identified by exome sequencing in the trio
Gene Nucleotide 
position a
Variant  
cDNA
Amino acid 
change
phyloP CADD  
PHRED-like 
score
Probability of 
intolerance of LoF 
variations (pLI)
PTGER4  
(NM_000958; P35408)
g.40691969C>T c.956C>T Ser319Phe 5.693 18.57 0.90
IFIT2  
(NM_001547; O15111)
g.91066224A>G c.511A>G Asn171Asp 0.36 13.1 0.00
CHUK  
(NM_001278; P09913)
g.101980394T>C c.425A>G His142Arg 4.382 23.6 1.00
a Human genome build hg19 is used to annotate the variants.
All three variants were confirmed to be present in the patient and absent in both parents. The PTGER4 
(p.Ser319Phe) variant occurs at a highly conserved nucleotide (phyloP: 5.69) and affects a moderately 
conserved amino acid. There is a large physicochemical difference between the reference amino acid 
serine and the variant amino acid phenylalanine (Grantham score: 155). The variant in IFIT2, p.Asn171Asp 
occurs at a weakly conserved nucleotide (phyloP: 0.29) and affects a moderately conserved amino acid. 
There is a small physicochemical difference between the reference amino acid asparagine and the 
variant amino acid aspartic acid (Grantham score: 23). The C-terminal part of IFIT2 folds into a super-
helical structure containing nine tetratricopeptide repeats (TPR). The identified IFIT2 variant affects 
an amino acid in the TPR3 domain. Molecular structural modeling predicted the mutation to be on 
the surface of the protein, and it is unlikely to have a major effect on its function (Figure 6.2). The 
CHUK variant (p.His142Arg) occurs at a highly conserved nucleotide (phyloP: 4.32) and affects a highly 
conserved amino acid, close to the amino acid Asp144 responsible for the kinase activity. Using human 
IKKβ that shows 56% amino acid sequence identity with CHUK as a template, molecular structural 
modeling predicted that the affected amino acid is located at the core of the protein 3D structure, and 
the change is likely to affect the 3D structure of the protein. In ExAC database, based on the observed 
and expected variants counts, the probability of intolerance of loss-of-function variations (pLI) was 
determined [Lek et al., 2016]. Based on this, PTGER4 and CHUK are highly intolerant to loss-of-function 
mutations (pLI=0.90 and 1.00, respectively), while IFIT2 is not intolerant at all (pLI=0.0).
CHUK is known to be directly regulated by p63. To assess whether CHUK and TP63 share similar 
expression pattern in epithelial cells, we examined expression of these two genes using our previously 
reported RNA-Seq data of primary human keratinocytes (HKC) [Kouwenhoven et al., 2010a] and 
publicly available RNA-Seq data of normal human epidermal keratinocytes (NHEK) and those of a 
breast adenocarcinoma cell line MCF-7 [Dong et al., 2012; The ENCODE Project Consortium, 2012].
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Figure 6.2 Structural model of CHUK protein. The CHUK monomers are depicted in different shades of 
gray. The position of the mutation (p.His142Arg) is shown in red, and the substrate is shown in yellow. The 
inset shows the different sidechains of the mutant (red) and wildtype (green) amino acids. This indicates the 
difference in size. The yellow substrate is also visible, which shows the proximity of the active site residues. 
As expected, both CHUK and TP63 were found to be expressed in all three cell lines (Figure 6.3). 
Mutations in CHUK have been associated with cocoon syndrome (OMIM #613630) and Bartsocas-Papas 
Syndrome (BPS, OMIM # 263650), two disorders that have overlapping but much severe phenotypes, 
as compared to EEC/AEC syndrome. Therefore, the variant in CHUK was considered to be most likely 
causative for the ectodermal dysplasia features. Eleven other patients with EEC or AEC who do not carry 
any TP63 mutation were assessed for mutations in CHUK. No pathogenic variant in CHUK was identified 
in these patients.
 
6.5 Discussion
The index patient exhibited a phenotype similar to EEC/AEC syndrome with additional immunodeficiency. 
Thus, the TP63 gene which has been implicated in EEC and AEC syndrome was tested. No mutation in 
TP63 or CNV containing TP63 was identified. Subsequently, trio exome sequencing was performed and 
three de novo variants were identified in CHUK, PTGER4, and IFIT2 genes. CHUK forms the IKK complex 
together with IKKβ and IKKγ (also known as NEMO). The canonical NF-κB pathway is dependent on the 
kinase activity of the IKK complex to phosphorylate and degrade inhibitors to activate NF-κB [Smahi 
et al., 2002; Yamamoto et al., 2003]. It has been shown that both CHUK and IKKβ work in homodimer 
or heterodimer form [Huynh et al., 2000]. The kinase domain of CHUK is located at the N-terminal 
region of the protein and is followed by a leucine zipper domain which facilitates homo- and hetero-
dimerization. At the C-terminal region of CHUK, there is a NEMO (NF-κB essential modulator; IKKγ) 
binding region. The variant in CHUK (g.101980394T>C; c.425A>G; p.His142Arg) occurs in the core of 
the kinase domain, close to the amino acid Asp144 that is responsible for phosphorylation activity. 
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CHUK is extremely intolerant to the loss-of-function variations. Therefore, this variant is highly likely to 
disrupt the kinase activity and be possibly causal.
Homozygous CHUK mutations that lead to severe ectodermal defects have been reported. A 
homozygous nonsense mutation of CHUK (c.1264C>T; p.Gln422X) was identified in two fetuses with 
severe fetal malformations in a Finnish family, named as cocoon syndrome [Lahtela et al., 2010]. The 
mutation was inherited from heterozygous carrier parents, who were phenotypically unremarkable. 
Both the fetuses had an abnormal cyst in the cranial region, a large defect of the craniofacial area, and 
an omphalocele, as well as immotile and hypoplastic limbs. This CHUK mutation is predicted to result in 
a truncation after the kinase domain. Another homozygous CHUK mutation was identified in a patient 
with Bartsocas-Papas syndrome (BPS), which is considered to be a milder form of cocoon syndrome 
[Leslie et al., 2015]. This patient presented multiple abnormalities including skin, limb, orofacial and 
genital defects. This mutation is at the exon 10 splice acceptor site (c.934-2A>G) and also predicted 
to result in protein truncation after the kinase domain. In both cases, the described mutations are 
homozygous and lead to truncation of the dimer forming leucine zipper and very likely the complete 
loss of the protein. Heterozygous carriers of these loss-of-function alleles do not present any features 
of ectodermal dysplasia. In contrast, the CHUK heterozygous missense variant identified in the EEC/
AEC-like patient with immunodeficiency in the current study appears to act in a dominant fashion. This 
variant is located in the kinase domain of CHUK, and is predicted to impair CHUK kinase activity, but not 
its capacity to engage in homomeric and heteromeric complexes. Therefore, it is likely that the mutant 
CHUK protein with this variant can heterodimerize with IKKβ in the IKK complex and exhibit a dominant 
negative effect towards the wild type protein to affect the canonical NF-κB activation.
In agreement with this dominant-negative model of de-regulating the canonical NF-κB pathway, 
many mutations in NEMO including nonsense, frameshift and sometimes missense mutations have 
been found to lead to ectodermal dysplasia syndromes with immune deficiency. These conditions 
include Incontinentia pigmenti (IP), Anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), 
Anhidrotic ectodermal dysplasia with immune deficiency, osteopetrosis and lymphoedema (OL-EDA-
ID) and hypomorphic mutations to a less severe phenotype of hypohidrotic/anhidrotic ectodermal 
dysplasia (HED/EDA) [Senegas et al., 2015]. Sometimes point mutations in NEMO can also give rise to 
immunodeficiency without ectodermal dysplasia phenotype. Furthermore, a frameshift mutation has 
also been reported in IKKβ to cause a severe combined immunodeficiency (SCID) that is characterized 
by recurrent infections and hypogammaglobulinemia/agammaglobulinemia [Pannicke et al., 2013. 
Mutations in other genes involved in NF-κB, namely EDA1, EDAR, and EDARADD have also been found 
to cause EDA [Smahi et al., 2002]. These studies suggest that gene mutations perturbing the canonical 
NF-κB pathway can affect immunity. On the other hand, immunodeficiency observed in the patient 
in the current study was not reported in previous studies on cocoon syndrome and BPS. This raises 
the question whether the severe cocoon syndrome and BPS phenotypes prohibited the observation 
of possible immune phenotypes, or whether the complete loss of CHUK does not significantly affect 
the canonical NF-κB pathway. Although the IKK complex and the NF-κB pathway are well known for 
their roles in immunohomeostasis, CHUK itself has a minor contribution to the overall kinase activity of 
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the complex among the three IKK complex members [Hu et al., 1999; Descargues et al., 2008]. CHUK-
deficient mice show terminal differentiation problems of the epidermis, whereas the activation of NF-
κB was not affected [Li et al., 1999; Descargues et al., 2008].
In addition to the role in the canonical NF-κB pathway, CHUK serves a key role in negative feedback of 
canonical and non-canonical NF-κB signaling [Razani et al., 2010; Shembade et al., 2011]. The negative 
feedback depends on the kinase activity of CHUK, but not on IKKβ nor NEMO [Razani et al., 2010]. Both 
canonical and non-canonical NF-κB signaling, and the feedback loop seem to be involved in epidermal 
development [Smahi et al., 2002]. The mutation identified in this study may affect the negative feedback 
of both canonical and non-canonical NF-κB signaling pathways. 
Furthermore, CHUK directly regulates epidermal differentiation through an NF-κB independent route. 
It has been shown that a Nuclear Localization Signal (NLS) that is located in the kinase domain of CHUK 
is essential for CHUK to enter the nucleus and to directly regulate epidermal genes [Sil et al., 2004]. This 
variant in the kinase domain may also disrupt the NLS that lies nearby, and abolish the ability of CHUK 
to enter the nucleus. This can lead to the complete loss of the NF-κB independent function of CHUK 
through which it regulates direct target genes important for epidermal differentiation. 
Consistent with NF-κB independent role of CHUK in epidermal differentiation and development, 
CHUK is a direct p63 transcriptional target [Candi et al., 2006]. Loss of Chuk in mice leads to multiple 
morphogenetic defects in limb and skeletal patterning, and in proliferation and differentiation 
of epidermal keratinocytes [Hu et al., 1999; Takeda et al., 1999], which is very similar to phenotypic 
features observed in Tp63-knockout mice [McKeon et al., 1999]. Koster and colleagues showed that the 
downregulation of ΔNp63 in the epidermis of newborn mice results in CHUK mRNA down-regulation 
as well as in severe skin fragility characterized by multiple skin erosions. This skin phenotype is similar 
to that observed in AEC syndrome [Koster et al., 2007; Marinari et al., 2008]. In accordance, Marinari 
and colleagues confirmed that CHUK and p63 are co-localized in the human epidermis and the 
ΔNp63 isoform is required for CHUK expression in differentiating keratinocytes. Furthermore, mutant 
p63 protein expressed in ectodermal dysplasia patients exhibit defects in inducing CHUK expression 
[Marinari et al., 2008]. Consistent with these findings, we showed that CHUK and p63 co-express in 
several epithelial cells (Figure 6.3). Taken together, CHUK acts as a critical p63 downstream target gene 
in the regulation of epidermal morphogenesis and therefore the variant we identified in this patient is 
highly likely to be causal for the EEC/AEC-like phenotypes. It will also be interesting to test the effect of 
this variant on the kinase activity and nuclear localization of CHUK and the CHUK-mediated negative 
feedback loop.
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Figure 6.3 Expression of CHUK and TP63 in various epithelial cells. The UCSC genome browser screenshot 
shows the RNA-Seq tracks for the CHUK and TP63 loci of Human Skin Keratinocytes (HKC), Normal Human 
Epidermal Keratinocytes (NHEK), and Michigan Cancer Foundation-7 (MCF-7) cells, obtained from previously 
published or publically available data. The signal at the exons in the RNA-Seq tracks represents the abundance 
of mRNA and hence the expression of the gene. The label on the left of each track represents the level of 
expression.
Besides the CHUK variant, two other de novo variants were identified, affecting PTGER4 and IFIT2. Neither 
of these genes seems to have a function in epidermal development or to be a part of the TP63 network. 
PTGER4 (Prostaglandin E Receptor 4) encodes a transmembrane receptor which is a member of the 
G-protein coupled receptor (GPCR) family. It is one of the four receptors for prostaglandin E2, which 
regulates multiple aspects of the immune system and may be involved in the neonatal adaptation 
of the circulatory system [Segi et al., 1998], osteoporosis [Yoshida et al., 2002], as well as initiation of 
skin immune responses [Kabashima et al., 2003]. This receptor is involved in T-cell factor signaling. 
PTGER4 has been implicated in inflammatory bowel disease (IBD). The PTGER4 variant (g.40691969 
C>T; p.Ser319Phe) identified in the index patient affects an amino acid in the TM-7 transmembrane 
region of the protein. Therefore, this variant could affect the function of PTGER4 and may have a 
role in the immune and growth-related phenotypes present in the patient. IFIT2 (Interferon-Induced 
protein with tetratricopeptide repeats 2) encodes for an antiviral protein which inhibits expression of 
viral messenger RNAs. Based on the nature of the variant, and molecular structural position and the 
function of the gene, the IFIT2 variant (g. 91066224 A>G; p. Asn171 Asp) identified in the index patient 
is unlikely to contribute to the diseases.
In conclusion, we report a patient with EEC/AEC syndrome-like phenotype with additional hypo-
gammaglobulinemia. The heterozygous de novo variant in CHUK identified in the index patient is 
most likely causative for the EEC/AEC-like phenotypes. The difference in zygosity of the mutations and 
potentially affected pathways could explain the less severe ED phenotype and the additional immune-
related phenotype in the present patient, as compared to those with previously reported Cocoon 
syndrome and BPS that are also caused by CHUK mutations. The PTGER4 variant could have a role, 
alone or in combination with the CHUK variant, in the immune and growth-related phenotypes present 
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in the patient. Further functional analysis of this variant would be necessary to confirm its contribution 
to the observed phenotypes in the patient. We also suggest testing CHUK for mutations in additional 
patients with the combination of EEC/AEC syndrome-like and immune-related phenotypes, such as 
one presented here to affirm the role of CHUK further.
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Functional variants in p63-bound 
non-coding regulatory elements 
involved in orofacial clefting
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Abstract
The transcription factor p63 encoded by TP63 is a master regulator of ectodermal development, 
which binds to cis-regulatory elements in the genome to regulate expression of genes involved in 
ectodermal development. Mutations in TP63 cause syndromic orofacial clefting in developmental 
disorders. Mutations in p63-bound regulatory elements, also known as p63 binding sites, have been 
shown to result in conditions with defects in ectodermal structures. This study presents a systematic 
genome-wide analysis for the identification of functional variants (polymorphisms) residing in p63 
binding sites that possibly affect the binding of p63 protein and hence its ability to regulate genes 
associated with orofacial clefting (OFC). Using bioinformatics tools, p63 binding sites containing 
a common polymorphism in the core p63 recognition motif were selected based on four criteria: (I) 
Motifs that are in proximity to the OFC-related genes, (II) Motifs that overlap with the IRF6 binding sites, 
(III) Motifs that lie in the OFC-associated GWAS loci, and (IV) Motifs that lie upstream to ARHGAP29/ 
ABCA4 gene. Transactivation assays revealed 14 binding sites responsive to p63. Four of these p63 
binding sites, which were either co-bound by IRF6 or present in an OFC-associated locus, were also 
tested in a transgenic zebrafish reporter assay to assess how it drives developmental gene expression. 
One binding site in ABCA4, BS abca4.5, was found be active in neural tissues and in ventral cells that will 
form facial structures in zebrafish. The data presented in this report provides a list of p63 binding sites 
which could act at non-coding regulatory elements controlling the expression of novel or known OFC 
genes. The variants present in such binding sites could disrupt the ability of p63 to recognize the DNA 
and its binding and hence, the regulation of distantly or nearby located OFC-related genes. 
7.1 Introduction
Orofacial clefting (OFC) affects 1 in ~700 live births, and thus represents one of the most common 
congenital dysmorphisms.1 It is caused by disruption in the development, migration or fusion of 
orofacial tissues. In syndromic forms of OFC, affected individuals also present with other abnormalities 
besides OFC, such as ectodermal dysplasia, limb malformations, and lip pits. Such syndromic forms 
of OFC are often the result of a genomic variant or single gene mutation, which occur either de novo 
or show a Mendelian inheritance pattern.2,3 Two major genes involved in syndromic forms of OFC 
are TP63 and IRF6. On the other hand, individuals affected with nonsyndromic form of OFC have no 
additional phenotypic abnormalities. Nonsyndromic forms of OFC (nsOFC) are generally considered 
to have multifactorial inheritance involving multiple genetic and environmental factors. The genetic 
heterogeneity and complex etiology make it difficult to identify specific genetic mutations that cause 
OFC.1 
Genome-wide associated studies (GWAS) have identified at least 12 loci that are significantly 
associated with nsOFC.4–9 These loci are expected to harbor one or more “risk variants”, which impart 
risk towards development of the disorder. It is believed that statistically significant variants identified 
in GWAS may not have functional impact themselves on the phenotype. Instead, other variants in 
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linkage disequilibrium (LD) with the risk variants may be the true “functional variants”. Such functional 
variants might be identified by their location in regulatory regions.10 Most risk variants identified by 
GWAS are found in non-coding regions of the genome. For example, an OFC-associated locus identified 
in multiple GWAS studies is located in a gene-desert on chromosome 8q24.21. Other recurrent risk 
variants have been identified in the gene ABCA4, a gene that plays a major role in the etiology of 
macular degeneration and related retinopathies but with no obvious relationship with clefting.7 It was 
later established that altered expression of the nearby gene ARHGAP29 and, not ABCA4 itself, by the risk 
allele likely accounts for the risk to develop OFC.11
Studies on genes identified for syndromic OFC have provided insight into the molecular mechanisms 
of nsOFC. Mutations in TP63 and IRF6 cause various syndromes where OFC is part of the phenotype. 
TP63 is a member of the p53 family of transcription factors. It encodes p63, which has a key role in 
ectodermal development. Mutations in TP63 are known to cause several developmental disorders, 
such as, Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome (EEC), Ankyloblepharon –
ectodermal defects-cleft lip/palate syndrome (AEC), and Limb mammary syndrome (LMS). OFC is one 
of the hallmarks of these disorders. Missense mutations in TP63 have also been identified in nsOFC.12 
The transcription factor interferon regulatory factor 6 (IRF6) regulates craniofacial development and 
epidermal proliferation. Like TP63, missense mutations in IRF6, as well as nonsense mutations are 
known to cause syndro6mic orofacial clefting (OFC), such as, Van der Woude syndrome (VWS; MIM 
#119300), and popliteal pterygium syndrome (PPS; MIM #119500). Common variants in IRF6 have also 
been identified as risk factors for nsOFC. GWAS in large cohorts of subjects with nsOFC have identified 
risk variants in both TP63 and IRF6.6,9
Both mutations in TP63 and the disruption of p63 binding sites (p63 BSs) can result in dysregulation of 
genes involved in proper ectodermal development, and consequently lead to various developmental 
disorders. For example, a family with van der Woude syndrome-like phenotype has been identified 
where the affected individuals do not contain any pathogenic mutation in IRF6 itself, but in an upstream 
p63 BS.14 This mutations maps to the MCS9.7 region, a conserved non-coding element upstream to 
the IRF6, which harbours a common polymorphism representing a risk factor for nonsyndromic cleft 
lip.13we use multispecies sequence comparisons to identify a common SNP (rs642961, G>A The familial 
mutation is an insertion of an Adenosine (A) in this upstream BS was identified as the etiologic mutation 
in the affected individuals of the family.14 This insertion was present in the p63 motif which is a 19 bp 
long recognition sequence in the p63 BS (Figure 7.1).15 The Cytosines (Cs) and Guanines (Gs) at the 
positions 3rd, 6th, 13th and 16th are highly conserved among all the motifs. These nucleotides and their 
position and distance are important for p63 binding.15 This A insertion affected the positioning of three 
of these nucleotides, and disrupted p63 binding and transactivation activity. This specific example 
shows that genetic variants in p63BS can lead to abnormalities in lip and palate development. 
In the current study, we systematically analyzed the previously published genome-wide p63 BSs16 to 
identify variants in these p63 BSs which may contribute to OFC. 
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7.2 Material and methods
7.2.1 Bioinformatics analysis 
The p63 BSs were filtered using Galaxy, a platform for interactive large-scale genome analysis.17 The 
various actions of intersecting, joining, and merging two or more datasets were performed using the 
tool “Operate on genomic intervals” in Galaxy. Details of actions and settings of Galaxy tools used are 
indicated in Figure S7.1 and elaborated in the Results section. The SNPs information (dbSNP141) was 
retrieved from UCSC Genome Browser.18
7.2.2 Gateway cloning
The p63 BSs were cloned using the Gateway™ Cloning Technology (Life Technologies). p63 BSs 
from control (no disease phenotype)  human genomic DNA were amplified via PCR using Phusion® 
High-Fidelity DNA Polymerases (New England BioLabs). By designing primers containing the attB 
recombination sites (Table S7.1), the PCR product obtained was flanked by attB recombination sites. 
Amplified BSs were cloned into a pDONR201 vector using BP Clonase™ yielding a pENTRY vector. 
These pENTRY vectors containing BSs were used to recombine in different destination vectors using 
LR Clonase™.  A modified mammalian pGL3-Enhancer Reporter vector containing a firefly luciferase 
reporter gene followed by a SV40 enhancer was used to test the luciferase activity.16 A modified mintol2 
vector, that contained a Gateway cassette, followed by a zebrafish Gata2 promoter, GFP reporter gene 
and a Z48 enhancer element was used to assess where the BSs drive gene expression in orofacial 
structures during zebrafish development.16
7.2.3 Cell culture and transfection
The Saos-2 cell line was maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% 
fetal bovine serum, 1% sodium pyruvate at 37°C, 5% CO2.
2 Cells were transfected using Effectene™ 
Transfection Reagent (Qiagen). Approximately 2×105 cells were seeded into one well of a 6-well tissue 
culture plate. The next day, upon reaching 40–60% confluency, cells were transfected with 100ng of the 
modified mammalian pGL3-Enhancer Reporter vector containing the desired p63 BS. An empty pGL3-
Enhancer Reporter vector was the negative control and a pGL3-Enhancer Reporter vector containing 
a p63 BS (peak 229 from the MCS9.7 region) that has been shown before to work as an enhancer was 
the positive control.19,20 Two master mixes were prepared; one containing 100ng of mouse wildtype 
(wt)ΔNp63α expression vector (plus p63) and the other without p63 expression vector (minus p63). For 
some BSs, two additional master mixes were prepared, each containing an vector expressing mutant 
p63: p63 mutant I (R343W) and p63 mutant II (R243W). Transfection was carried out as described 
previously.3
7.2.4 Luciferase assay
Twenty-four hours after transfection, subconfluent cells were collected for luciferase (transactivation) 
assay. Cells were lysed and the luciferase assay was performed using the Dual Luciferase assay system 
(Promega) according to the manufacturer’s instructions. For the measurements a Lumat LB 9507 
(Berthold Technologies) was used. To quantify the output of firefly luciferase and thus the activity of 
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the p63 BS, firefly/renilla luciferase ratio of the technical duplicates of each transfection sample was 
averaged and the ratio of each construct between the plus ΔNp63α and minus ΔNp63α condition was 
compared. The average firefly/renilla luciferase ratio of the expression construct in the minus p63 was 
set to 1.0 and functioned as a baseline ratio for the average ratio in the plus p63.
7.2.5 Transgenesis in zebrafish
Transgenesis assays were performed as previously reported.21 Putative enhancers were amplified by 
PCR from genomic DNA using the primers listed in Table S7.1. The PCR fragments were subcloned 
in PCR8/GW/TOPO vector and, using Gateway technology (Life Technologies), and shuttled into an 
enhancer detection vector composed of a gata2 minimal promoter, an enhanced GFP reporter gene, 
and a strong midbrain enhancer (z48) that works as an internal control for transgenesis in zebrafish.22 
Zebrafish transgenic embryos were generated using the Tol2 transposon/transposase method23, 
with minor modifications. One-cell embryos were injected with a 2nL volume containing 25ng/μL 
of transposase mRNA, 20ng/μL of purified constructs and 0.05% of phenol red. In order to ensure 
the reproducibility of the expression patterns observed in the reporter assays, at least three stable 
transgenic lines derived from different founders were generated for each construct.
7.3 Results
7.3.1 Identification of potential functional variants in p63 BSs
The previously published p63 ChIP-seq data16 was utilized to identify potential functional variants in 
p63 motif contained in these BSs. For this, a selection of p63 motifs was made based on the presence of 
a SNP (both common and rare) at one or more of the four critical positions for p63 binding: the C and 
G nucleotides at positions 3, 6, 13 and 16 in the motifs (Figure 7.1). From the total 34,646 p63 motifs 
found in the p63 binding sites across the human genome, 10,700 motifs were identified with 13,553 
SNPs (Table S7.2). Out of these 10,700 motifs, 3,184 unique motifs contained 3,425 SNPs at one or more 
of the four important Cs and Gs (Figure 7.1; Table S7.3). This list of p63 motifs was further prioritized 
based on the following four criteria. 
(I) Motifs that are in proximity to genes previously implicated in OFC. The list of OFC-related genes 
was retrieved from Human Phenotype Ontology (HPO)24 and Mouse Genome Informatics (MGI)25 (Table 
S7.4). A total of 170 motifs was obtained based on this criterion (Table S7.5). (II) Motifs that overlap with 
the IRF6 BSs. Both p63 and IRF6 are known to play important role in orofacial development and have 
been shown to work cooperatively. Thus, the genomic regions bound by both p63 and IRF6 might be 
engaged in the co-regulation of genes involved in orofacial development by these two transcription 
factors. The list of IRF6 BSs was retrieved from a previous publication.26 Twelve motifs were obtained 
based on this criterion (Table7.1). (III) Motifs that are located in OFC-associated GWAS loci. The variant 
in the p63 motif could be the “functional variant” in LD with the “risk variant” of such GWAS loci. The list 
of OFC-associated loci was compiled using various references (Table S7.6).4–8 A total of six motifs was 
obtained on this criterion (Table 7.1). (IV) Motifs that lie upstream to ARHGAP29/in ABCA4 gene. Strong 
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risk variants have been identified with in the ABCA4 gene, but later it was shown that the ARHGAP29 
gene and not ABCA4 is relevant for OFC. ARHGAP29 is located ~48kb upstream of ABCA4, and encodes 
a GTPase activating protein with a role in craniofacial development. Thus, the p63 BSs adjacent to 
ARHGAP29 could regulate its expression. A total of four motifs were obtained based on this criterion 
(Table 7.1). All the genomic coordinates are in GRCh37/hg19 assembly. 
Figure 7.1 Flowchart depicting four criteria for filtering the p63 motifs with sequential steps. The inset 
depicts the 19 bp long consensus p63 motif.
In total 188 p63 motifs were prioritized from the four criteria (Table 7.1 and S7.5). The 166 motifs 
obtained from criterion I need further prioritization before being assessed functionally. Therefore, we 
first chose the 22 motifs obtained based on criteria II, III and IV as examples to be further assessed. 
7.3.2 Binding sites that act as enhancer elements in Saos-2 cells
Out of the 22 motifs containing BSs from the criteria II, III, and IV, 21 were successfully cloned with the 
major alleles into the mammalian pGL3-Enhancer Reporter vector3 and a modified mintol2 zebrafish 
vector (Table 7.1).16 
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All the 21 cloned BSs were transiently transfected in p63-null Saos-2 cells, to test their responsiveness 
towards p63 using a luciferase reporter gene. A known p63 enhancer peak 229 from the MCS9.7 region 
upstream of IRF6 was used as positive control (PC)19 , while an empty vector was taken as negative 
control (NC). Fourteen of the transfected BSs showed >1.5-fold induction upon p63 co-transfection 
compared to the NC.  These 14 BSs are: irf6.1, irf6.2, irf6.5, irf6.7, irf6.8, and irf6.9 from criterion II; r20378, 
r40508, loc2, and loc4 from criteria III; and abca4.2, abca4.3, and abca4.5 from criterion IV (Figure 7.2 
and S7.2; Table 7.1). To analyze whether the activation is specific for p63 and whether p63 mutations 
could disrupt the activation, we also tested eight of the 21 BSs (irf6.5, irf6.6, irf6.7, irf6.8, irf6.9, r40508, 
loc4, and abca4.2) with two transactivation-deficient p63 mutant proteins, R343W and R243W, both 
of which are known to cause EEC syndrome.2 Seven of these BSs were found to be not responsive to 
mutant p63 (Figure S7.2), demonstrating that the activation at these enhancers was dependent on WT 
p63 protein. For the BS irf6.6, the induction was similar for WT and mutant p63 vectors (Figure S7.2). 
Table 7.1 The filtered p63 binding sites that were cloned and transfected in Saos-2 cells
Attribute p63 motif Chromo-
some
Peak start Peak end Fold Induction 
with p63
Fold induction 
with mutant I 
(R304W)
Fold induction 
with mutant II 
(R204W)
(II
) O
ve
rla
p 
w
ith
 ir
f6
 B
S
irf6.1 chr4 11497988 11498302 3.16 – –
irf6.2 chr1 24643483 24643881 2.11 – –
irf6.3 chr18 38448071 38448381 1.08 – –
irf6.4 chr6 57357955 57358206 0.85 – –
irf6.5 chr3 5114092 5114589 1.61 0.46 1.12
irf6.6 chr3 195073891 195074208 0.97 0.78 1.01
irf6.7 chr1 151996562 151997003 1.88 1.00 0.95
irf6.8 chr1 214612789 214613170 1.85 1.30 1.07
irf6.9 chr8 32490755 32491167 2.86 1.20 1.10
irf6.10 chrX 115403554 115403914 0.48 – –
irf6.11 chr6 116522076 116522416 1.50 – –
irf6.12 chr2 100317989 100318381 0.81 – –
(II
I) 
O
ve
rla
p 
w
ith
  
G
W
A
S 
lo
ci
r20378# chr2 43630476 43630817 3.17 – –
r40508 chr8 129895470 129895867 1.90 0.74 0.92
loc2 chr8 86206034 86206210 4.68 – –
loc3 chr8 83408707 83409277 – – –
loc4 chr8 87442515 87442831 1.97 1.06 0.91
abca4.4_
loc1
chr1 94550565 94550844 0.88 – –
(IV
) U
ps
tr
ea
m
 
to
 A
RH
G
AP
29 abca4.1* chr1 94487951 94488216 0.75 – –
abca4.2 chr1 94493361 94493716 1.64 0.96 0.83
abca4.3* chr1 94547399 94547780 2.47 – –
abca4.5* chr1 94569207 94569583 1.96 – –
*Motif does not contain a SNP at one or more important positions
#The BS r20378 was cloned with the
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Figure 7.2 The five p63 binding sites, irf6.2, r20378, r40508, abca4.3, and abca4.5, that are concluded to 
be most likely involved in OFC-gene regulation. The UCSC Genome Browser screenshot shows the location 
of each binding site and the close by genes, with an inset of the motif (blue) and the position of SNPs. The four 
important positions of the motif are shown in red. The other tracks in the screenshot represent the overlap 
of p63 BS with IRF6 BS or with a GWAS locus. Along with each screenshot is the corresponding Saos-2 cells 
transactivation result. NC: Negative control, PC: Positive control
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7.3.3 Enhancer element abca4.5 activates gene expression during orofacial 
 development  
To gain more insight into the developmental role of the enhancer elements containing BSs r40508, 
r20378, abca4.3, and abca4.5, they were cloned in a zebrafish reporter vector and tested in stable 
transgenic enhancer assays. Fragments containing r40508 and abca4.3 BSs promoted expression in the 
epidermis at 48 hours post fertilization. In contrast, BSs r20378 was found to be active in the hindbrain. 
Embryos transgenic for BS abca4.5 also showed expression in neural tissues. In addition, this enhancer 
was also active in ventral cells that will form facial structures. Both structures are territories expressing 
the Arhgap29 gene in developing mouse embryos.11,25
7.4 Discussion
We performed a genome-wide systematic analysis of the p63BSs to select p63 BSs harboring common 
polymorphisms that might contribute to the occurrence of OFC. By making use of a previously published 
dataset of p63 ChIP-seq16, a collection of 188 p63 BSs was obtained. The selected p63 BSs contained a 
DNA variant at one or more of the four important Cs and Gs in the motif, which are critical for bonding 
by p63. These variants, either SNPs or indels, were predicted to disrupt p63 binding and hence cause 
deregulation of the gene expression. The BSs with variants at crucial nucleotides within the core p63 
motif were further filtered by four criteria. The 22 BSs filtered from criteria II, III, and IV were functionally 
tested for their responsiveness towards p63 through a transactivation assay in Saos-2 cells. Fourteen 
BSs showed at least 1.5-fold induction of transactivation activity by wtp63 protein as compared to the 
negative control. These BSs are apparently effectively bound by p63 (Figure 7.2 and S7.2), which was 
confirmed by the lack of responsiveness of seven BSs for DNA-binding deficient mutant p63 proteins 
(Figure S7.2). Seven of the other 22 BSs that we tested did not show activity in the transactivation assay. 
This could be due to the fact that they are not genuine or weak BSs, or because cofactors required for 
p63 binding and activation at these sites are not present in Saos-2 cells. 
The 14 BSs that gave more than 1.5-fold induction in transactivation assay comprised seven sites 
that overlap with IRF6 binding sites (II), four that are contained in OFC risk loci (III), and three that are 
upstream of ARHGAP29 (IV). Out of the 14 BSs that gave more than 1.5-fold induction, only two BSs 
(irf6.9 and loc2) showed similar level of induction as peak 229, a strong p63 BS which was used as a 
positive control in the transactivation assays. These 14 BSs were further studied for their potential role 
as regulatory elements during orofacial development. For this, we first analyzed which genes are in 
proximity of these motifs (Figure S7.1). Among the BSs that were selected based on criterion (II), BS 
irf6.2 was found to be 2 kb upstream of GRHL3, which is known to be involved in VWS27often but not 
always associated with lower lip pits. Recently, \u223c5% of VWS-affected individuals were identified 
with mutations in the grainy head-like 3 gene (GRHL3, a syndromic form of OFC (Figure 7.2). Mutations 
in IRF6 are also responsible for VWS. Hence, this BS which is bound by both p63 and IRF6 appears to be 
a cis-regulatory element controlling the expression of the GRHL3 gene. 
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Figure 7.3 GFP expression in transgenic assays in zebrafish. In stable transgenic enhancer assays, r40508, 
r20378, abca4.3, and abca4.5 were tested. Asterisk point to expression promoted by the midbrain enhancer 
used as the positive control for transgenesis. Expression patterns controlled by the BSs are indicated by 
arrows. BS abca4.5 was found to be active in neural tissues and in ventral cells, both of which express the 
Arhgap29 gene in developing mouse embryos. 
Other BSs selected from IRF6 BSs overlap and GWAS loci were not close to any known OFC gene. The 
genes in proximity of these BSs include genes that appear to be involved in tumorgenesis, cell signaling, 
and other cellular process. It is possible that such genes also contribute to orofacial development. 
Alternatively, these BSs may be involved in controlling the expression of distant OFC genes, which 
may temporally or spatially come in proximity to the p63 BS by the 3D conformation of the chromatin. 
Such interactions between p63 BSs and OFC genes can be identified using chromosome conformation 
capture techniques.28
Four of the BSs that were selected based on criteria (III) and (IV), BSs r20378, r40508, abca4.3, and 
abca4.5, were further studied in zebrafish to examine their spatiotemporal role in the control of gene 
expression (Figure 7.3). BS r20378, which was identified in an OFC GWAS locus, is located in an intron 
of the thyroid adenoma associated gene THADA.29 Chromosomal aberrations of the genomic region 
containing THADA have been observed in benign thyroid adenomas. Moreover, SNPs in THADA have 
been associated with type 2 diabetes30 and polycystic ovary syndrome.31,32 THADA has been also 
identified as a regulator of thermogenesis balance.33 BS r40508 identified in another OFC GWAS locus 
is located in a gene desert on chromosome 8q24.21. Hence, both r20378 and r40508 could regulate 
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distant OFC genes which may come in proximity to them in 3D conformation. The genomic locus 
covering ABCA4 is associated with OFC. Recent studies have identified that it is not the ABCA4 gene 
but the upstream ARHGAP29 that plays a role in craniofacial development. We have now shown that BS 
abca4.5 drives expression in a pattern overlapping that of ARHGAP29. 
The 166 BSs obtained from that were selected based on their proximity to the OFC-related gene 
(criterion I) were not further studied here. Just like the peak 229 which regulates the nearby IRF6 gene, 
which is involved in OFC, these identified BSs could also regulate other genes involved in OFC. These 
motifs from criterion I could be further prioritized based on the strength of the BS, and reduced to 
most important motifs, by applying more stringent filters. These filters could be minor allele frequency 
(MAF)<0.01 of the SNPs affecting the motif, function of the nearby OFC-related gene, or overlap with 
epigenetic markers indicative of enhancer activity.
Overall, the data presented in this report provide a list of p63 BSs which could act at non-coding 
regulatory elements controlling the expression of novel or known and distant or nearby OFC genes. 
The SNPs or variants present in these BSs at the important positions of the motif could be the functional 
variants involved in OFC. For understanding the functional role of these variants in BSs, transactivation 
studies in cellular models and in vivo should be performed, comparing the activation of gene expression 
by a BS containing major allele versus the same BS with the identified SNP at the important position or 
an insertion which would disrupt more than one important positions. Further screening OFC patients 
for the identified SNPs can provide the evidence of contribution of these variants in p63 BSs to OFC. 
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Supplementary data
Tables S7.2, S7.3, S7.4, and S7.5 are available upon request to Dr. Jo Huiqing Zhou, j.zhou@science.ru.nl.
Table S7.1 Primer sequences for amplification of the p63 binding site
p63 Binding site Forward primer Reverse primer
irf6.1 TCCCCAACTTCAGTGAAACC TCTCTCCACGTATATGCCAATG
irf6.2 GGGATGAAGGCCTAGAAAGC GGCTGAAGGGCTATTTGGTG
irf6.3 AGCAAACGTGTGTTGAGTAGC TTCCCACAAGAACAGAATTGC
irf6.4 CAGATAGTTCTGCCTGGATGC GCTTCAACAGTGCTCTCATTTG
irf6.5 GGGGTGGATCAGCATAGAAC CTTTCAATACCCCCACCAAC
irf6.6 TGCTGCTCTTGGATCACTTG CTCCCTTCTTCCCTCATTCC
irf6.7 CAGACTGGACTTGCAACTTTCC CCCTGCACCTCAGGAAGACT
irf6.8 TTTGCTTCCAACATTGCTTC GCGAGCATTATGTAGAGAGTGG
irf6.9 TTGTGCTTTGGTATCACCAGT TGCAATCGTTTCTGCTTCTG
irf6.10 TCTTTGCCCATCCAAATCTC TCACTTGCCTTTTGTCAAGC
irf6.11 CCCCACCCACTCAGAAATAC AATGGCTACAGCCAAAAAGG
irf6.12 AGCTGCTTCTTTGAGAATGATG CAGGGAATTTATGCTGAGTGG
r20378 GACCGTGAAGCAGAACAACG GGGGCATCTAGAGCAAGTGG
r40508 GCTTCCCTTTCTTCATGCTGC GTGGCCTAGATGTCACTTTGC
loc2 TGGCCTGTTGACTAATGTTTTC TGTTTGCTCTCTCAGAGTTGG
loc3 GTGAGAGAGATTGGGTGATTTG CAACTTCCGAATATGCAAGC
loc4 GGGTAATAGAGCAGGAAGATCC GAAATAAGCCAAGCATGTGG
abca4.4_loc1 AGACTGCCTGCATGTCTCTG GCTGACATGTATGTGCTTTCC
abca4.1 GCTCCCATTATTTGCTCCTC GTGGGAAAGCACAGGTATGG
abca4.2 GTGGAGCTGCCAGTAGCTTG GAACAGCCCCTTCATCTCTG
abca4.3 AAGGGAGGAAGCAAGTAGGC GCTCCCATGGATCTATCACC
abca4.5 CCCAAGTGTCAGTGATGCTG GCCTGGGAGCTAAGCACTTC
Primer sequences are depicted in the 5’ to 3’ direction.
Forward primer sequence without addition of attB1 recognition sequence (ggggacaagtttgtacaaaaaagcaggcttc). 
Reverse primer sequence without addition of attB2 recognition sequence (ggggaccactttgtacaagaaagctgggtg).
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Table S7.6 List of the CL/P-associated GWAS loci
Region Chr Start End Size Strongest SNP-risk allele
8q24.21 chr8 129640852 130225011 584160 rs987525
1q32.2 chr1 209885318 210370590 485273 rs642961
10q25 chr10 118641396 118834991 193596 rs7078160
17q22 chr17 54615617 54778904 163288 rs227731
20q12 chr20 39255548 39282720 27173 rs13041247
1p22 chr1 94525623 94850443 324821 rs560426
1p36 chr1 18929842 18990793 60952 rs742071
2p21 chr2 43484556 43931176 446621 rs7590268
3p11.1 chr3 89307931 89597679 289749 rs7632427
8q21.3 chr8 82916953 88981540 6064588 rs12543318
13q31.1 chr13 80440491 80874281 433791 rs8001641
15q22.2 chr15 63303416 63327533 24118 rs1873147
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Figure S7.1 Details of actions and settings of Galaxy tools used for filtering p63 motifs
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This thesis aimed at using novel genomic approaches to decipher the genetic mechanisms of orofacial 
clefting (OFC) and identifying missing heritability. This aim was approached from three directions: 
 • identifying novel mutations in previously known genes for OFC (chapters 3 and 4),
 • identifying mutations when genes known to be associated with the disease have been ruled out 
(chapters 5 and 6), and 
 • identifying mutations in non-coding regulatory elements (chapter 7).
At the beginning of my PhD study, I reviewed the conventional methods that were being employed 
for the identification of chromosomal aberrations. I discussed how the conventional methods have 
given way for high resolution candidate gene and genome-wide methods in deciphering the genetic 
mechanisms underpinning OFC (chapter 2). Subsequently, I used traditional as well as novel genome-
wide approaches for the identification of mutations causing syndromic and nonsyndromic OFCs in the 
genes (chapter 3, 4, 5, and 6). In addition, as an explorative approach, I performed analyses to search for 
genetic variation in non-coding regulatory elements (chapter 7). 
8.1 Genomic approaches used for studying orofacial clefting
Syndromic and nonsyndromic OFCs typically have different inheritance patterns. Syndromic forms, 
which account for ~30% of the total OFC cases, mostly follow a Mendelian inheritance pattern and 
are caused by single gene mutations or chromosomal aberrations. In contrast, nonsyndromic forms 
usually have a complex etiology with multiple genetic and environmental factors acting together.1 Due 
to this difference in inheritance patterns, the syndromic and the nonsyndromic OFCs require tailored 
approaches for the identification of genetic causes. Chapter 2 reviews the traditional as well as modern 
techniques that are being used in deciphering the genetic mechanism behind the two forms. 
The earliest genome-wide methods used were cytogenetic techniques, such as G banding and 
fluorescent in situ hybridization (FISH), and comparative genomic hybridization (CGH). These 
techniques helped in identifying a number of structural and numerical chromosome aberrations, such 
as, insertions, deletions, duplications, and translocations, which are mostly causative in syndromic 
forms. Many deletions and duplications have been identified so far by using FISH and CGH.2–6 One such 
important locus identified by FISH contained SATB2.2 However, the copy number variants identified 
by FISH and CGH are typically large and can cover several genes. Later, other methods that provided 
higher resolution were used. These methods were genome-wide linkage studies, and candidate 
gene association studies, which was extensively applied to nonsyndromic OFC (nsOFC). Linkage 
studies helped in identifying mutations in MSX1, PVRL1, TBX22, IRF6, and TP63 as causes of various 
OFC syndromes.7–11 Candidate gene association studies confirmed MSX1 and the family of TGF genes 
in nsOFC.1
With the advent of high throughput techniques, DNA microarray and next-generation sequencing 
(NGS), new identification methods were developed which had much higher resolution than previous 
520163-L-bw-Khandelwal
Processed on: 6-6-2018 PDF page: 144
144 | Chapter 8
generation methods. DNA microarray found its application in array CGH (aCGH) methods, CNV arrays, 
and SNP array which are used in genome-wide association studies (GWAS). Array CGH, just like CGH, 
is used in syndromic forms and helps in the detection of chromosomal aberrations but at a higher 
resolution. Many different genomic loci have been identified for syndromic OFCs by aCGH, for 
example, loci that cover FGFR2, ESR1, DAB1 etc.3,4 GWAS on the other hand, makes use of SNP arrays 
and gives the genome-wide information about single nucleotide risk variants in risk loci. This method 
has been extensively applied in non-Mendelian form, that is, nsOFC. While some nsOFC GWAS have 
found association with genes well known for syndromic OFC, like TP63 and IRF6, others have identified 
associations with novel genes and non-coding gene deserts, like 8q24.21.12–16
NGS has also enabled whole genome sequencing (WGS), exome sequencing (ES) and more targeted 
sequencing as in using molecular inversion probes (MIPs). Whole genome sequencing and exome 
sequencing are widely applied to identify the genetic cause for various syndromic forms of OFC. Some 
of the examples are, RIPK4 mutations causing Bartsocas–Papas syndrome, and FGFR1 mutations causing 
Hartsfield syndrome.17,18 Chapters 5 and 6 of this thesis also report the use of ES in order to identify the 
genetic cause for syndromic OFCs. MIPs are used for targeted sequencing of genomic regions in large 
cohorts of individuals. These genomic regions are usually obtained after filtering from WGS or ES in few 
families. Chapters 3, 4, and 5 of this thesis report the first use of MIPs sequencing in large cohorts of 
individuals affected with OFC or tooth agenesis (TA).
For both syndromic and nonsyndromic OFCs, regulatory elements have been identified that play an 
important role in lip and palate development.19,20 Variations in these non-coding elements have been 
shown to cause both nsOFC as well as syndromic OFC, such as Pierre Robin sequence and van der 
Woude syndrome (VWS).19,21 In chapter 7 of this thesis, I presented an approach to the exploration 
of the non-coding genome for identifying functional variants in p63-bound regulatory elements 
imparting risk for OFC.
8.2 Novel mutations identified in genes previously implicated in OFC 
It is a general concept in genetics that genes in which mutations are responsible for a certain syndrome, 
can also be a candidate gene for disorders with phenotypes partially overlapping to that of syndrome. 
Mutations in TP63 and IRF6 are well known to underlie various syndromic forms of OFC. In addition, 
GWAS have identified risk variants for nsOFC in these two genes.14,22 Both p63 and IRF6 are transcription 
factors regulating the expression of genes important for orofacial development. This thesis reports 
novel deletions and mutations affecting TP63 and IRF6 in individuals with syndromic and nonsyndromic 
OFC. MIPs sequencing was used to analyze TP63 and IRF6 to identify variants in 1,072 individuals with 
nsOFC, 67 with TA, and 706 controls. 
Chapter 3 describes the first ever heterozygous loss-of-function TP63 deletions identified using CNV 
microarrays in families with syndromic OFC, and nonsense variants identified using MIPs in individuals 
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affected with nsOFC. Moreover, this study revealed the first missense variants in the oligomerization 
domain (OD) of p63 in individuals with nsOFC. The data uncover dosage-dependent functions of 
p63 and indicate that loss-of-function alleles can also be risk factors with strong effect size for OFC 
phenotypes. 
Hitherto, individuals with deletions encompassing TP63 were not reported to have the typical 
clinical manifestations that are seen for other p63 mutations.23 Similarly, mice carrying heterozygous 
deletion of Trp63 do not present any ectodermal defects.24,25 Finally, transactivation assays with p63 
protein isoforms carrying disease-associated mutations showed evidence for dominant-negative 
and gain-of-function effects of these mutations rather than loss-of-function effects.11,26–28 Therefore, a 
haploinsufficiency model was never considered for TP63 mutations. However, in this thesis (chapter 3) I 
report the identification of partial deletions of TP63 in individuals from three families affected with OFC 
and other minor phenotypes, such as hypodontia, nail abnormalities, and pre-axial polydactyly. These 
findings reveal that TP63 works in dosage-dependent manner and requires two functional copies to 
bring about the wild-type condition. 
Besides these partial TP63 deletions, I have also identified TP63 variants with loss-of-function effects 
in individuals with nsOFC, including a frameshift variant p.Ser189Serfs*6, and a nonsense variant 
p.Gln333* that introduces a premature stop codon in the DNA-binding domain. Lastly, two missense 
variants p.Val405Met and p.Arg408His in the OD of p63 are reported in individuals with nsOFC. This 
is the first time that mutations in the OD of p63 have been linked to a human phenotype. Thus, my 
research has extended the pattern of mutations and variants affecting the TP63 gene and has revealed 
haploinsufficiency as a novel pathogenic mechanism.
In Chapter 4, I report de novo IRF6 mutations, p.Pro380Gln and p.Arg9Trp in nsOFC, p.Asp225His in a 
patient with a VWS, and three rare variants, p.Phe374Ser, p.Thr129leufs*3, and p.Arg35Cys in nsOFC. 
Many of the variants identified in nsOFC individuals in TP63 and IRF6 were found to be inherited 
from an unaffected parent. For example, the frameshift nonsense variant p.Ser189Serfs*6, and the 
OD variants p.Val405Met and p.Arg408His in TP63 were all paternally inherited. Similarly, the variants 
p.Thr129leufs*3, and p.Arg35Cys in IRF6 were paternally and maternally inherited, respectively. 
This shows that these variants have strongly reduced penetrance. Incomplete penetrance can be 
considered as stepping stone towards models of more complex inheritance. Such variants with high 
to medium effect size have phenotypic consequences only in the presence of other genetic variants; 
typically, more common variants with small effect size. Such variants can reside in the other allele of the 
same gene, in other genes involved in same biological processes, or in non-coding regulatory elements 
controlling the expression of these genes (chapter 7). 
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8.3 Novel mutations identified using explorative approach of exome 
 sequencing 
Mutations in TP63, IRF6 and other genes account for a proportion of syndromic OFC cases. However, 
ever so often, cases are described with novel combination of phenotypes. Occasionally, another 
clinical diagnosis may guide testing of another gene that has already been implicated in OFC, but the 
identification of a causative mutation can be worked more efficiently by ES. In this thesis I report two 
studies in which ES was used to identify the causative mutation in a novel OFC gene. 
Chapter 5 describes novel mutations in LRP6 identified using ES in two unrelated index patients 
with TA-OFC, and TA-only, respectively. The chapter also reports five additional variants identified in 
individuals affected with TA-only through targeted resequencing using MIPs.
Individuals with OFC present with higher prevalence of TA compared to controls. It is believed that 
the additional TA phenotype in such cases is the result of acquired disturbances of the physical 
environment surrounding the developing dentition.29,31 Some TA-OFC phenotypes have been shown 
to result from mutations in MSX1, TP63 or IRF6,33,35 whereas most isolated TA cases contain mutations 
in WNT10A.37 This thesis reports the identification of mutations LRP6, a gene which functions as co-
receptor for WNT, transmitting signals in canonical WNT/β-catenin-TCF signaling cascade.39 This 
signaling cascade plays a crucial role in dental and orofacial development.41 The frameshift mutation 
p.Cys1532fs was identified in an TA-OFC patient and a splice site mutation c.3398-2A>C in an unrelated 
TA only patient. Resequencing of LRP6 revealed significant enrichment of unique variants in TA patients 
but not in nsOFC patients. The five variants identified included three missense variants p.Arg173Gly, 
p.Pro469Leu, p.Gly537Arg, and two splice-site variants c.2994+1G>A and c.4082-2A>G. Notably, the 
variant p.Pro469Leu was de novo. Based on these finding it was inferred that mutations in LRP6 are a 
major cause of TA.
Chapter 6 describes a novel mutation in CHUK identified using trio ES in a patient with an EEC/AEC 
syndrome-like phenotype and additional hypogammaglobulinemia. It also compares the previously 
known CHUK mutations and associated phenotypes to the one identified here. Finally, the different 
pathways where CHUK plays a role are discussed in context of amalgamation of the EEC/AEC syndrome-
like and the immune-related phenotypes. 
Mutations in TP63 can cause various syndromes, two of which are Ectrodactyly, Ectodermal dysplasia, 
Cleft lip/palate (EEC), and Ankyloblepharon-Ectodermal defects-Cleft lip/palate (AEC).30 The patient 
reported in this study presents with ankyloblepharon, ectodermal dysplasia, cleft palate, ectrodactyly, 
syndactyly, thus a EEC/AEC syndrome-like phenotype, and additional hypogammaglobulinemia, 
that is, a immune-related phenotype. None of the parents presented any such phenotype. When no 
pathogenic mutations in TP63 or CNVs at the TP63 locus were identified, trio ES was performed. ES 
revealed three de novo heterozygous variants, including the variant in CHUK (p.His142Arg). Since CHUK 
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is a direct target gene of p63 and encodes a component of the IKK complex that plays a key role in 
NF-κB pathway activation, the CHUK missense variant was considered to be likely causative. 
CHUK contains a kinase domain at the N-terminal, which is followed by a leucine zipper domain 
that facilitates homo- and hetero-dimerization with IKKβ.32,34 At the C-terminal, there is a NEMO (NF-
κB essential modulator; IKKγ) binding region. CHUK forms the IKK complex together with IKKβ and 
NEMO (IKKγ). The identified heterozygous CHUK variant p.His142Arg is located in the core of the 
kinase domain and affects a highly conserved amino acid, close to Asp144 required for CHUK kinase 
activity. The variant is predicted to impair the kinase activity of the protein, but not its capacity to 
engage in homomeric and heteromeric complexes. Hence, it is likely that this mutant CHUK protein can 
heterodimerize with IKKβ in the IKK complex and exhibit a dominant negative effect toward the wild-
type protein to affect the canonical NF-κB activation. On the other hand, previously known mutations 
in CHUK, p.Gln422X responsible for cocoon syndrome, and c.934-2A>G responsible for Bartsocas-Papas 
syndrome (BPS), are both homozygous and predicted to result in protein truncation after the kinase 
domain ablating the dimer forming leucine zipper and very likely the complete loss of the protein.36,38 
This difference in zygosity of the mutations and their effects on the protein explain the less severe 
ED phenotype and the additional immune-related phenotype in the present patient, as compared to 
cocoon syndrome and BPS.
The variant presented in this study is located in the kinase domain and may contribute to the disease 
phenotype in three ways: (1) the variant exhibits a dominant negative effect and results in an inactive 
IKK complex that affects the canonical NF-κB pathway; (2) it affects the feedback loop of the canonical 
and non-canonical NF-κB pathways that are CHUK kinase activity-dependent; and (3) it disrupts NF-κB 
independent epidermal development that is often p63-dependent. Involvement of these three distinct 
but interrelated pathways explains the presence of both EEC/AEC syndrome-like and immune-related 
phenotypes in the patient. Thus, this study recommends examining CHUK for mutations in patients 
with similar combination of phenotypes.
8.4 Mutations in non-coding regulatory elements
Non-coding regions constitute approximately 98% of the total human genome. One of the functional 
components in non-coding regions are regulatory elements that control the expression of the 2% of 
coding sequences of the genome. Disruption of such regulatory elements may play an important role 
in the etiology of human diseases, although the true extent of that is unknown because mutation 
analysis studies have hitherto been confined mostly to coding sequences. Nonetheless, for IHH, which 
is a master regulator of skeletal development, it has been shown that deletions of enhancer cluster of 
Ihh in mice, result in growth defects of limbs causing extreme shortening of bones.40
There is increasing evidence for the role of non-coding regulatory elements also in OFC etiology.42 
GWAS performed for nsOFC so far have identified risk loci both in coding and even more so in 
non-coding regulatory regions of the genome.12–16,42 The functional effect of risk loci in non-coding 
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regions is challenging to understand. Many cases with syndromic and nonsyndromic OFC have been 
described where mutations were identified not in the known gene, but in the p63-bound regulatory 
element controlling the expression of that known gene.19,20the most common syndromic form of cleft 
lip and palate (CLP For example, disruptions of cis-regulatory element have been reported as causal 
mechanism of disease in VWS where the affected individuals do not contain any pathogenic mutation 
in the IRF6 itself, but in an upstream p63-bound regulatory element which is co-localized with the 
MCS9.7 region.19,45
Therefore, in my thesis I have set out a strategy to use various publicly available datasets and 
bioinformatics analysis tools to explore the involvement of p63-bound non-coding regulatory elements 
in normal and disrupted orofacial development (Chapter 7).
In order to systematically select p63 motifs for their role as regulatory elements involved in orofacial 
clefting, four criteria were used: (I) Those motifs that are in proximity to the CL/P-related genes. The 
p63-bound regions could act as enhancer and regulate the proximal CL/P-related gene. (II) Those motifs 
that overlap with the IRF6 BSs. p63 and IRF6 are known to play important role in orofacial development 
and have been shown to work cooperatively.43 Thus, the genomic regions bound by both p63 and 
IRF6 could provide an insight into the mechanism of co-regulation of proximal genes by these two 
transcription factors. (III) Those motifs that lie in the CL/P-associated GWAS loci. The variant in the p63 
motif could be the real “functional variant” in LD with the “risk variant” of the GWAS loci. (IV) Those 
motifs that lie upstream to ARHGAP29 which plays a role in craniofacial development.44 Thus, the p63-
bound enhancers upstream to ARHGAP29 could regulate its expression.
The motifs obtained based on criteria II, III and IV were further assessed for their responsiveness towards 
p63 through transactivation assay and 14 motifs were identified to be effectively bound by p63. Five 
of the 14 motifs were further analyzed for their role in lip and palate development. The motif irf6.2 was 
found to be upstream to GRHL3, mutations in which are known to cause VWS. Motifs r20378, r40508, 
abca4.3 and abca4.5 were tested in zebrafish to confirm their responsiveness to p63 in vivo and to 
examine their control of gene expression. The role of these motifs as p63-bound regulatory elements in 
OFC etiology can be established with further studies focusing on the effects of the SNPs in these motifs.
8.5 Closing remarks and future perspectives
The work presented in this thesis exemplifies the use of different technologies for different objectives. 
Candidate gene strategy was employed for identification of novel deletions and mutations in TP63 
and IRF6, the two genes previously implicated in OFC. MIPs sequencing provided a cost-effective 
resequencing of these genes in cohorts of patients and controls. For identifying the mutations when 
known gene associated with the disease has been ruled out, exome sequencing (ES) was used. With 
the help of ES, novel mutations in LRP6 and CHUK were identified in multiple families. For identifying 
the functional variants in p63-bound non-coding regulatory elements, more explorative method 
was used. The p63-bound elements containing variants were filtered based on various criteria using 
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bioinformatic tools. Filtered elements were functionally tested if the variant they contained could 
affect orofacial development.
The results presented in this thesis highlight the need for careful and accurate phenotyping in OFC 
patients. In chapter 4, the patient with a variant in IRF6 was initially diagnosed with CLA only. But 
after in-depth phenotyping, patient was found to have lip pits. In chapter 5, after careful inspection 
of medical records of TA patients harboring additional LRP6 variants, additional dental anomalies, 
including tooth ankylosis, abnormal tooth shape, enamel defects, and other symptoms, such as 
clinodactyly were identified.
As evident from our MIPs sequencing in OFC cohort, even the genes previously implicated in OFC, IRF6 
and TP63, account for a small number of nsOFC cases. Thus, to decipher the genetics and genomics 
of nsOFC, and also syndromic OFC, and identify all the genes, candidate gene approach may not be 
sufficient. It requires genome-wide approaches, such as ES or whole genome sequencing (WGS). With 
the advent of new sequencing platforms, WGS is becoming less expensive. WGS can be used to get 
the information about all types of variations, including structural rearrangements as well as point 
variations, in coding and as well as non-coding region of the genome. WGS when applied to familial 
cases of OFC can provide insight into the patterns of deletions and/or mutations responsible for a 
particular phenotype and uncover the combinations of coding and non-coding variants with large or 
medium or small effect size, all at the same time. Functional studies, just like presented in chapter 7 of 
this thesis, can help to identify the putative enhancers disrupted by these variations in the non-coding 
regions. 
This thesis reports the identification of many variants in different genes in individuals affected with 
OFC, which explain a part of the missing heritability. However, the exact mechanism of how these 
variants contribute to the phenotype can only be understood after more functional analyses. Targeted 
genome editing tools, such as CRISPR/Cas9, can be used to mimic the identified coding as well as 
non-coding variations in mice.40 CRISPR/Cas9 can further be used to analyze isogenic cell lines from 
patients that differ only in a single variation, which can help to understand the molecular and cellular 
consequences of the variation. These disease models can reveal the mechanism of how the variations 
lead to disruption of orofacial development and cause OFC. This will also help to ascertain the causality 
of the identified coding and non-coding variations, which is difficult to establish based on genetic 
studies alone.
In conclusion, NGS techniques have proven to be of significant help in the understanding of genetics 
of OFC. More studies need to be performed in larger and well-phenotyped cohorts for both coding and 
non-coding parts of the genome to identify more mutations. However, only functional analyses can 
pave the way from the identified mutations to the disease mechanism. Identification of new mutations 
leading to OFC is imperative to the prediction of the disease. Elucidating these mutations and the 
related disease mechanisms is crucial towards the diagnosis of the disease and improving clinical 
management for providing better patient care.
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Orofacial clefts (OFCs) are congenital structural anomalies of the lip, the alveolus and/or the palate, 
which affect around 1 in 700 live births. They are characterized by incomplete formation and/or fusion 
of structures separating the oral and the nasal cavities. OFCs have a complex etiology with multiple 
genetic and environmental factors that can lead to the disruption of normal embryonic development 
of the lip and palate. This thesis aimed to use novel genomic approaches to decipher the genetics of 
OFC.
Chapter 1 is a brief introduction about the normal development of the lip and palate structures in 
humans, underlying cellular processes and molecular mechanisms, and how perturbations in these 
mechanisms result in orofacial abnormalities. The two forms of OFCs, syndromic and nonsyndromic and 
their genetic models are then discussed. Finally, the chapter gives the outline of the thesis, highlighting 
the various approaches used to decipher the genetics of OFC.
Chapter 2 reviews the various genomic approaches used for studying OFC. It discusses the genome-
wide approaches used in genetic studies of OFC including copy number variations (CNVs), genome-
wide linkage studies, genome-wide association studies (GWAS), exome sequencing (ES), and the 
identification of genetic variants in non-coding regulatory elements. The applicability of these 
approaches and future perspectives of genomic studies in OFCs are also discussed.
Chapter 3 describes a study to identify novel deletions and variants of TP63 associated with orofacial 
clefting (OFC). Copy-number variants were assessed in three OFC families using microarray analysis. 
A cohort of 1072 individuals affected with OFC and 706 population-based controls were analyzed 
using Molecular Inversion Probes (MIPs). Partial deletions of TP63 were identified in individuals from 
three families affected with OFC. In the OFC cohort, we identified several TP63 variants predicting to 
cause loss-of-function alleles, including a frameshift variant (p.Ser189Serfs*6) and a nonsense variant 
(p.Gln333*) that introduces a premature stop codon in the DNA-binding domain. In addition, the first 
missense variants were identified in the oligomerization domain (p.Val405Met), which occurred in 
individuals with OFC. This variant was shown to abrogate oligomerization of mutant p63 protein into 
oligomeric complexes, and therefore likely represents a loss-of-function allele rather than a dominant-
negative. All these variants and deletions uncover a dosage dependent function of p63 and a loss-of-
function mechanism behind nonsyndromic OFC. These findings suggest modifications to the previous 
model that loss-of-function alleles in TP63 do not give rise to any clinical phenotype.
Chapter 4 describes a study that aims at identifying novel IRF6 mutations in orofacial cleft patients. 
Targeted multiplex sequencing using MIPs was performed in 1072 OFC patients, 67 patients with 
tooth agenesis (TA), and 706 controls, which included IRF6 and other genes as well. Three potentially 
pathogenic de novo mutations of IRF6 (Pro380Gln, Asp225His and Arg9Trp) were identified in OFC 
patients. In addition, three rare missense variants were identified (Phe375Ser, Thr129Leufs*3 and 
Arg35Cys), for which pathogenicity could not unequivocally be shown. Retrospective investigation of 
the patients with these variants revealed the presence of lip pits in one of the patients with a de novo 
mutation (Asp225His) suggesting a Van der Woude syndrome phenotype, while in other patients no 
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lip pits were identified. These findings add to the increasing evidence that rare IRF6 variants play a 
role in the etiology of nonsyndromic OFCs. Moreover, this study highlights the need for deep clinical 
phenotyping and medical history of families that present at genetic counselling and the advantage of 
a “genotype first” approach when studying large patient cohorts.
Chapter 5 describes a study that aims to identify a novel genetic cause of TA and/or OFC by combining 
whole-exome sequencing (WES) and targeted resequencing in a large cohort of TA and OFC patients. 
WES was performed in two unrelated patients: one with severe TA and OFC and another with severe 
TA only. A frameshift (c.4594delG, p.Cys1532fs) and a canonical splice-site mutation (c.3398-2A>C, 
p.?) were identified in a gene encoding low-density lipoprotein receptor-related protein 6 (LRP6), 
respectively, in the patient with TA and OFC and in the patient with severe TA only. After deleterious 
mutations were identified in LRP6, all its exons were resequenced with molecular inversion probes in 
67 patients with TA, 1,072 patients with OFC, and 706 controls. The targeted resequencing showed 
significant enrichment of unique LRP6 variants in TA patients but not in nonsyndromic OFC patients. 
Of the five variants in patients with TA, two affected the canonical splice site and three were missense 
variants; all variants segregated with the dominant phenotype, and in one case the missense mutation 
occurred de novo. This study showed that LRP6 mutations cause severe TA with or without other dental 
anomalies such as ankylosis, enamel defects, and tooth-shape anomalies. However, the genetic data 
do not provide evidence that rare monogenic LRP6 mutations underlie nonsyndromic orofacial clefts.
Chapter 6 reports the identification of a de novo variant in CHUK in a patient with an EEC/AEC syndrome-
like phenotype and additional hypogammaglobulinemia. Neither pathogenic mutations in TP63 nor 
CNVs at the TP63 locus were identified. Exome sequencing revealed de novo heterozygous variants 
in CHUK, PTGER4, and IFIT2. The variant in CHUK appeared to be most relevant for the EEC/AEC-like 
phenotype. CHUK is a direct target gene of p63 and encodes a component of the IKK complex that 
plays a key role in NF-κB pathway activation. The identified CHUK variant (g.101980394T>C; c.425A>G; 
p.His142Arg) was located in the kinase domain which is responsible for the phosphorylation activity 
of the protein. The variant may affect CHUK function and thus contribute to the disease phenotype in 
three ways: 1) the variant exhibits a dominant negative effect and results in an inactive IKK complex 
that affects the canonical NF-κB pathway; 2) it affects the feedback loop of the canonical and non-
canonical NF-κB pathways that are CHUK kinase activity-dependent; 3) it disrupts NF-κB independent 
epidermal development that is often p63-dependent. The difference in zygosity of the mutations 
and potentially affected pathways could explain the less severe ectodermal dysplasia phenotype and 
the additional immune-related phenotype in the present patient, as compared to Cocoon syndrome 
and Bartsocas-Papas syndrome, which are caused by recessively manifesting CHUK mutations. The 
PTGER4 variant could have a role, alone or in combination with the CHUK variant, in the immune and 
growth-related phenotypes present in the patient. Further functional analysis of this variant would 
be necessary to confirm its contribution to the observed phenotypes in the patient. These findings 
support the testing of CHUK for mutations in patients with the combination of EEC/AEC syndrome-like 
and immune-related phenotypes, such as one presented here to affirm the role of CHUK further.
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Chapter 7 presents a systematic genome-wide analysis to identify functional variants in p63-bound 
non-coding regulatory elements involved in orofacial clefting. p63 binding sites containing a common 
polymorphism in the core p63 recognition motif were selected based on four criteria: (I) Motifs that 
are in proximity to the OFC-related genes, (II) Motifs that overlap with the IRF6 binding sites, (III) Motifs 
that lie in the OFC-associated GWAS loci, and (IV) Motifs that lie upstream to ARHGAP29/ in ABCA4 
gene. Transactivation assays revealed 14 binding sites responsive to p63. Four of these p63 binding 
sites, which were either co-bound by IRF6 or present in an OFC-associated locus, were also tested in 
a transgenic zebrafish reporter assay to assess how they drive developmental gene expression. One 
binding site in ABCA4, BS abca4.5, was found to be active in neural tissues and in ventral cells that will 
form facial structures in zebrafish. The data presented in this report provides a list of p63 binding sites 
which could act at non-coding regulatory elements controlling the expression of novel or known OFC 
genes. The variants present in such binding sites could disrupt the ability of p63 to recognize the DNA 
and its binding and hence, the regulation of distantly or nearby located OFC-related genes.
Chapter 8 is a general discussion of the major contributions of the work, methodological problems and 
the limitations, and future perspectives. 
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1
Schisis is een aangeboren afwijking van de lip, de kaak en/of het gehemelte, wat voorkomt bij ongeveer 
1 op de 700 levend geboren baby’s. Het wordt gekenmerkt door een onvolledige vorming of een 
afwijkende fusie van de structuren die de mond- en neusholte van elkaar scheiden. De etiologie van 
schisis is zeer complex omdat er meerdere genetische en omgevingsfactoren een rol bij spelen. Deze 
factoren leiden tot een verstoring van de normale ontwikkeling van de lip en het gehemelte. Het doel 
van dit proefschrift was om de genetische achtergronden van schisis te ontrafelen met behulp van 
moderne genomische technieken.
Hoofdstuk 1 is een korte inleiding in de normale ontwikkeling van de lip en de palatinale structuren 
bij de mens, de achterliggende cellulaire processen en moleculaire mechanismen, en hoe verstoringen 
daarvan leiden tot orofaciale afwijkingen. Vervolgens worden de twee vormen van schisis, syndromale 
en niet-syndromale schisis, en de bijbehorende genetische modellen besproken. Tenslotte wordt 
er een overzicht gegeven van het proefschrift met de nadruk op de verschillende methodieken die 
gebruikt zijn om de genetica van schisis te ontrafelen.
Hoofdstuk 2 geeft een overzicht van de verschillende genomische technieken die gebruikt worden 
om schisis te bestuderen. Het bediscussieert de genoombrede technieken voor de genetische studie 
van schisis zoals copy number variations (CNVs), genome-wide linkage studies, genome-wide association 
studies (GWAS), exome sequencing (ES), en de identificatie van genetische variaties in niet-coderende 
regulerende sequenties. De toepasbaarheid van deze technieken en de toekomstperspectieven voor 
genomisch onderzoek naar schisis worden bediscussieerd.
Hoofdstuk 3 beschrijft een studie naar nieuwe deleties en variaties in TP63 die geassocieerd zijn 
met schisis. Met behulp van microarray analyse werden CNVs in het TP63 gen gedetecteerd in drie 
schisisfamilies. Een cohort van 1072 personen met schisis en 706 controle personen werd geanalyseerd 
met behulp van molecular inversion probes (MIPs). In de schisis groep vonden we meerdere TP63 
variaties die mogelijk een niet-functioneel allel veroorzaken. Daarbij ook een frameshift variant 
(p.Ser189Serfs*6) en een nonsense variant (p.Gln333*) die een prematuur stopcodon in het DNA-
bindende domein geven. Verder werden de eerste missense varianten geidentificeerd in het 
oligomerizatiedomein (p.Val405Met) bij personen met schisis. Deze variant stopt de oligomerizatie van 
het mutante p63 eiwit tot oligomere complexen en leidt waarschijnlijk tot een niet-functioneel eiwit 
in plaats van een eiwit met dominant-negatieve kenmerken. Al deze varianten en deleties wijzen op 
een dosisafhankelijke functie van p63 en een loss-of-function mechanisme bij niet-syndromale schisis. 
Deze resultaten suggereren een aanpassing van het eerdere model waarin loss-of-function allel geen 
klinisch fenotype veroorzaken.
Hoofdstuk 4 beschrijft een studie om nieuwe IRF6 mutaties te vinden in schisis patiënten. Targeted 
multiplex sequencing met behulp van MIPs werd uitgevoerd in 1072 schisispatiënten, 67 patiënten met 
tandagenesieën en 706 controles, en betrof ook IRF6 en andere genen. Drie mogelijk pathogene de 
novo mutaties in IRF6 (Pro380Gln, Asp225His and Arg9Trp) werden in de schisis patiënten gevonden. 
Verder werden drie zeldzame missense variants gevonden (Phe375Ser, Thr129Leufs*3 and Arg35Cys) 
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waarvan de pathogeniciteit niet eenduidig vastgesteld kon worden. Een retrospectief onderzoek van 
de patiënten met deze varianten liet zien dat één van de patiënten met een de novo mutatie (Asp225His) 
ook deukjes in de lip had, wat wijst op het Van der Woude syndroom. De andere patiënten hadden deze 
deukjes in de lip echter niet. Deze resultaten dragen bij aan het bewijs dat zeldzame IRF6 varianten 
een rol spelen in de etiologie van niet-syndromale schisis. Daarbij benadrukt deze studie de noodzaak 
voor een diepgaande klinische fenotypering en onderzoek naar de medische geschiedenis van families 
die komen voor genetische counseling. Bij het onderzoek met grote cohorten van patiënten het de 
“genotype first” aanpak een voordeel.
Hoofdstuk 5 beschrijft een studie om nieuwe genetische oorzaken van tandagenesieën en/of schisis 
te vinden met behulp van een combinatie van ES en targeted resequencing in een groot cohort van 
patiënten. ES is uitgevoerd bij twee ongerelateerde patiënten; één met ernstige tandagenesie en 
schisis, en een ander met alleen ernstige tandagenesie. Een frameshift (c.4594delG, p.Cys1532fs) en een 
canonical splice-site mutatie (c.3398-2A>C, p.?) werden gevonden in het gen dat codeert voor low- density 
lipoprotein receptor-related protein 6 (LRP6), respectievelijk in de patiënt met ernstige tandagenesie en 
schisis en degene met uitsluitend ernstige tandagenesie. Na het vinden van de verstorende mutatie in 
LRP6, werden alle exonen daarvan opnieuw gesequenced met MIPs in 67 patiënten met tandagenesie, 
1072 patiënten met schisis en 706 controles. Dit onderzoek liet een significante verrijking van unieke 
LRP6 varianten zien in patiënten met tandagenesie, maar niet in patiënten met niet-syndromale schisis. 
Van de vijf varianten in patiënten met tandagenesie beïnvloedden er twee de strikt geconserveerde 
splice site sequentie en drie waren missense varianten. Alle varianten segregeerden samen met het 
dominante fenotype, maar in één geval was het een de novo missense mutatie. Deze studie laat zien 
dat LRP6 mutaties ernstige tandagenesie kunnen veroorzaken met of zonder ander tandafwijkingen 
zoals ankylose, glazuurdefecten en vormveranderingen. Echter, de genetische resultaten vormen geen 
bewijs dat zeldzame monogene IRF6 mutaties de oorzaak zijn van niet-syndromale schisis.
Hoofdstuk 6 beschrijft de identificatie van een de novo variant in CHUK in een patiënt met een op het 
EEC/AEC syndroom lijkend fenotype en daarbij hypogammaglobulinemie. Er werden geen pathogene 
mutaties in TP63 of CNVs in de TP63 locus gevonden. Met ES werden de novo heterozygote varianten 
gevonden in CHUK, PTGER4 en IFIT2. De variant in CHUK leek de meest relevante te zijn voor het EEC/
AEC-gelijkende fenotype. CHUK is een direct target gen van p63 en codeert voor een component van 
het IKK complex dat een belangrijke rol speelt in de activatie van NF-kB. De gevonden CHUK variant 
(g.101980394T>C; c.425A>G; p.His142Arg) lag in het kinase domein, wat verantwoordelijk is voor de 
fosforylatie activiteit. De variant kan de functie van CHUK op drie verschillende manieren beïnvloeden 
en daarmee ook bijdragen aan het fenotype: 1) de variant heeft een dominant negatief effect en 
inactiveert het IKK complex, wat de standaard NF-κB route verstoort 2) het tast de feedback aan van 
de standaard en alternatieve NF-κB routes, die afhangen van CHUK kinase activiteit 3) het verstoort de 
NF-κB onafhankelijke epidermale ontwikkeling die vaak p63-afhankelijk is. Het verschil in zygositeit 
van de mutaties en de mogelijk aangedane moleculaire routes zou het minder ernstige ectodermale 
dysplasia fenotype kunnen verklaren en ook het immuun-gerelateerde fenotype van deze patiënt. Dit 
in vergelijking met het Cocoon syndroom en het Bartsocas-Papas syndroom, die veroorzaakt worden 
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door recessieve CHUK mutaties. De PTGER4 variant, alleen of in combinatie met de CHUK variant, zou een 
rol kunnen spelen bij het immuun- en groeigerelateerde fenotype van de patiënt. Deze bevindingen 
ondersteunen het nut van testen op CHUK mutaties in patiënten met een combinatie van EEC/AEC- en 
immuungerelateerde fenotypes, zoals hier beschreven.
Hoofdstuk 7 presenteert een systematisch genoombreed onderzoek naar p63 gebonden niet-
coderende regulatoire elementen die betrokken zijn bij schisis. P63 bindingsplaatsen met een 
overeenkomend polymorfisme in de kern van het p63 herkenningsmotief werden geselecteerd op 
basis van vier criteria: (I) Motieven die in de buurt van schisis-gerelateerde genen liggen, (II) Motieven 
die overlappen met IRF6 bindingsplaatsen, (III) Motieven die in met schisis geassocieerde GWAS 
loci liggen,en (IV) Motieven die in de buurt van ARHGAP29 en het ABCA4 gen liggen. Transactivatie 
testen lieten 14 bindingsplaatsen zien die reageren op p63. Vier van deze p63 bindingsplaatsen, die 
ook gebonden werden door IRF6 of in een schisis locus liggen, werden in een transgene zebravisjes 
getest om te zien hoe zij de expressie van ontwikkelingsgenen aansturen. Een bindingsplaats in ABCA4, 
abca4.5, bleek actief te zijn in neurale weefsels en in ventrale cellen die de faciale structuren vormen 
in de zebravis. De gepresenteerde data bevat een lijst met p63 bindingsplaatsen, die mogelijk niet-
coderende regulatoire elementen beïnvloeden die de expressie van nieuwe of bekende schisisgenen 
aanstuurt. De varianten in dergelijke bindingsplaatsen verstoren mogelijk de capaciteit van p63 om het 
DNA te herkennen en eraan te binden, en dus mogelijk ook de regulatie van ver weg of nabijgelegen 
schisis-gerelateerde genen.
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